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TIIVISTELMÄ 
Viime vuosien ahkera tutkimustyö ei ole kyennyt täysin selvittämään 
eturauhassyövän syntyyn ja etenemiseen liittyviä solutason molekulaarisia 
mekanismeja. Yleisimmät kromosomimuutokset tunnetaan, mutta useat kohdegeenit 
ovat vielä tunnistamatta. Kastraatioresistentti eturauhassyöpä, joka syntyy 
hormonihoidon jälkeen, on tappava tauti. Toistaiseksi ainoa geeni, jonka tiedetään 
liittyvän kastraatioresistentin syövän syntyyn on androgeenireseptori (AR).  
Yksi yleisimmistä kromosomaalisista muutoksista, joka löytyy kastraatio-
resistentistä syövästä, on kromosomi 8 pitkän käsivarren (q) monistuma. Monistuma 
löytyy 60-90% kasvaimista ja sen on osoitettu olevan yhteydessä potilaiden 
huonoon ennusteeseen eturauhassyöpäleikkauksen jälkeen. Alueella on useita 
minimaalisia monistumia, mikä viittaa useampien kohdegeenien olemassaoloon. 
Tässä tutkimuksessa tutkitiiin toiminnallisin kokein neljää mahdollista kohdegeeniä 
(EIF3H, TCEB1, KIAA0196 ja RAD21). Näistä TCEB1:n, joka sijaitsee 
kromosomialueella 8q21, osoitettiin edistävän syöpäsolujen invaasiota ja alustasta 
riippumatonta kasvua. Tämän lisäksi TCEB1:n yli-ilmentäminen hiiren 
fibroblastisolulinjassa lisäsi solujen kasvua. Tulosten perusteella näyttää siltä, että 
TCEB1 on mahdollinen kohdegeeni 8q21 alueen monistumalle.  
mikro-RNA:t (miRNA:t) ovat lyhyitä ei-koodaavia RNA:ita, jotka negatiivisesti 
säätelevät geenien ilmentymistä. miRNAt voivat toimia sekä syöpägeeneinä että 
kasvurajoitegeeneinä. miRNA:den ilmentymismuutoksia eturauhassyövässä 
tutkittiin kahdesta eri kliinisten näytteiden sarjasta (102 ja 54 näytettä). Näin 
pyrittiin löytämään eturauhassyövän etenemiseen liittyviä miRNA:ita. 
Tutkimuksessa löydettiin 25:n miRNA:n paneeli, jonka ilmentymismuutokset 
pystyivät erottamaan aggressiiviset kasvaimet ei-aggressiivisista. 
Androgeenien säätelemiä ja kastraatioresistentin syövän syntyyn liittyviä 
miRNA:ita etsittiin yhdistämällä tietoa AR:n sitoutumiskohdista genomissa ja 
miRNA:den ilmentymisen muutoksista kastraatioresistentissä syövässä. 
Tutkimuksessa löydettiin yhteensä 28 miRNA:a, joiden ilmentymien on muuttunut 
kastraatioresistentissä syövässä ja joissa on AR:n sitoutumiskohta. Kahden 
miRNA:n, miR-32:n ja miR-148a:n endogeeninen ilmentäminen solulinjassa lisäsi 
solujen kasvua, miR-32 vähentäen solukuolleisuutta. Androgeenit lisäävät 
molempien miRNA:iden ilmentymistä, ja AR sitoutumiskohta löytyy läheltä 
molempien miRNA:iden genomista sijaintia. miR-32:n kohdegeeniksi löydettiin 
BTG2 ja miR-148a:n PIK3IP1. BTG2 proteiinin ilmentyminen vähenee 
huomattavasti kastraatio-resistentissä syövässä. Lisäksi BTG2 proteiinin häviämisen 
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osoitettiin olevan yhteydessä lyhyempään leikkauksen jälkeiseen 
progressiovapaaseen aikaan. 
Yhteenvetona, TCEB1:lla, miR-148a:lla ja miR-32:lla osoitettiin olevan 
onkogeenisiä ominaisuuksia eturauhassyövässä. Ne ovat kaikki yli-ilmentyneitä 
kastraatioresistentissä syövässä ja solupohjaisten tutkimusten mukaan niillä on 
vaikutuksia solujen invaasioon, proliferaatioon ja apoptoosiin. Lisäksi miR-32:n ja 
miR-148a:n osoitettiin olevan androgeenisäädeltyjä. Tutkimuksissa osoitettiin myös, 
että miRNA:iden ilmentymisprofiilin avulla voidaan ennustaa potilaiden 
leikkauksen jälkeistä prognoosia. Lisää tutkimuksia kuitenkin vaaditaan, jotta 
miRNA:ita voitaisiin käyttää eturauhassyövän prognostisena indikaattorina.  
11 
ABSTRACT 
Despite extensive research in recent years, the molecular mechanisms underlying 
prostate cancer initiation and progression are not fully understood. Key 
chromosomal aberrations have been identified, yet many of the target genes remain 
elusive. Castration-resistant prostate cancer (CRPC) is a lethal disease that emerges 
after hormonal therapy. So far, the only gene known to be involved in the formation 
of CRPC is the androgen receptor (AR). 
A gain of the long arm of chromosome 8 is one of the most common findings in 
CRPC; in fact, 60-90% of these tumors harbor this particular gain. In addition, 8q 
gain is associated with poor prognosis in prostatectomy-treated patients. Several 
minimal regions have been identified, suggesting the existence of multiple target 
genes. Four of the putative target genes (EIF3H, TCEB1, KIAA0196 and RAD21) 
within the 8q gain region have been functionally evaluated. Of these, TCEB1, 
located at 8q21, was shown to promote invasion and to affect the anchorage-
independent growth of prostate cancer cells. Furthermore, TCEB1 overexpression 
enhanced the growth of murine fibroblasts. These data indicate that TCEB1 is a 
putative target gene for gain of the minimal 8q21 region. 
microRNAs (miRNA) are short, non-coding RNAs that negatively regulate gene 
expression and can function as tumor suppressor miRs or oncomiRs. To address 
whether miRNAs are involved in prostate cancer progression, their expression was 
investigated in two different clinical datasets (102 samples and 54 samples). A panel 
of 25 miRNAs was able to distinguish aggressive from less aggressive tumors.  
Androgen-regulated miRNAs involved in CRPC were identified by combining 
information on androgen receptor binding sites (ARBS) and CRPC miRNA 
expression profiles. Twenty-eight miRNAs were deregulated in CRPC and 
contained ARBS. Exogenous overexpression of miR-32 and miR-148a enhanced the 
growth of an androgen-responsive cell line; miR-32 accomplished this by reducing 
apoptosis. The expression of these two miRNAs was demonstrated to be up-
regulated by androgens and increased in CRPC. In addition, ARBS were detected in 
close proximity to these miRNAs. BTG2 and PIK3IP1 were identified as target 
genes for miR-32 and miR-148a, respectively. BTG2 expression was markedly 
decreased in CRPC, and the loss of BTG2 expression was associated with shorter 
progression-free survival in prostatectomy-treated patients. 
In conclusion, TCEB1, miR-148a and miR-32 were demonstrated to possess 
oncogenic functions in prostate cancer. They are all overexpressed in CRPC and, in 
initial cell-based studies, affected invasion, proliferation and apoptosis. miR-32 and 
miR-148a were determined to be androgen-regulated. In addition, miRNA 
12 
expression profiling was effective in predicting the prognosis of prostatectomy-
treated patients.  However, additional studies are necessary to evaluate the role of 
miRNAs as prognostic indicators in prostate cancer.  
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INTRODUCTION 
Cancer is a disease caused by the accumulation of genetic and epigenetic alterations 
in the genome. Under normal conditions, cells are strictly controlled by a gene 
network that regulates cell growth, proliferation, death and differentiation. During 
tumorigenesis, alterations in these regulatory genes occur over time. The first 
mutation that occurs in a gatekeeper pathway provides a selective growth advantage 
to the cell. The developing tumor then acquires mutations in oncogenes, tumor 
suppressors or stability genes (for example, DNA repair genes), which eventually 
lead to clonal expansion and the creation of a mass of cells that forms the primary 
tumor (Vogelstein & Kinzler 2004). Genomic mutations that lead to cancer are 
inherited or caused by environmental factors or result from random errors that occur 
during DNA replication. 
In males, prostate cancer is the most common malignancy in Finland and other 
Western countries and is the second most common cause of cancer-related death 
(Jemal et al. 2011; Finnish Cancer Register 2011). Both environmental and genetic 
factors have been implicated in the etiology of prostate cancer; well-established risk 
factors include age, ethnicity and family history (Crawford et al. 2003). The 
incidence of prostate cancer varies considerably among different populations (Jemal 
et al. 2011). Indeed, up to 42% of the risk for prostate cancer is due to heritable 
factors (Lichtenstein et al. 2000). 
Prostate cancer is a complex and heterogeneous disease. Typically, prostate 
cancer is relatively indolent, and only a small minority of men with this disease 
eventually dies of the cancer. In contrast, a fraction of prostate tumors display an 
aggressive phenotype and progress rapidly (Shen & Abate-Shen, 2010; Jemal et al. 
2011). A major clinical challenge is to distinguish the indolent from the aggressive 
tumors. Currently, outcome prediction methods are based on the Gleason score and 
the level of prostate specific antigen (PSA), which are considered inadequate 
(Walsh et al. 2007). The Gleason scoring system classifies prostate tumors based on 
their histology (most to least differentiated) (Mellinger et al. 1967; Epstein 2010). 
PSA is secreted by the normal prostate but is released into the bloodstream when 
normal prostate architecture is disrupted (Lilja et al. 2008).  Several factors other 
than cancer can elevate PSA levels, such as benign prostatic hyperplasia (BPH). 
PSA is used for early prostate cancer detection, but a biopsy is always necessary to 
confirm the presence of cancerous cells in the prostate. In a large European study, 
PSA screening reduced prostate cancer mortality by 20%. However, overdiagnosis 
and overtreatment are significant adverse effects of PSA screening, as 1410 men had 
to be screened and 48 treated to prevent one death (Schröder et al. 2009).  
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Extensive research during recent years has identified common alterations and 
frequent sites of chromosomal gains and losses in prostate cancer. However, many 
of the target genes remain unknown, and attempts to develop better diagnostic and 
prognostic markers for prostate cancer have so far been unsuccessful. The main 
oncogenic drivers for prostate cancer are androgens and AR signaling. It has been 
known for more than half a century that castration is an effective prostate cancer 
treatment, and hormonal therapy remains the standard treatment for advanced 
disease (Huggins & Hodges, 1941).  
The standard treatments for localized prostate cancer are surgery (radical 
prostatectomy) and radiation therapy (Klein et al. 2009).  Patients who relapse, or 
who are initially diagnosed with advanced disease, are given androgen deprivation 
therapy. Initially, 70-80% of these patients respond to the therapy and experience 
tumor regression (Huggins & Hodges, 1941 & 1972, Knudsen & Scher, 2009). The 
effect can last for months to years, but eventually, castration-resistant prostate 
cancer (CRPC) arises, marked initially by rising PSA values (biochemical relapse). 
CRPC is a fatal disease with no curative treatment, but it remains driven by 
androgens (Goktas et al. 1999; Knudsen & Scher, 2009). Novel drugs that 
effectively inhibit androgen action or biosynthesis prolong the survival of CRPC 
patients (de Bono et al. 2011; Scher et al. 2010). 
A more thorough understanding of the molecular mechanisms underlying 
prostate cancer tumorigenesis will hopefully reveal novel diagnostic and prognostic 
biomarkers and lead to the development of innovative therapeutics. 
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REVIEW OF THE LITERATURE 
1.1 Prostate cancer carcinogenesis 
Prostate cancer is a slow-growing disease. Prostatic intraepithelial neoplasia (PIN) is 
the pre-malignant precursor of prostate cancer. Prostate cancer progresses from 
early, androgen-dependent localized tumors to metastatic, invasive disease. 
Hormonal therapy leads to tumor regression; however, castration-resistant disease 
eventually emerges (Fig 1). In the following chapters, the protein-coding genes and 
miRNAs involved in prostate cancer progression are summarized. 
 
 
 
 
Figure 1:  Molecular mechanisms of prostate cancer. (Adapted from: Wright et al. 2005) 
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1.1.1 Inheritable factors 
 
Family history, which reveals the inherited genetic background, is a significant risk 
factor for the development of prostate cancer. Epidemiological studies have shown 
that having a first-degree relative (brother or father) with prostate cancer increases 
an individual’s risk by two to three fold.  
Hereditary prostate cancer (HPC) is a subtype of familial prostate cancer that is 
marked by a pattern of Mendelian inheritance and accounts for 5-10% of prostate 
cancer cases (Carter et al. 1993; Cerhan et al. 1999). 
HPC is likely caused by multiple genes with varying levels of penetrance that 
interact with each other and with environmental factors. Highly penetrant genes are 
rare but increase the risk for prostate cancer by several fold. In contrast, genes with 
low penetrance are more common and contribute only modestly to the risk for 
prostate cancer (Witte et al. 2009). Genes with high penetrance that have already 
been identified include RNASEL, BRCA2, MSR1 and ELAC, but these genes 
underlie only a minority of HPC cases (Xu  et al. 2001 & 2002; Carpten et al. 2002; 
Edwards et al. 2003). 
Genome-wide association studies have identified several chromosomal loci 
across multiple populations that are associated with prostate cancer risk, including 
17q21, Xp11 and 10q21 (Witte et al. 2009). One of the most interesting recent 
findings is that a series of sequence variants located in 8q24 are significantly 
associated with prostate cancer risk. These risk variants are located upstream of the 
oncogene MYC (myelocytomatosis viral oncogene homolog (avian)) and do not alter 
the coding sequence of any known genes (Amundadottir et al. 2006; Haiman et al. 
2007; Al Olama et al. 2009; Gudmundsson et al. 2009; Yeger et al. 2009). The 8q24 
region is currently considered the most important susceptibility region for prostate 
cancer. The combination of different SNPs in 8q24 accounts for approximately 8% 
of the 2-fold increased risk observed among first-degree relatives (Al Olama et al. 
2009). 
1.1.2 Chromosomal alterations 
During the past twenty years, extensive genomic analyses of prostate cancer have 
identified regions of frequent gains and losses in the prostate cancer genome. Losses 
are frequently located in the chromosomal areas 6q, 8p, 10q, 13q, 15q, 16q, 17p/q 
18q, 19p/q and 22q, whereas gains, being more abundant, are located in on 1q, 3q, 
7p/q, 8q and Xq (Saramäki & Visakorpi 2007). Several key regulatory genes have 
been mapped to these regions, namely, AR (Xq), NKX3.1 (NK3 homeobox 1) (8p21) 
and PTEN (phosphatase and tensin homolog) (10q23). However, many target genes 
remain to be identified (Visakorpi et al. 1995a; Cairns et al. 1997; He et al. 1997; 
Jenkins et al. 1997; Steck et al. 1997; Bowen et al. 2000). In addition to losses and 
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gains, a recurrent chromosomal rearrangement in chromosome 21 has been 
identified; this will be discussed later.  
1.1.2.1 8q amplification 
Gain of the long arm of chromosome 8 (q) is detected at very low frequencies (>8%) 
in early-stage prostate tumors. However, the frequency of 8q gain increase sharply 
with tumor stage and grade, with 60-90% of castration-resistant or metastatic 
prostate cancers eventually harboring this gain (Visakorpi et al. 1995b; Cher et al. 
1994; Nupponen et al. 1998a; El Gammal et al. 2010). The gain of 8q is associated 
with poor prognosis for prostatectomy-treated patients (van Dekken et al. 2003; 
Ribeiro et al. 2006 & 2007; El Gammal et al. 2010; Barros-Silva et al. 2011). In 
addition, 8q genes have been implicated in the metastatic process in numerous 
cancer types (Liu et al. 2009b). 
The overall 8q gain contains several minimal gain regions, such as 8q21, 8q22 
and 8q24 (Figure 2), suggesting the presence of multiple target genes (van Duin et 
al. 2005; Saramäki et al. 2006). The MYC oncogene is located at 8q24 and is the 
most studied putative target gene for 8q gains. MYC amplification is present in one-
third of CRPC tumors, but it is commonly overexpressed in primary tumors, 
suggesting that mechanisms other than amplification increase MYC expression 
(Nupponen et al. 1998a; Saramäki et al. 2001; Koh et al. 2010). In addition, MYC 
expression levels do not correlate with gene copy number (Savinainen et al. 2004; 
Gurel et al. 2008).  
There are several genes that have been suggested as targets of 8q gains. Putative 
targets for the gain of 8q24 include EIF3H (eukaryotic translation initiation factor 3, 
subunit H, also known as EIF3S3 and p40), RAD21 (RAD21 homolog (S. pombe)), 
KIAA0196 and PSCA (prostate stem cell antigen) (Nupponen et al. 1999; Reiter et 
al. 2000; Porkka et al. 2004). Putative target genes located at 8q21 include TCEB1 
(transcription elongation factor B (SIII), polypeptide 1 (15 kDa, elongin C)) and 
TPD52 (tumor protein D52) (Porkka et al. 2002; Wang et al. 2004). The androgen-
regulated gene NCOA2 (nuclear receptor coactivator 2) has been suggested to be an 
8q target gene, but it is located at 8q13, an area that is not commonly amplified 
(Taylor et al. 2010). 
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Figure 2: Minimal common regions of copy number aberrations of chromosome 8. Bars 
represent regions of gains according to the different studies and boxes are 
common minimal areas of gains. (Adapted from: Saramäki et al. 2007) 
1.1.3 Early events 
High-grade PIN is thought to be the pre-malignant lesion preceding prostatic 
adenocarcinoma. PIN is characterized by cellular proliferation and cytologic 
changes that mimic cancer. However, the basal cell layer is still present in PIN, 
whereas it is absent in adenocarcinoma. Additionally, PIN does not cause elevated 
PSA levels (Bostwick & Brawer, 1987; Meiers et al. 2007). 
Some of the genetic and epigenetic aberrations identified in cancer samples are 
present in PIN lesions; these may represent gatekeeper alterations for prostate 
cancer initiation.   
GSTP1 (glutathione S-transferase pi 1) promoter hypermethylation is one of the 
earliest events identified in prostate cancer progression (Lee et al. 1994; Maruyama 
et al. 2002). GSTP1 is a detoxifying enzyme that inactivates electrophilic 
carcinogens by conjugating them with glutathione. As such, GSTP1 is thought to be 
a caretaker gene wherein its inactivation makes prostate cells more vulnerable to 
somatic aberrations.  GSTP1 hypermethylation is detected in 70% of PIN and 90% 
of primary tumors and therefore is one of the most frequently observed aberrations 
(Meiers et al. 2007). Genetic instability is also caused by telomere shortening, 
which is detected in PIN lesions (Meeker et al. 2002).  
APC (adenomatous polyposis coli) hypermethylation has also been reported to 
occur in 30% of PIN and 55-85% of prostate cancer samples (Kang et al. 2004; 
Yegnasubramanian et al. 2004). APC, a known tumor suppressor gene in colon 
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cancer, regulates a variety of downstream targets, including Wnt signaling, β-
catenin and MYC (He et al. 1998; Fodde et al. 2001). 
1.1.3.1 NKX3.1 down-regulation 
Transcription factor NKX3.1 (NK3 homeobox 1) is a key regulator of the 
differentiation of the prostate epithelium. It is one of the earliest markers for 
prostate development during embryogenesis, and it continues to be expressed 
throughout all stages of prostate differentiation and adulthood. Studies indicate that 
NKX3.1 functions as transcriptional repressor, and number of its effects is 
determined by interacting with various proteins (Abate-Shen et al. 2008). Since the 
initial cloning of NKX3.1, it has been evident that NKX3.1 is positively regulated by 
androgens (He et al. 1997). In addition, expression levels of NKX3.1 are 
significantly reduced upon castration (Sciavolino et al. 1997). However, proximal 
promoter of NKX3.1 is non-responsive to androgens. Recent study suggests that AR 
is recruited to androgen responsive elements (AREs) located in 3´UTR of NKX3.1, 
leading to positive transcriptional activity (Thomas et al. 2010).   In addition, it has 
been shown that NKX3.1 can associate with the AR promoter and inhibit AR 
activity, forming a negative feedback loop (Lei et al. 2006).  
 NKX3.1 maps to the 8p21 chromosomal region that frequently undergoes allelic 
loss during the early stage of prostate cancer and in high grade PIN (Emmet-Buck et 
al. 1995; Vocke et al. 1996; Häggman et al. 1997; Asatiani et al. 2005; Bowen et al. 
2000). Mutations of the remaining NKX3.1 allele are not observed (Voeller et al. 
1997; Ornstein et al. 2001), and it appears that some expression remains in prostate 
tumors (Gurel et al. 2010). In addition, there is evidence of epigenetic down-
regulation of NKX3.1, perhaps through promoter methylation (Asatiani et al. 2005). 
In vivo mouse studies have revealed that homo- or heterozygous deletion of 
Nkx3.1 leads to the development of PIN-like lesions (Kim et al. 2002a), and 
together with the loss of Pten or cdkn1b (cyclin-dependent kinase inhibitor 1B), 
these mice develop adenocarcinoma. As deletion of only one allele of Nkx3.1 leads 
to the phenotype, Nkx3.1 appears to function as a haploinsufficient tumor 
suppressor gene (Kim et al. 2002b; Abate-Shen et al. 2003; Gary et al. 2004). In 
addition, it has been demonstrated that NKX3.1 target genes are sensitive to 
NKX3.1 dosage in a stochastic manner (Magee et al. 2003). 
Mouse studies demonstrated that Nkx3.1 loss-of-function leads to an impaired 
response to oxidative damage (Ouyang et al. 2005). Studies with cell lines suggest 
that NKX3.1 plays a role in maintaining DNA integrity in prostate epithelial cells 
(Bowen & Gelmann, 2010). In conclusion, NKX3.1 down-regulation may 
predispose premalignant prostate tissue to the accumulation of mutations. 
 
 
20 
1.1.3.2 ETS translocations 
Translocations are a relatively recent finding in prostate cancer. In 2005, Tomlins et 
al. described the fusion between the promoter region of the androgen-regulated gene 
TMPRSS2 (transmembrane protease, serine 2) and the truncated form of the ETS 
(avian erythroblastosis virus E26 homolog) transcription factor family member ERG 
(v-ets erythroblastosis virus E26 oncogene homolog (avian)) that results in 
androgen-driven overexpression of ERG.  
After that initial discovery, several novel fusions have been reported, primarily 
between different ETS family members (ERG, ETV1, ETV4, ETV5 and ELK4) and a 
diverse set of 5´ upstream fusion partners, many of which are androgen-responsive. 
For example, fusions have been observed between ERG and SLC45A3 (solute 
carrier family 45, member 3), HERPUD1 (homocysteine-inducible, endoplasmic 
reticulum stress-inducible, ubiquitin-like domain member 1), FKBP5 (FK506 
binding protein 5) and NDRG1 (N-myc downstream regulated 1) (Pflueger et al. 
2011; Rubin et al. 2011). AR signaling is hypothesized to be mechanistically 
involved in the formation of the TMPRSS2:ERG fusion because it brings the 
TMPRSS2 and ERG genes in close proximity and potentially induces DNA double-
strand breaks and facilitates the subsequent recombination event (Lin et al. 2009; 
Mani et al. 2009; Haffner et al. 2010). 
The TMPRSS2:ERG fusion is the most common and appears to be an early event 
in prostate cancer tumorigenesis. It has been detected in 15% of high-grade PIN 
lesions and in 30-70% of localized prostate cancers (Tomlins et al. 2005; Perner et 
al. 2006 & 2007; Mosquera et al. 2008 & 2009; Saramäki et al. 2008). Other fusions 
are less studied but are likely present in fewer than 10% of prostate cancers (Mehra 
et al. 2007; Rubin et al. 2011). Attempts to identify an association between the 
TMPRSS2:ERG fusion and patient prognosis have produced conflicting data. While 
most of the studies report an association between the fusion and poor prognosis, 
other studies found no such clinical association or identified an association with 
favorable prognosis (Perner et al. 2006; Demichelis et al. 2007; Mehra et al. 2008; 
Attard et al. 2008a; Saramäki et al. 2008; Hermans et al. 2009; Leinonen et al. 
2010; Toubaji et al. 2011). Translocations are present at the same frequency in 
advanced tumors as in primary tumors, indicating that clonal selection for the fusion 
does not occur at later stages of prostate cancer progression (Perner et al. 2007; 
Saramäki et al. 2008). 
The functional significance of the TMPRSS2:ERG fusion has been analyzed in 
vivo and in vitro. Loss-of-function and gain-of-function studies in prostate cancer 
cell lines have revealed that TMPRSS2:ERG promotes an invasive phenotype, 
without an effect on proliferation (Klezovitch et al. 2008; Tomlins et al. 2008). 
ERG induces metalloproteinase and plasminogen activator pathway genes, such as 
MMP3 (matrix metallopeptidase 3), PLAT (plasminogen activator, tissue) and 
PLAU (plasminogen activator, urokinase), in prostate cancer cells. ERG silencing 
also increase expression of genes associated with differentiated luminal prostate 
epithelial cells, suggesting that ERG expression may be involved in maintaining de-
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differentiated state of prostate cancer cells (Tomlins et al. 2008). This idea is 
supported with study by Yu et al., which demonstrated that ERG is direct activator 
of polycomp group protein EZH2 (Enhancer of zeste homolog 2), which induces de-
differentiation program in the cells (Yu et al. 2010).  
Although genetic rearrangement of ERG is considered to be early event in 
prostate cancer progression, it is rarely found from PIN lesions and thus it does not 
seem to be initiative event in prostate carcinogenesis (Mosquera et al. 2008; Carver 
et al. 2009; King et al. 2009). It has been shown that in human prostate tumors, 
PTEN  loss is enriched for ERG rearrangement. It has been hypothesized, that PTEN 
loss and ERG rearrangement are concomitant events (Carver et al. 2009; King et al. 
2009). In vivo, expression of TMPRSS2:ERG alone is insufficient to induce 
neoplasia in mice, resulting subtle phenotype of hyperplasia and PIN (Tomlins et al. 
2008; Carver et al. 2009). Pten heterozygous mice develop high-grade PIN with 
increased proliferation, but no adenocarcinoma (Di Cristofano et al. 1998). 
However, in Pten null mice, Erg expression results in high-grade PIN and invasive 
carcinoma, suggesting that these two events cooperate in prostate tumorigenesis 
(Klezovitch et al. 2008; Tomlins et al. 2008; Carver et al. 2009; King et al. 2009).  
1.1.4 Androgen receptor signaling  
1.1.4.1 Normal functions of AR 
The normal prostate is dependent on androgens, acting through the androgen 
receptor (AR), for its development, maintenance and physiological function 
(Heinlein & Chang, 2004).  
AR belongs to a family of nuclear transcription factors that mediate the action of 
steroid hormones. Without a ligand, AR is primarily localized in the cytoplasm 
associated with heat-shock proteins (HSP), cytoskeletal proteins and chaperones. 
The AR protein contains four domains: the ligand-binding domain, the DNA-
binding domain, the hinge region and the N-terminal domain. The ligand-binding 
domain of AR undergoes a conformational change upon binding to androgens, such 
as testosterone and the more potent dihydrotestosterone (DHT). This conformational 
change enables AR to dissociate from HSP and to interact with diverse co-
regulators. These interactions facilitate the dimerization and nuclear localization of 
AR (Dehm & Tindall, 2007). In the nucleus, AR binds via its DNA-binding domain 
to specific DNA sequences, termed androgen responsive elements (ARE), in the 
promoter and regulatory regions of AR target genes. Together with coactivators and 
collaborating transcription factors, AR triggers the transcription of target genes 
(Hodgson et al. 2011). 
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1.1.4.2 AR function in prostate cancer 
AR signaling is crucial to prostate cancer development as evidenced by the fact that 
men castrated early in life do not develop prostate cancer (Isaacs, 1994). AR 
signaling is maintained during all stages of prostate cancer including castration-
resistant disease (Ruizeveld de Winter et al. 1994; Hobisch et al. 1995; Visakorpi et 
al. 1995a; Linja et al. 2001).  
In the normal prostate, AR specifies the lineage-specific differentiation of 
prostate cells by inducing the expression of prostate-specific genes and maintaining 
the differentiated prostate epithelium phenotype (Heinlein & Chang, 2004). By 
contrast, cellular de-differentiation is observed in malignant cells. There is a shift in 
both AR activity and its target genes, which converts AR from a pro-differentiation 
to a pro-proliferation factor during prostate cancer progression (Nelson et al. 2002; 
Wang et al. 2009c).  
One mechanism hypothesized to contribute to altered AR function is AR 
reprogramming by other transcription factors. Cell linage-specific factors may have 
an important regulatory role in establishing the proper environment for AR 
recruitment to the chromatin; one such factor is FOXA1 (forkhead box A1), which 
acts as a pioneering transcription factor that engages chromatin prior to other 
transcription factors (Kaestner, 2010). FOXA1 binding sites are proximally located 
to AR binding sites, and FOXA1 interacts with the DNA-binding domain of AR 
(Gao et al. 2003; Lee et al. 2008). FOXA1 was reported to prevent AR from binding 
to specific AR binding sites, thereby revealing a mechanism by which altered 
FOXA1 expression may contribute to the regulation of AR-mediated signaling 
pathways in prostate cancer. Silencing FOXA1 in prostate cancer cells increased AR 
binding to genes involved in hormonal signaling and cell proliferation (Sahu et al. 
2011). In addition, strong nuclear expression of FOXA1 protein is associated with 
increased prostate cancer mortality (Sahu et al. 2011; Wang et al. 2011a). ETS 
transcription factors may also modulate AR binding to DNA. ETS motifs are 
enriched at AR binding sites, and almost half of the areas in the genome that 
recruited AR also recruited ETS family member ERG (Massie et al. 2007; Yu et al. 
2010). Overexpression of the ETS and FOXA1 transcription factors may be a 
mechanism for reprogramming AR to drive the expression of oncogenes rather than 
genes important for maintaining the differentiation status of the prostate epithelium 
(Yu et al. 2010; Sahu et al. 2011; Wang et al. 2011a). 
1.1.4.3 AR function in CRPC 
The molecular mechanisms responsible for the emergence of CRPC are not 
completely understood. The most consistent finding in CRPC is a universal 
upregulation of AR, and it is known that increased AR expression is necessary and 
sufficient to convert cells from an androgen-dependent to an androgen-independent 
state (Chen et al. 2004; Holzbeierlein et al. 2004; Stanbrough et al. 2006). High 
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expression levels, increased stability, and nuclear localization of AR sensitize 
prostate cancer cells to low androgen levels and enable cell survival in such 
environments (Gregory  et al. 2001; Waltering et al. 2009). There are multiple 
mechanisms that sustain active AR signaling under androgen-depleted conditions. 
AR can be activated via mutations, alterations in coregulators, and increased 
intratumoral androgen production as well as via mechanisms leading to ligand-
independent activity (Shen & Abate-Shen, 2010). 
Copy number amplification of the AR gene is detected in one-third of CRPCs, but 
is undetectable in primary tumors, suggesting that this amplification is a by-product 
of hormone therapy (Visakorpi et al. 1995a; Koivisto et al. 1997; Linja et al. 2001). 
Gain-of-function mutations increase AR activity; mutations in AR are rare in 
untreated tumors, but their prevalence increases during disease progression. The 
highest frequency of AR mutations is detected in antiandrogen-treated patients, with 
10-30% harboring mutated AR (Linja & Visakorpi, 2004).  
 Alternative splicing of AR was recently identified as a mechanism for AR 
activation. AR gene spans 180kb of DNA and contains 8 canonical exons. Recently, 
cryptic exons that locate within introns flanking the canonical exons have been 
described (Figure 3). First AR splice variants were discovered in 2002 when 
truncated AR was observed (Tepper et al. 2002). Since initial discovery, numerous 
AR splice variants have been described.  Most variants lack the ligand-binding 
domain partially or entirely and majority also lacks the hinge region, which contains 
nuclear localization signal. In addition, many variants have unique sequences 
encoded by cryptic exones corresponding to introns 2, 3 and 3´ untranslated region 
(3´ UTR) of the full length AR (fl-AR) (Figure 3) (Haile & Sadar, 2011). Functional 
studies indicate that deletion of LBD results in a constitutively active AR (Jenster et 
al. 1991). Still, clinical relevance of the AR variants is not established. Many of the 
variants are expressed in both malignant and non-malignant cells but at higher levels 
in tumors and upon castration. In addition, the expression of certain variants is 
associated with poor prognosis after radical prostatectomy (Haile & Sadar 2011).  
AR interacts with coregulatory proteins to assemble a productive transcriptional 
complex (Bennett et al. 2010). Cofactor imbalance has been suggested to be 
involved in the development of CRPC. The overexpression of AR coactivators has 
been reported, but only in a small number of samples (Fujimoto et al. 2001; 
Agoulnik et al. 2006; Mäki et al. 2006 & 2007; Zou et al. 2009). Genetic alterations 
affecting AR coregulators appear to be rare (Hodgson et al. 2011). 
In androgen deprivation therapy, serum androgen levels are depleted, which 
induces de novo androgen production in prostate tumors. In an androgen-depleted 
environment, prostate cancer cells up-regulate the enzymes necessary for steroid 
synthesis. It has been suggested that CRPCs synthesize sufficient androgens to 
activate AR (Stanbrough et al. 2006; Locke et al. 2008; Montgomery et al. 2008). 
It has been demonstrated in vitro and in mouse studies that AR negatively 
regulates itself via a negative feedback loop (Quarmby et al. 1990; Shan et al. 1990; 
Krongrad et al. 1991). AR binds to an AR binding site within the promoter of the 
AR gene in response to androgen stimulation and withdrawal. In CRPC, it has been 
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hypothesized that AR escapes AR-mediated regulation, leading to increased AR 
mRNA expression (Cai et al. 2011). 
 
 
 
Figure 3: Structure of AR mRNA with exones marked with numbers. Cryptic exones are 
indicated in gray. Structure of full length AR (fl-AR) mRNA after splicing and AR 
protein product. NTD, N-terminal domain; DBD, DNA binding domain; LBD, 
ligand binding domain; HR, hinge-region. (Adapted from Haile & Sadar, 2011) 
1.1.4.4 Therapeutic strategies of targeting AR pathway 
Prostate cancer cells are dependent on AR pathway. This dependency has been the 
basis for treatment of prostate cancer for decades. AR functions are mediated by its 
ligands, testosterone and DHT. Testosterone is produced from the testicles, in 
response to luteinizing hormone (LH), which is synthesized in the anterior pituitary. 
For the synthesis and release of LH, pulsative stimulus of gonadotropin releasing 
hormone (GnRH), produced from hypothalamus, is needed (Conn & Crowley, 
1994). Testosterone is the primary circulating androgen in men, but in the prostate it 
is converted to more potent DHT by intracellular enzyme 5α-reductase (Zhu & 
Imperato-McGinley, 2009).  
 Androgen synthesis in the testicle can be blocked with GnRH agonists, which 
induce regulatory changes and inhibit LH release. There are several GnRH agonists 
available, including goserelin and leuprolide. Also GnRH antagonists are available, 
which binds directly to the GnRH receptor in the pituitary blocking the release of 
LH. GnRH agonists and antagonist effectively block testicular testosterone 
production. However, testosterone is produced also the andrenal glands under 
independent control (Tammela, 2012). 
Antiandrogens inhibit androgen action by binding to the ligand-binding pocket of 
AR and by that blocking the interaction with AR and DHT. There are several 
antiandrogens available, bicalutamide, flutamide and nilutamide are non-steroidal 
antiandrogens and cyproterone acetate is steroidal antiandrogen, which also inhibits 
the release of LH. However, these agents show relatively low affinity for AR as 
compared to DHT and they have shown to have agonistic effects in some 
circumstances (Tammela, 2012). MDV3100 is novel AR antagonist, currently in 
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clinical trials, which binds to AR with a 4- to 8 fold higher affinity than 
bicalutamide. It also inhibits AR nuclear translocation and DNA binding and do not 
seem to have agonistic activity (Tran et al. 2009). MDV3100 have shown to have 
antitumor activity in patients with CRPC in phase I-II studies (Scher et al. 2010). 
Abiraterone acetate is another novel drug. It targets androgen biosynthesis by 
selectively inhibiting CYP17 (cytochrome P450, family 17), an enzyme which 
catalyzes androgen synthesis from its precursors. It inhibits both testicular-derived 
androgen production and tumor-derived androgen synthesis (Attard et al. 2008b). 
Abiraterone prolonged the survival of patients with metastatic prostate cancer (de 
Bono et al. 2011).  
Despite of initial response to androgen deprivation therapy, advanced prostate 
cancer eventually progress to CRPC. CRPC often remain responsive to second line 
hormonal therapies, and it is still dependent on AR pathway (Tammela, 2012). 
However, none of these therapies are curative and median survival of patients with 
CRPC is 9 to 30 months (Kirby et al. 2011). 
1.1.5 MYC 
MYC is a transcription factor that plays a key role in regulating numerous cellular 
processes, including cell cycle progression, metabolism, ribosome biogenesis, 
protein synthesis, mitochondrial function, and stem cell renewal. Overexpression of 
MYC is detected in numerous tumor types, particularly those harboring genetic 
alterations (Albihn et al. 2010). 
In prostate cancer, MYC up-regulation at the mRNA level has been confirmed by 
numerous mRNA microarrays and qPCR experiments. MYC up-regulation has been 
detected in a majority of primary prostate cancers (Koh et al. 2010). At the protein 
level, MYC is subject to tight posttranscriptional regulation (Adhikary & Eilers, 
2005). However, studies on MYC protein expression are controversial due to the 
lack of a suitable antibody (Koh et al. 2010). MYC protein has been reported to be 
overexpressed in localized primary prostate tumors and metastatic tumors as well as 
in PIN lesions (Jenkins et al. 1997; Gurel et al. 2008). 
MYC is located at 8q24, which is frequently gained in prostate cancer (Jenkins et 
al. 1997; Visakorpi et al. 1995b; Nupponen et al. 1998a; Cher et al. 1994). Gain of 
8q24 is strongly associated with poor prognosis (Sato et al. 1999; El Gammal et al. 
2010; Ribero et al. 2006, 2007; van Dekken et al. 2003; Barros-Silva et al. 2011). A 
gain of 8q is observed in 70% of CRPCs, and MYC amplification is present in one-
third of these tumors (Saramäki et al. 2001; Nupponen et al. 1998a). However, 
amplification of MYC does not correlate with its expression level, indicating that 
amplification is not the primary mechanism for increasing MYC expression 
(Savinainen et al. 2004; Gurel et al. 2008). In addition, the gain of 8q24 is rare in 
localized prostate tumors, where MYC overexpression is common. Although none 
have been yet established, other mechanisms for MYC up-regulation have been 
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suggested, including APC inactivation (He et al. 1998; Yegnasubramanian et al. 
2004; Kang et al. 2004) and FOXP3 (forkhead box P3) down-regulation (Wang et 
al. 2009a).  
Prostate epithelial cells are transformed by overexpressing MYC (Gil et al. 2005; 
Williams et al. 2005). In addition, transgenic mice overexpressing Myc in prostate 
epithelial cells develop adenocarcinoma (Iwata et al. 2010; Ellwood-Yen et al. 
2003). 
MYC regulates several genes that are known to be involved in prostate cancer 
tumorigenesis. MYC has been suggested to negatively regulate NKX3.1 and to 
positively regulate EZH2 via direct or indirect mechanisms (Iwata et al. 2010; Koh 
et al. 2011). In addition, PIM1, whose overexpression in prostate cancer correlates 
with poor clinical outcome, synergizes with MYC in prostate cancer progression. 
PIM1 has been reported to enhance MYC transcriptional activity and to regulate 
several MYC target genes (Kim et al. 2010; Zippo et al. 2007; Wang et al. 2010 & 
2011b). In addition, MYC tumorigenicity is in part due to its ability to regulate 
miRNAs, which will be discussed later (Dews et al. 2006). 
1.1.6 PI3K pathway and PTEN 
The PI3K (phosphatidylinositol 3-kinase) signaling pathway is important in prostate 
cancer progression because approximately 40% of primary and 70% of metastatic 
prostate cancers contain genomic alterations in this pathway (Taylor et al. 2010). 
PI3K pathway is driver of cell proliferation and cell survival. When pathway is 
activated, it creates a second messenger lipid phosphatidylinositol (3,4,5) 
trisphosphate (PIP3), which recruits downstream signaling cascade. AKT (v-akt 
murine thymoma viral oncogene) mediates signals downstream of PI3K activation. 
Substrates of AKT phosphorylation have crucial role in cell-cycle regulation. In 
addition, PI3K pathway interacts with other signaling networks (Cully et al. 2006). 
One major player in PI3K signaling is the tumor suppressor PTEN, which 
negatively regulates the activity of the PI3K pathway. PTEN is one of the most 
frequently mutated tumor suppressors in human cancer. PTEN germ line mutations 
cause a group of autosomal dominant syndromes, called PTEN hamartoma tumor 
syndrome, which are characterized by increased risk for several cancers among 
other deficits (Hobert & Eng, 2009). Mouse models have shown that in some tissue 
types Pten deletion is sufficient to cause tumorigenesis alone but frequently Pten 
deletion contributes to tumorigenesis with other genetic alterations. PTEN is a lipid 
phosphatase which dephosphorylates its targets. Tumor suppressor function of 
PTEN requires functional phosphatase domain, however, other functions of PTEN 
may be important but yet less studied (Hollander et al. 2011).  
PTEN is inactivated in a wide variety of cancers, including prostate cancer (Li et 
al. 1997; Steck et al. 1997; Salmena et al. 2008). The substrates for PTEN 
dephosphorylation are products (PIP2 and PIP3) of PI3K, which when 
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phosphorylated, activate the PI3K pathway (Maehama & Dixon, 1998). PTEN-null 
cells are shown to harbor constitutively activated AKT (Sun et al. 1999). AKT 
activates downstream targets involved in survival, proliferation, cell cycle 
progression, growth, migration, and angiogenesis. In addition, expression of PTEN 
induces cell cycle arrest, inhibits cell adhesion and motility and triggers apoptosis 
(Persad et al. 2000; Pourmand et al. 2007; Davies et al. 1999).  
PTEN also has AKT-independent functions, such as increasing the protein 
stability, expression level and transcriptional activity of the tumor suppressor TP53 
(tumor protein p53, also called p53) and regulating cell cycle arrest through cyclin 
D interactions (Chang et al. 2008a; Radu et al. 2003).  
PTEN maps to the chromosomal region 10q23 that frequently undergoes copy 
number deletion (Lundgren et al. 1988; Cairns et al. 1997). PTEN loss has been 
reported to occur in a subset of high grade PIN, suggesting a role for PTEN in 
prostate cancer initiation (Bettendorf et al. 2008). It has been suggested that PTEN 
is a haploinsufficient tumor suppressor. Recent mouse studies demonstrated that 
even a subtle reduction in Pten expression promoted cancer susceptibility, thereby 
adding more complexity to the notion of haploinsufficiency (Alimonti et al. 2010). 
Primary tumors possess heterogeneous PTEN protein expression; however, disease 
progression is associated with an increased frequency of PTEN loss (Halvorsen et 
al. 2003; McMenamin et al. 1999; Fenic et al. 2004). The highest frequency of 
PTEN loss or mutation occurs in metastatic tumors, of which approximately 40% 
contain PTEN alterations (Pourmand et al. 2007; Taylor et al. 2010). Furthermore, 
dysregulation of the PTEN/PI3K pathway has been associated with resistance to 
anti-androgen therapies, and mouse studies have indicated a potential role for Pten 
in castration-resistance (Ham et al. 2009; Zhang et al. 2009).  
Numerous key proteins have been hypothesized to cooperate with PTEN loss in 
prostate cancer progression, including TMPRSS2:ERG, NKX3.1, MYC and AR 
(Carver et al. 2009 & 2011; King et al. 2009; Lei et al. 2006; Kim et al. 2009). 
There is bidirectional crosstalk between the AR and PI3K pathways, illustrated in 
Figure 4. PI3K pathway activation by PTEN-deficiency represses AR signaling in 
mouse and also in human prostate cancers. On the other hand, when PI3K pathway 
is inhibited, the AR is activated. (Carver et al. 2011). AR-mediated AKT inhibition 
occurs via activation of PHLPP1 (PH domain and leucine-rich repeat protein 
phosphatase 1), which dephoshorylates AKT. PHLPP1 is a novel tumor suppressor 
gene located in chromosome 18q21 and often deleted in metastatic prostate cancer 
(Brognard et al. 2007; Gao et al. 2005; Chen et al. 2011). Activation of PHLPP1 by 
AR occurs via AR target gene FKBP5 (FK506 binding protein 5), which in turn 
stabilizes PHLPP1 (Carver et al. 2011). It has been hypothesized that PI3K pathway 
activation may be sufficient to compensate for the blockade in AR signaling during 
androgen ablation therapy, thereby promoting CRPC development (Mulholland et 
al. 2011).  
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Figure 4: Simplified illustration of PI3K pathway crosstalk with AR pathway and PTEN PI3K 
independent functions. The mechanisms are described in detail in the text.  
1.1.7 Metastatic prostate cancer 
Metastatic prostate cancer is the lethal form of the disease. The 5-year survival rate 
for prostate cancer patients with distant metastasis is 30% compared with 
approximately 100% for patients with localized cancer (Jemal et al. 2010). Prostate 
cancer metastasizes to distant organs, including the liver, lungs and brain, with a 
very high predilection for metastasizing to the bone (Bubendorf et al. 2000).  
The formation of metastases is complex; cells must first disseminate from their 
primary location and degrade local stroma, then escape into and survive in the blood 
or lymphatic circulation, and finally hone to a metastatic location. At a distant site, 
the cells must induce neovascularization and proliferate to create a secondary mass 
(Arya et al. 2006). Prostate cancer cells have the ability to metastasize early during 
tumor formation as evidenced by the presence of disseminated cancer cells in the 
bone marrow of the majority of patients with low-grade cancer (Morgan et al. 
2009). It has been reported that metastatic prostate cancer is clonally related, 
indicating a monoclonal origin that differs from the vast heterogeneity of primary 
tumors (Liu et al. 2009a). 
The molecular mechanisms underlying prostate cancer metastasis are poorly 
understood. Cell adhesion molecules must be down-regulated to disrupt cell-cell 
interactions, and protease expression is necessary to degrade the surrounding 
stroma. E-cadherin down-regulation and N-cadherin up-regulation are associated 
with prostate cancer progression (Gravdal et al. 2007; Jaggi et al. 2005). Decreased 
cell-cell adhesion is involved in the epithelial mesenchymal transition (EMT) that 
leads to the development of a more invasive and migratory phenotype in epithelial 
cells. uPA (plasminogen activator, urokinase, also known as PLAU), a serine 
protease family member involved in extracellular matrix degradation, is 
overexpressed in a subset of prostate cancers and its expression has been shown to 
correlate with prostate cancer aggressiveness (Gaylis et al. 1989; Van Veldhuizen et 
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al. 1996; Cozzi et al. 2006). In addition, uPa amplification has been detected in 
prostate cancer cell lines and castration-resistant disease (Helenius et al. 2001). 
Promoter demethylation is another mechanism proposed for increasing uPA 
expression (Pulukuri et al. 2007). 
Metastatic disease is treated by androgen deprivation therapy. These therapies 
can inhibit the disease for several years, but eventually the cancer progresses and 
CRPC arises. In CRPC, many AR-regulated genes, such as KLK3 (PSA) and 
TMPRSS2:ERG, are reactivated (Feldman and Feldman, 2001; Stanbrough et al. 
2006; Cai et al. 2009). Certain molecular changes are found exclusively in CRPC 
due to the adaptation or clonal selection of cancer cells able to exist in low androgen 
levels. For example, the gain of chromosome Xq, which contains the AR gene, is 
specific for CRPC (Cher et al. 1996). The role of AR in CRPC is discussed in more 
detail under the title “AR pathway”. However, the genes other than AR that drive 
CRPC formation are unknown.  
1.1.7.1 EZH2 
EZH2 is a polycomb group protein that catalyzes the trimethylation of histone H3 
lysine 27 (H3K27me3) and thereby represses gene transcription (Kirmizis et al. 
2004). Many genes involved in development, stem cell maintenance, and 
differentiation are targets of H3K27 methylation (Sparmann & van Lohuizen, 2006). 
EZH2 is frequently up-regulated in advanced prostate tumors, and one 
mechanism by which this occurs is through gene amplification (Varambally et al. 
2002; Saramäki et al. 2006). Other mechanisms leading to EZH2 overexpression in 
tumors involve regulation by miR-101 (discussed later) and ERG (Varambally et al. 
2008; Yu et al. 2010). ERG binds directly to the EZH2 promoter, which enhances its 
transcription and regulates the epigenetic silencing of EZH2 target genes (Yu et al. 
2010). 
EZH2 protein levels correlate with the aggressiveness of prostate cancer 
(Varambally et al. 2002; Laitinen et al. 2008). Target genes for EZH2-mediated 
epigenetic silencing include DAB2IP and E-cadherin (Chen et al. 2005; Cao et al. 
2008). Loss of DAB2IP promotes primary tumor growth by activating Ras signaling 
and metastasis by activating NF-κB (Min et al. 2010). In addition, EZH2 regulates 
the expression of several miRNAs, which will be discussed later.  
1.1.7.2 TP53 
TP53 is a transcription factor that is commonly inactivated in tumors by mutation of 
TP53 or inactivation of the TP53 signaling pathway. TP53 is essential for protecting 
the cell from DNA damage and oncogene activation. TP53 activates the 
transcription of genes that promote apoptosis, senescence and cell cycle arrest. 
Mutated TP53 have dominant-negative activity over the remaining wild-type allele. 
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In addition to losing tumor suppressive functions, many TP53 mutants also gain new 
oncogenic properties. These include inhibitory interactions with p63 and p73, 
thereby reducing their transcriptional activity.  Mutant TP53 is more stable than 
wild-type TP53 as evidenced by the nuclear accumulation of mutated protein 
(Brown et al. 2009). 
In prostate cancer, a discrepancy exists in the frequency at which TP53 mutations 
are detected. However, recent large-scale studies reached concordant results in 
finding that TP53 mutations in primary tumors are rare at approximately 5% 
(Schlomm et al. 2008; Agell et al. 2008). Much higher frequencies of TP53 
mutations were detected in metastatic (16%) and castration-resistant tumors (26%). 
In addition, TP53 mutations are independent predictors for biochemical relapse after 
radical prostatectomy (Schlomm et al. 2008; Visakorpi et al. 1992). Recent large-
scale genomic profiling of primary prostate tumors confirmed the low frequency of 
TP53 mutations. In contrast, homo- and heterozygous deletions of TP53 were 
present in 24% of the tumors, indicating that copy number loss is the primary 
mechanism for altering TP53 expression (Taylor et al. 2010). In vitro and in vivo 
studies demonstrated that mutant TP53 induces androgen-independent growth, 
indicating that TP53 may have a role in the development of castration-resistant 
tumors (Nesslinger et al. 2003; Vinall et al. 2006). 
1.1.8 miRNAs in prostate cancer 
1.1.8.1 microRNA biogenesis and target recognition 
microRNAs (miRNA, miR) are short (approximately 21 nucleotides), non-coding 
RNAs that function as endogenous negative regulators of gene expression. Figure 5 
illustrates miRNA biogenesis pathway. miRNAs are transcribed as long primary 
molecules (pri-miRNAs). These transcripts are subsequently processed by the 
enzyme Drosha into precursor miRNAs (pre-miRNA). These hairpin-structured 
molecules are exported to the cytoplasm for further processing into short, double-
stranded RNAs. One strand of this molecule represents the mature miRNA, which 
joins specific Argonaute proteins to form a complex called RNA-induced silencing 
complex (RISC). Within the RISC complex, miRNA guides the complex to the 
miRNA response element (MRE) located commonly in the 3’ UTR of the target 
mRNA (Krol et al. 2010). Individual miRNAs frequently target several transcripts, 
and individual genes can be targeted by multiple distinct miRNAs (Friedman et al. 
2009b). 
miRNAs regulate the expression of their targets by various mechanisms, 
including mRNA destabilization, translational repression and even activation of 
gene expression (Huntzinger & Izaurralde, 2011). Perfect pairing of miRNA to the 
target results endonucleotic cleavage of the mRNA by Argonaute (Yekta et al. 
2004). However, this mechanism is rare in animals. Other mechanisms for target 
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destabilization exist. miRNA binding to the target mRNA by imperfect pairing can 
make mRNA susceptible to exonucleolytic cleavage, by recruiting deadenylation 
factors that remove the polyA tail of the mRNA. There are also cases when miRNA 
binding reduces the protein level without an effect on mRNA. Detailed mechanisms 
for this are not fully known, there is evidence for inhibition of translation initiation 
or elongation and direct proteolysis of synthesized peptide (Huntzinger & 
Izaurralde, 2011). 
Identifying miRNA targets is challenging, mainly because of the limited 
complementary between miRNAs and their targets. Traditionally, miRNA binding 
sites are classified into three categories: 5´prime dominant sites have perfect pairing 
in the seed sequence located in positions 2-7 from the 5´ end of the miRNA and in 
addition, they have extensive base pairing in the 3  ´ end of the miRNA. Seed only 
sites have perfect pairing in the seed region and imperfect pairing in the 3’ end of 
the miRNA. 3´compensatory sites have a mismatch in the seed region but have a 
long stretch of base pairing in the 3´end of the miRNA (Min &Yoon, 2010). In 
addition to these three categories, also centered sites have been described, in which 
the middle region of miRNA makes perfect match with target mRNA (Pasquinelle, 
2012). 
 In silico algorithms uses these criteria to predict putative miRNA targets. 
However, these algorithms produce divergent predictions with degrees of false 
positives and false negatives (Min &Yoon, 2010). Bioinformatics analyses are often 
coupled with genetic or biochemical methods in order to identify miRNA targets. 
Silencing or transfecting miRNA to a cell line followed by analysis of altered 
phenotype by quantitative real-time PCR (qRT-PCR) or microarray is commonly 
used. When miRNA is silenced target mRNA should be up-regulated and vise versa. 
Also putative target can be knocked out or mutated which should mimic the 
phenotype obtained by miRNA expression. These methods are, however, unable to 
distinguish direct and indirect targets. Putative interaction between target mRNA 
and miRNA can be tested by fusing sequences containing target site to reporter gene 
and assaying for regulation in the presence or absence of the cognate miRNA 
(Pasquinelle, 2012). Recently, genome wide mechanisms to study endogenous 
miRNA target sites have been developed. These methods use ultraviolet light to 
crosslink RISC bound RNA to the complex, followed by immunoprecipitation of 
RISC and high-throughput sequencing of the RNAs bound with RISC complex 
(CLIP experiments) (Chi et al. 2009; Hafner et al. 2010). However, detection of 
mRNA binding to the RISC does not guarantee that it is actually being regulated by 
miRNA (Pasquinelle, 2012). 
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Figure 5.  MicroRNA biogenesis. miRNAs are transcribed by RNA polymerase II or III (Pol 
II/ Pol III) into primary miRNA (pri-miRNA) transcripts.  pri-miRNAs are cleaved 
by enzyme Drosha to form pre-miRNAs, which are exported to cytoplasm by 
Exportin 5. In the cytoplasm, RNase Dicer cleaves the pre-miRNA hairpin to its 
mature length.  The functional strand of the mature miRNA is loaded together 
with Ago proteins into RNA-induced silencing complex (RISC), where it guides 
RISC to silence target mRNAs (Adapted from Winter et al. 2009). 
1.1.8.2 Expression profiling of miRNAs 
The importance of miRNAs in cancer is highlighted by the observation that half of 
miRNAs are located in fragile sites in the genome, which are often altered in cancer 
(Calin et al. 2004). In addition, large-scale miRNA profiling has revealed a 
deregulation of miRNAs and the miRNA-processing machinery in cancer (Kumar et 
al. 2007; Calin & Croce 2006), and miRNA expression profile was demonstrated to 
better classify cancers than an mRNA expression profile (Rosenfeld et al. 2008). 
There are several reports on altered miRNA expression in prostate cancer. 
However, discrepancy is rampant in these studies, most likely because of the use of 
different expression platforms. The results of seven different expression profiles of 
primary prostate cancer are summarized in Table 1. miRNAs that were implicated in 
at least two different studies are included. In addition, only studies of more than 10 
primary cancer samples were taken into account (Volinia et al. 2006; Ambs et al.  
2008; Ozen et al. 2008; Tong et al. 2009; Schaefer et al. 2010; Carlsson et al. 2011; 
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Wach et al. 2012). The most consistently down-regulated miRNAs in primary 
prostate tumors were miR-145, miR-205, miR-221, miR-222 and miR-24; these 
were all down-regulated in at least three independent studies. The up-regulated 
miRNAs included miR-182, miR-25, miR-375 and miR-93.  
Fewer studies have been performed on advanced or metastatic disease, and the 
sample number is often limited. One of the most consistent findings is the down-
regulation of miR-145 in metastatic (Porkka et al. 2007; Peng et al. 2011; Watahiki 
et al. 2011) or aggressive tumors (Wang et al. 2009b). 
There is significant variation in the miRNAs that have been reported to have 
altered expression in prostate cancer. There are several possible reasons for the 
inconsistency. Sample selection and preparation may affect to the results. Freshly 
frozen samples are commonly used for miRNA studies, since in these samples RNA 
is least degraded. However, in some studies formalin-fixed, paraffin-empedded 
tissue specimen is used, in which RNA integrity is compromised (Tong et al. 2009; 
Carlsson et al. 2011; Watch et al. 2011; Evers et al. 2011).  Sample storage time and 
conditions, mainly temperature, also alters the RNA integrity, as well as different 
RNA extraction methods may give varying results (Evers et al. 2011). 
Prostatectomy specimen are often used for miRNA expression studies, these are 
usually from untreated patients. When metastatic and castration-resistant disease is 
studied, patients have been given different kind of therapeutic agents, which can 
cause variation the miRNA profile, especially in miRNAs involved in the AR 
pathway. One important factor is the selection of controls. In some studies, normal 
adjacent tissue is used (Schaefer et al. 2010; Carlsson et al. 2011), some have used 
matched controls from the same patients (Tong et al. 2009; Watch et al. 2011) and 
in some studies BPH is used as a control (Porkka et al. 2007; Ozen et al. 2007).   
There are several different platforms available for miRNA research; each has its 
own limitations. There is no gold-standard method for measuring miRNA 
expression. For the genome-wide miRNA expression profiling, array based methods 
are most commonly used. Short length of the miRNA causes challenges in array 
design, as the whole mature sequence is used as a probe. Consequently, melting 
temperatures of miRNA probes may vary >20º (Git et al. 2010). In addition, there 
are miRNA families, like let-7 family, in which different family members differ 
only by one nucleotide from each other (Boyerinas et al. 2010).  It has been recently 
discovered that miRNA isoforms exist. miRNAs can have sequence heterogeneity, 
mainly deletion/addition of nucleotide in 3´ or in 5´end or internal modifications 
(Ryan et al. 2010). Different platforms detect these variants differentially; in 
example Agilent miRNA microarray probes have loop in 3´end, which does not 
allow heterogeneity in 3´end (Wang et al. 2007). It should be also noted that 
annotations of mature miRNA sequences are updated frequently, according to the 
miRBase registry (Kozomara & Griffiths-Jones, 2011). This may explain some of 
the inconsistencies, especially when comparing older miRNA expression studies to 
the newer studies.  
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Table 1: Combined results of 7 independent miRNA expression profiling of primary 
prostate tumors 
miRNA ID Volinia Ambs Ozen Tong Schaefer Carlsson Wach 
Let-7b  down down     
let-7d up  down     
let-7i up up down     
miR-100    down  down  
miR-101 up      up 
miR-106a up      up 
miR-106b  up     up 
miR-125a  up down     
miR-125b   down down    
miR-128a  down down      
miR-141    up   up 
miR-143    down  down  
miR-145  down  down   down 
miR-149 down    down   
miR-16 up  down  down   
miR-17 up      up 
miR-181b up    down   
miR-182  up   up  up 
miR-191  up     up   
miR-195  up     down  
miR-196-1  up up      
miR-200b   down    up 
miR-200c  up    up  up 
miR-205  down  down down   
miR-20a up   up   up 
miR-21 up      up 
miR-214  up      down 
miR-221  down  down down  down 
miR-222    down down  down 
miR-24 down   down  down  
miR-25 up up  up    
miR-26a up up down   down  
miR-29a  up  down     
miR-30a   down   up   
miR-30b   down   down  
miR-30d   down   up   
miR-30e   down   up   
miR-31  up   down   
miR-32  up up      
miR-345  down    down  
miR-34a  up down down     
miR-375  up   up   
miR-92-2 up up     down 
miR-93 up up    up   
miR-99b   up down       up 
Appreviations: up, up-regulated; down, down-regulated; blank, regulation was insignificant 
or miRNA was not included in the study. (Volinia et al. 2006; Ambs et al.  2008; Ozen et al. 
2008; Tong et al. 2009; Schaefer et al. 2010; Carlsson et al. 2011; Wach et al. 2012) 
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1.1.8.3 Tumor suppressor miRs 
There are few miRNAs that have been confirmed to be functionally involved in 
prostate cancer tumorigenesis. miRNAs are classified as tumor suppressors when 
they target oncogenes and have decreased expression in cancer. 
The miRNA that has been reported most frequently to be down-regulated in 
prostate cancer is miR-205. When miR-205 expression was restored, prostate cancer 
cells underwent morphological changes and exhibited impaired migratory and 
invasive capabilities. The expression levels of E-cadherin and miR-205 correlated, 
and the serine/threonine kinase protein kinase C epsilon (PKCε) was identified as a 
target of miR-205. Interestingly, the same phenotype was observed after PKCε 
silencing and after miR-205 restoration (Gandellini et al. 2009).  PKCε have been 
linked to the regulation of diverse cellular functions, including cell growth, 
migration and malignant transformation (Griner & Kazanietz, 2007). In prostate 
cancer cells, PKCε expression has shown to be sufficient for transforming androgen 
dependent cells into androgen independent (Wu et al. 2002).  In addition, PKCε  
expression correlates with prostate cancer aggressiveness (Aziz et al. 2007). miR-
205 was also shown to up-regulate the tumor suppressor genes IL24 and IL32 by 
binding to their promoters (Majid et al. 2010).  
miR-145 has consistently been reported to be down-regulated in primary and 
metastatic prostate cancer. It has been demonstrated that miR-145 is expressed in 
response to stress via the PI3K/AKT and TP53 pathways. TP53 induces miR-145 
expression by interacting with the miR-145 promoter (Sachdeva et al. 2009; Suh et 
al. 2011). In prostate cancer cells that overexpress miR-145, increased cell cycle 
arrest and apoptosis are observed (Zaman et al. 2010). One mechanism for 
inactivating miR-145 in prostate cancer cell lines is promoter methylation (Suh et al. 
2011; Zaman et al. 2010). In colon and breast cancer cell lines, miR-145 directly 
targets the oncogene MYC and is therefore the mediator of the TP53-induced post-
transcriptional regulation of this particular oncogene (Sachdeva et al. 2009). In 
prostate cancer, the pro-apoptotic gene TNFSF10 (tumor necrosis factor (ligand) 
superfamily, member 10) and the actin-binding protein SWAP70 (SWAP switching 
B-cell complex 70kDa subunit) have been suggested as targets of miR-145 (Zaman 
et al. 2010; Chiyomaru et al. 2011). 
The miR-34 family has demonstrated tumor suppressive function in prostate 
cancer. miR-34a is down-regulated in CD44-positive cells, which are considered to 
be prostate cancer stem cells. Reduced expression of miR-34a in prostate cancer 
stem cells contributes to prostate cancer development and metastasis by regulating 
CD44 expression and their migratory, invasive and metastatic potential (Liu et al. 
2011). In addition, miR-34 family members have been identified as direct targets of 
TP53 that induce cell cycle arrest and apoptosis (Hermeking, 2010). Down-
regulation of miR-34c has been linked to prostate cancer aggressiveness (Hagman et 
al. 2010). 
miR-15a and miR-16 are transcribed as a cluster from genomic region 13q14, 
which is a region of frequent allelic loss in prostate cancer. Loss of 13q correlates 
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with tumor progression, and up to 90% of advanced tumors exhibit this particular 
loss (Hyytinen et al. 1999; Dong et al. 2001). The miR-15a-miR-16-1 cluster is 
commonly deleted in advanced prostate cancer; homozygous deletion has even been 
observed (Bonci et al. 2008; Porkka et al. 2011). In addition, down-regulation of 
miR-15a and miR-16 is detected in approximately 80% of tumor samples. 
Knockdown of miR-15a and miR-16 in prostate cancer cell lines and in mice 
resulted in enhanced proliferation, survival and invasion, indicative of their tumor 
suppressor function. BCL2 (B-cell CLL/lymphoma 2), CCND1 (encoding cyclin 
D1) and WNT3A (wingless-type MMTV integration site family, member 3A) have 
been hypothesized as target genes for miR-15a and miR-16 (Bonci et al. 2008; 
Cimmino et al. 2005). Recently, it was reported that the expression of miR-15 and 
miR-16 is decreased in cancerous stroma, and novel targets that mediate crosstalk 
between the stroma and the epithelium, such as FGF2 (fibroblast growth factor 2) 
and FGFR (fibroblast growth factor receptor), were identified (Musumeci et al. 
2011). 
miR-101 regulates histone methylation by targeting EZH2 (the role of EZH2 is 
discussed above). Overexpression of miR-101 attenuates cell migration, invasion 
and anchorage-independent growth. Expression of miR-101 is decreased in 
metastatic prostate cancers, and copy number loss of miR-101 has been identified in 
66% of metastatic prostate cancers, which leads to upregulation of EZH2 
(Varambally et al. 2008; Friedman et al. 2009a). In addition, EZH2 regulates 
miRNA expression by epigenetic silencing, repressing targets such as miR-181a, 
miR-181b, miR-200b, miR-200c and miR-203. Overexpression of these miRNAs in 
prostate cancer cells attenuates cell invasion and anchorage-independent growth 
(Cao et al. 2011). miR-449 has also been reported to influence epigenetic regulation 
by targeting histone deacetylase 1 (HDAC1), which is often up-regulated in prostate 
cancer (Noonan et al. 2009; Weichert et al. 2008). Decreased expression of miR-
449 is observed in prostate cancer, and reintroducing this miRNA into prostate 
cancer cells resulted in growth arrest and apoptosis (Noonan et al. 2009). 
1.1.8.4 OncomiRs 
Oncogenic miRNAs (oncomiRs) target tumor suppressor genes, and their expression 
is up-regulated in cancer. In prostate cancer, oncomiRs have been studied less than 
tumor suppressor miRNAs. 
The miRNA cluster encompassing miR-106b, miR-93, and miR-25 is transcribed 
together from the same genomic locus and targets the tumor suppressor PTEN 
(Poliseno et al. 2010). This miRNA cluster is located within the intron of the gene 
MCM7, which is overexpressed and amplified in prostate cancer (Ren et al. 2006). It 
has been suggested that these miRNAs cooperate with MCM7 in its tumorigenic 
functions. When mcm7 and the miRNA cluster were co-overexpressed, transgenic 
mice developed highly penetrant PIN with an onset and features similar to Pten 
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heterozygous mice. In contrast, MCM7 overexpression alone is not sufficient to 
drive oncogenesis in vitro or in vivo (Poliseno et al. 2010). 
Several oncogenic functions of MYC can be explained by the activation or 
suppression of miRNAs (Dews et al. 2006; Chang et al. 2008b). MYC activates the 
miR-17-92 cluster, comprised of six miRNAs (miR-17, miR-18a, miR-19a, miR-
20a, miR-19b-1, and miR-92a-1), that promotes cell proliferation and induces 
angiogenesis (Dews et al. 2006). Many of these miRNAs have been reported to be 
up-regulated in prostate cancer, including miR-17, miR-20a and miR-92 (Volinia et 
al. 2006; Ambs et al. 2008; Wach et al. 2012). In contrast, induction of MYC results 
in widespread repression of miRNA expression because MYC directly binds to the 
promoters or enhancers of target miRNAs. Some of these miRNAs are down-
regulated in prostate cancer, including miR-15a, miR-16 and miR-34a (Bonci et al. 
2008; Chang et al. 2008b; Hagman et al. 2010). 
1.1.8.5 miRNAs and AR 
AR transcriptionally regulates the expression of target miRNAs and is subject to 
miRNA-mediated gene silencing.  
miR-21 is involved in pathways critical for controlling tumorigenesis and is 
overexpressed in several tumor types, including prostate cancer (Pan et al. 2011). 
For example, miR-21 is induced by AP-1 (adaptor-related protein complex 1) in 
response to expression of the Ras oncogene (Talotta et al. 2009). In addition, several 
tumor suppressors are miR-21 targets, including PTEN and BCL-2 (Pan et al. 2011). 
In prostate cancer, ANP32A (acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member A) and SMARCA4 (SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 4), tumor suppressor genes involved in 
chromatin remodeling, are validated miR-21 targets (Schramedei et al. 2011). miR-
21 is induced by androgens in androgen-responsive prostate cancer cell lines; 
however, the expression of miR-21 is also elevated in AR-negative cell lines. AR 
up-regulates miR-21 by binding directly to the miR-21 promoter. In mice, miR-21 
overexpression improved tumor establishment, increased tumor growth and induced 
a castration-resistant phenotype (Ribas et al. 2009). 
Additional miRNAs that have been suggested to be androgen-regulated are miR-
125b, miR-141, miR-338 and miR-221. miR-125b was discovered to be 
overexpressed in AR-positive cell lines and is up-regulated in a subset of primary 
prostate tumors. Transfection of miR-125 enhanced cell growth in the absence of 
androgens, and AR was demonstrated to bind to the miR-125b promoter. The BCL-
2 family member BAK1 (BCL2-antagonist/killer 1) was identified as a target of 
miR-125b (Shi et al. 2007). miR-141 is regulated by androgens in prostate cancer 
cell lines and xenografts. Transfection of miR-141 enhanced the growth of prostate 
cancer cells under low androgen conditions. In addition, miR-141 is overexpressed 
in both primary and castration-resistant tumors (Waltering et al. 2011). Androgens 
up-regulated miR-338 and down-regulated miR-221 in androgen-responsive prostate 
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cancer cells. However, these miRNAs have not been further studied (Ambs et al. 
2008). 
 miRNAs that target AR are less studied. In a large-scale screen, miR-34a and 
miR-34c were reported to directly regulate AR by binding to its 3’UTR. In addition, 
the expression levels of miR-34a and miR-34c inversely correlate with AR 
expression in clinical samples (Östling et al. 2011). miR-34 family members are 
considered to have tumor suppressive functions (discussed above in more detail). 
1.2 Experimental models of prostate cancer 
1.2.1 Cell lines 
Human prostate cancer derived cell lines have been used extensively to study 
prostate cancer, particularly in terms of genetic deregulation. Today, there are more 
than hundred prostate cancer cell lines available (Prostate cancer cell line database, 
capcelllines.ca), most of them been derivatives from other cell lines. The 
characteristics of most commonly used cell lines are summarized in Table 2. Only 
the cell lines that appear to be adenocarcinoma are included.  
Two cell lines 22Rv1 and PC-346C are established from primary tumors. LAPC-
4 and LNCaP are from lymph node metastasis, MDA PCa 2a/2b, PC-3 and VCaP 
are from bone metastasis. These sites are most common and earliest sites for 
prostate cancer metastasis. Prostate cancer cells metastasize less frequently to brain 
or dura mater, which are the sites where DU145 and DuCaP cells are derived, 
respectively (van Bokhoven et al. 2004). 
One important feature of the cell lines are their androgen dependency. There are 
three types of prostate cancer cell lines: (1) Androgen dependent cell lines which 
require androgens for their growth, (2) androgen responsive cell lines which do not 
require androgens but show growth response in presence of androgens and (3) 
androgen independent cell lines that do not require androgens and do not response to 
androgens. LAPC-4 and PC-346C are most androgen dependent cell lines, of these; 
LAPC-4 requires the addition of androgens to its growth medium. LNCaP, 22Rv1, 
MDA PCa 2a and 2b, DuCaP and VCaP are androgen responsive cell lines. These 
cell lines express AR and many of the AR target genes, including PSA. However, 
many of the cell lines have mutation in AR ligand binding domain, which may alter 
to the response to other steroids. LAPC-4, PC-346C, DuCaP and VCaP have intact 
AR, VCaP and DuCaP also have amplification of the gene. DU145, MDA PCa 1 
and PC-3 cells do not express AR and are androgen independent (van Bokhoven et 
al. 2004; Saramäki et al. 2008).  
Prostate cancer is very heterogenic disease and also cell lines derived from 
prostate tumors show heterogenic DNA profile. Some of the cell lines exhibit some 
chromosomal abnormalities, which are not commonly found from prostate cancer. 
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For example, LAPC-4 has a loss of chromosome 16 and deletion at chromosome 
12p12, and some cell lines have lost Y-chromosome (PC-3, VCaP) (Sobel & Sadar 
2005a & 2005b). Cell lines often lack the common DNA alteration found from 
clinical tumors and that should be taken into consideration when selecting cell line 
for different research purposes. VCaP and DuCaP harbors common rearrangement 
found from prostate tumors, TMPRSS2:ERG (Tomlins et al. 2005). In addition, PC-
3 is the only cell line that has 8q amplification, which is found from high percentage 
of advanced prostate tumors (Nupponen et al. 1998b).   
1.2.2 Xenografts 
In addition to cell lines, xenograft models have been widely used in prostate cancer 
studies. Xenografts are created by transplanting human prostate tumors into nude 
mice. As they are human origin, xenografts are more likely to possess molecular 
events involved in prostate tumorigenesis than cell lines grown in flask. Xenografts 
are especially useful in studying chemotherapeutic responses, as well as genetic and 
molecular mechanisms leading to cancer. Xenografts allow the amplification of 
small amount of starting material and also enrichment of homogenous cell 
population from heterogeneous tumor sample (Sobel & Sadar, 2005b).  
Two commonly used xenograft series are called the LuCaP and PC xenografts. 
Some characteristics of different xenografts are summarized in Table 2. Most of the 
xenografts do not grow in vitro, and they are maintained by serial passage in mice. 
They represent heterogeneity of human prostate cancer, some are derived from 
primary tumors, still majority of them are derived from different metastatic sites.  
From some of the androgen dependent xenografts androgen-independent form is 
developed. This is done by implanting primary xenografts into castrated mice. These 
xenograft series are particularly useful of studying mechanisms to castration-
resistance (Corey & Vessella 2007; van Weerden et al. 2009).  
1.2.3 Mouse models 
Mice do not spontaneously develop prostate carcinoma. In addition, mouse prostate 
anatomy is different from human prostate anatomy. Still, a lot of work has been 
done to manipulate mouse so that they develop prostate cancer that mimics human 
disease (Valkenburg & Williams, 2011). A few of the most commonly used prostate 
cancer mouse models are shortly summarized here.  
The first generation prostate cancer models used transgenes that overexpress viral 
oncogenes, resulting aggressive disease that often leads to metastatic cancer. Among 
these models is well-studied TRAMP (transgenic adenocarcinoma of the prostate). 
TRAMP express both large and small SV40 antigen by prostate specific probasin 
promoter. Similarly, LADY model was created using probasin promoter, however, 
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driving only the expression of large SV40 antigen. TRAMP model develop 
aggressive prostate cancer very fast, in LADY model cancer is more slowly growing 
(Valkenburg & Williams, 2011). However, mice that overexpress SV40 large T-
antigen develop cancer with features of neuroendocrine differentiation, which 
makes these models clinically suitable only a small population of patients which 
develop prostate cancer of neuroendocrine origin (Chiaverotti et al. 2008).  
Second generation of prostate cancer models has used loss-of function mutations 
in candidate genes implicated in prostate cancer. These popular models have 
employed mutations in genes of interest, including Nkx3.1 and Pten. Heterozygotic 
Pten knock-out develops PIN. Also Nkx3.1 knockouts develop hyperplasia and PIN 
but no tumors are detected (Valkenburg & Williams, 2011). Several double knock-
outs have been reported, in which loss of Pten with other tumor suppressors leads to 
development of more aggressive prostate cancer, and these tumors suppressors are 
thought to cooperate in prostate cancer progression. These include Nkx3.1, p53 and 
p27 (di Cristofano et al. 2001; Kim et al. 2002b; Couto et al. 2009).  
One of the newest models for prostate cancer is TMPRSS2:ERG transgenic 
mouse. Fusion transcript is expressed under ARR2-Probasin promoter, which drives 
the expression prostate specifically. TMPRSS2:ERG mice do not develop prostate 
cancer, nor PIN. However, when TMPRSS2:ERG mice are crossed with Pten +/- 
mice, PIN and low grade adenocarcinoma is detected (Carver et al. 2009; King et al. 
2009).  The development of this kind of models will shed more light into function of 
oncogenes and tumor suppressor genes that are initially found from clinical prostate 
cancers, whether these genes are involved in the initiation, progression or invasion 
of prostate cancer. However, several limitations of mouse models should be 
considered when attempting to extrapolate research conclusions from mice to man. 
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Table 2: Summary of most commonly used cell line and xenograft models of 
prostate cancer 
Cell lines Derived from  AR status Important features 
LNCaP Lymph node  Androgen responsive, express AR (mutated) and PSA PTEN mutation 
LAPC-4 Lymph node  Androgen responsive/dependent, express AR (WT) and PSA p53 (mutated). Tumorigenic 
PC-346C primary PCa Androgen responsive/dependent, express AR (WT) and PSA 
Composed of  2 subpopulations of 
cells.WT p53. Low number of 
chromosomal abnormalities 
22Rv1 primary PCa  Androgen responsive, express AR (mutated) and PSA 
p53 (mutated). Do not form 
colonies in soft agar 
DuCaP  Dura mater tissue 
AR amplification, Androgen 
responsive, express AR (WT) and 
PSA  
Contain mouse stromal cells. 
TMPRSS2:ERG translocation, p53 
and Rb pos. Tumorigenic 
VCaP 
Bone metastasis 
from the same 
patient than DuCaP, 
AR amplification, Androgen 
responsive, express AR (WT) and 
PSA  
TMPRSS2:ERG translocation, 
ERG pos. Express p53 and Rb. 
Tumorigenic 
MDA PCa 1  Ascites fluid AI Highly tumorigenic 
MDA PCa 2a Bone  AI WT p53, p21, Bcl-2, Bax and Rb. Tumorigenic. 
MDA PCa 2b 
Bone, from the 
same patient than 
MDA PC 2a 
Androgen responsive WT p53, p21, Bcl-2 and Rb Tumorigenic 
PC-3 Lumbar vertebrae  AI , AR neg 8q amplification. Tumorigenic. PTEN deletion 
DU145 Brain  AI, AR neg Tumorigenic 
Xenografts Derived from  AR status Important features 
LuCaP 23 
series 
23.1 & 23.8 lymph 
node, 23.12 liver 
metastasis, all from 
the same patient 
All androgen sensitive, express 
PSA  
LuCaP 23.1 AI LuCaP 23.1 AI 
Androgen independent form of 
LuCaP 23.1, maintained in 
castrated mice 
LuCaP 35 Lymph node  WT AR, androgen response 8p deletion, PTEN neg 
LuCaP 35V LuCaP 35 AI, express high levels of AR AI variant of LuCaP 35. 
LuCaP 49 omentum fat  AI, AR neg, PSA neg neuroendocrine /small cell  PCa 
LuCaP 58, 78, 
81, 115 Lymph node  AR & PSA pos.  
LuCaP 73, 93, 
96 primary tumor 
LuCaP 73 & 96 are androgen 
sensitive, AR pos. LuCaP 93 AR 
neg, AI 
 
LuCaP 96 AI LuCaP 96 AI form of LuCaP 96  
LuCaP 70 Liver  Express AR and PSA  
LuCaP 77 Femur  Androgen sensitive, express AR and PSA  
LuCaP 86.2 Bladder  Express AR and PSA  
LuCaP 105 Rib metastasis Express AR and PSA  
PC-82, EW, 
310, 329 prostate 
Androgen dependent, express AR 
and PSA 
TMPRSS2:ERG fusion , PC-82 
PTEN mutation 
PC-135 prostate AI  
PC- 133 bone AI, AR neg PTEN deletion 
PC-295 lymph node Androgen dependent, AR pos PTEN mutation 
PC-324, 339, 
346, 346B TURP 
PC-324 and 339 AI, PC-346 and 
346B androgen responsive in PC-346 PTEN mutation 
PC-346I PC-346 AI derivative of 346  
PC-346BI PC- 346B AI derivative of 346B  
PC-374 skin androgen responsive, express AR and PSA 
TMPRSS2:ETV1 gene fusion, 
PTEN mutation 
PCa, prostate cancer; AR, androgen receptor; AI, androgen independent; PSA, prostate 
specific antigen; TURP, transurethral resection of the prostate; PTEN, phosphatase and 
tensin homolog (Vlietstra et al. 1998; Sobel & Sadar 2005a & 2005b; Hermans et al. 2006; 
Corey & Vessella 2007; Saramäki et al. 2008; van Weerden et al. 2009) 
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AIMS OF THE STUDY 
The aim of this thesis was to identify and evaluate novel protein-coding genes and 
miRNAs that are involved in prostate cancer progression. The specific aims were as 
follows:   
1. To study the function of the putative 8q amplification target genes EIF3H, 
RAD21, KIAA0186 and TCEB1 in prostate cancer cell lines. 
2. To study the miRNA expression profile in clinical prostate cancer samples to 
identify prognostically significant miRNAs. 
3. To identify and functionally characterize androgen-regulated miRNAs that 
are differentially expressed in castration-resistant prostate cancer. 
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MATERIALS AND METHODS 
1.1 Cell lines and clinical samples (I, II, III) 
PC-3, DU145, NIH 3T3, HEK 293T/17 and LNCaP cell lines were obtained from 
American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured 
under the recommended conditions. LNCaP-derived AR-overexpressing cells were 
created by transfecting LNCaP cells with empty pcDNA3.1 vector (LNCaP-
pcDNA3.1) or with pcDNA3.1 containing a cDNA corresponding to wild-type AR 
(LNCaP-ARhi overexpresses AR by 4- to 5-fold and LNCaP-ARmo overexpresses 
AR 2- to 3-fold) (Waltering et al. 2009). 
The clinical samples used in original communications I, II and III are 
summarized in Table 3. In total, 51 (BPH, PC, and CRPC) freshly frozen clinical 
specimens were used for quantitative RT-PCR in original communication I. Fifty-
four (5 BPH, 28 PC, 7 BPH-TURP and 14 CRPC) freshly frozen clinical samples 
were used for the microarray in original communication III. These samples partially 
overlapped and were obtained from Tampere University Hospital (TAUH). The 
microarrays in communication II were performed on 102 samples (11 NAP, 50 PC, 
3 LN-normal, 12 LN-PC, 4 BPH-TURP and 22 PC-TURP) obtained from the tissue 
bank of Erasmus University Medical Center. All samples were snap-frozen in liquid 
nitrogen and were confirmed histologically by H&E staining to contain more than 
60% cancerous or hyperplastic tissue. The non-tumor samples contained 0% tumor 
cells. NAP samples were considered “normal” in study II, even though they were 
derived from prostates with adjacent tumor epithelium.   
Altogether, 264 (170 PC and 94 CRPC) formalin-fixed, paraffin-embedded tissue 
microarray (TMA) samples were obtained from TAUH and used for 
immunohistochemistry (described in original communication III). 
The use of clinical material was approved by the Erasmus MC Medical Ethics 
Committee (study II) or the Ethical Committee of the Tampere University Hospital 
and the National Authority for Medicolegal Affairs (study III). 
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Table 3: Clinical samples used in the study 
I II III 
 
Type of sample qPCR array array IHC 
BPH 9 5 
NAP 11 
PC 30 50 28 170 
BPH-turp / TURP-normal 4 7 
TURP-PCa 22 
CRPC 12 14 94 
LN-norm 3 
LN-PC 12 
pT1/T2 17 16 13 116 
pT3/T4 13 34 9 52 
not known 12 6 2 
Gleason score  <7 15 35 4 69 
                           7 3 17 10 81 
                         >7 6 32 3 18 
not known 18 11 2 
BPH, benign prostatic hyperplasia; NAP, normal adjacent tissue; PC, primary prostate 
carcer; BPH-turp / TURP-normal, non-malignant transurethral resection of the 
prostate; TURP-PCa, malignant transurethral resection of the prostate; CRPC, 
castration resistant prostate cancer; LN-norm, normal lymph node; LN-PC 
metastatic lymph node 
1.2 Microarrays (I, II, III) 
1.2.1 miRNA microarray (II, III) 
miRNA microarrays were purchased from Agilent Technologies (Santa Clara, CA, 
USA). Human miRNA V2 microarrays containing probe sets against 723 human 
miRNAs were utilized to analyze miRNA expression in two distinct sets of clinical 
samples (described in original communications II and III).  
RNA was extracted from freshly frozen clinical samples by TRI-reagent 
(Molecular Research Center Inc., Cincinnati, OH, USA) and the integrity was 
assessed by RNA-nano chip run with 2100 Bioanalyzer (Agilent Techn.) (Figure 6). 
miRNA microarrays were performed according to the manufacturer’s protocol. 
Briefly, total RNA was labeled using the miRNA Complete Labeling and Hyb Kit 
(Agilent Techn.) and hybridized to the microarrays. Microarrays were scanned with 
a DNA Microarray Scanner BA, and the data were extracted using Feature 
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Extraction software (v. 10.7.1.1) and analyzed using GeneSpring GX 10 (all from 
Agilent Techn.). Data were normalized using quantile normalization. miRNAs that 
were assigned a present call of at least 50% in any one of the six (original 
communication II) or four conditions (original communication III) were subjected to 
differential expression analysis. Welch’s T-test followed by correction by the 
Benjamini and Hochberg method with a corrected p-value cut-off of <0.05 and fold 
change cut-off >1.5 was used to identify differentially expressed miRNAs. 
Hierarchical clustering was performed using the standard uncentered correlation and 
average linkage methods. 
The array data from the 102 clinical samples described in original 
communication II and from the 54 clinical samples described in original 
communication III were submitted to the ArrayExpress database with accession 
numbers E-TABM-794 and E-MTAB-408, respectively.  
 
 
  
Figure 6: Two examples of RNA integrity of freshly frozen clinical samples. Prostatectomy 
specimen on the left, TURP specimen on the right. Ribosomal RNA peaks are 
marked with 18S and 28S. TURP, transurethral resection of the prostate 
1.2.2 cDNA microarray (I, III) 
Gene expression analysis was performed using Agilent’s Whole Human Genome 
Oligo Microarray (44k) platform.  
PC-3 cells transduced with shLUC or shTCEB1 (original communication I) and 
LNCaP cells transfected with pre-miR-32, pre-miR-148a, or pre-miR-control 
(original communication III) were subjected to microarray expression analysis. 
Three days after transduction or transfection, the cells were lysed in Trizol 
(Invitrogen) or TRI-reagent (Molecular Research Center Inc.), and RNA was 
extracted according to the manufacturer´s instructions. RNA (500 ng) was 
amplified, labeled using the Low RNA Input Linear Amplification PLUS, Two-
Color Kit (Agilent Techn.) (original communication I) or the Quick Amp Labeling 
Two-Color Kit (Agilent Techn.) (original communication III) and hybridized to the 
microarrays. Microarrays were scanned using Agilent’s DNA Microarray Scanner, 
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and the data were extracted using Agilent’s Feature Extraction software. Data were 
normalized either in Feature Extraction software using the ‘‘linear and lowess 
method’’ (original communication I) or in GeneSpring GX 10 (Agilent Technol.) 
(original communication III).  
Microarray data were deposited in the ArrayExpress database with accession 
numbers EMEXP-1627 (original communication I) and E-MEXP-2943 (original 
communication III).  
1.3 Real-time quantitative RT-PCR 
1.3.1 mRNA expression analysis (I, III) 
For mRNA expression analysis, first-strand cDNA synthesis from total RNA was 
performed with AMV reverse transcriptase (FinnZymes, Espoo, Finland) or 
Superscript II Reverse Transcriptase (Invitrogen Life Tech.) according to the 
manufacturer’s instructions. The expression levels of RAD21, KIAA0196, EIF3S3 
and TCEB1 were analyzed using a Light-CyclerTM apparatus (Roche Diagnostics, 
Mannheim, Germany) with the LC Fast Start DNA SYBR Green I Kit (Roche 
Diagnostics). The expression of BTG2 and PIK3IP1 was analyzed using MaximaTM 
SYBR Green qPCR master mix (Fermentas, Burlington, Canada) and a CFX96TM 
qPCR machine (Bio-Rad Laboratories). The expression of each target gene was 
normalized to TBP expression. 
1.3.2 miRNA expression analysis (II, III) 
qRT-PCR analysis of miRNA expression was performed on a CFX96TM qPCR 
machine (Bio-Rad Laboratories, Hercules, CA, USA) (III) or an ABI Prism 7700 
Sequence Detection System (Applied biosystems) (II). The TaqMan microRNA 
Assay (Applied Biosystems, Foster City, CA) was utilized to evaluate miRNA 
expression according to the manufacturer’s recommendations. Target gene 
expression was normalized to RNU44 (III) or to U6 (II) expression. 
1.3.3 Chip-qPCR (III) 
LNCaP-pcDNA3.1 and LNCaP-ARhi cells were treated with 1 nM DHT or ethanol 
for 2 hours. Cells were fixed (Merck KGaA, Darmstadt, Germany), pelleted and 
lysed. Chromatin was immunoprecipitated with 10 µg rabbit IgG (Santa Cruz Inc., 
Santa Cruz, California, USA) or 10 µl AR antibody (provided by Professor Olli 
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Jänne, Helsinki University, Finland), and qPCR was performed using MaximaTM 
SYBR Green qPCR master mix (Fermentas) and a CFX96TM qPCR machine (Bio-
Rad Laboratories) with primers for the putative ARBS in the proximity of miR-32 
and miR-148a. The relative enrichment was calculated according to the delta Ct 
method. 
1.4 Immunohistochemistry (III) 
In total, 264 clinical samples were utilized to evaluate BTG2 and PIK3IP1 protein 
expression in prostate cancer. BTG2 and PIK3IP1 were detected in formalin-fixed, 
paraffin-embedded TMA sections. First, deparaffinized TMA sections were pre-
treated by autoclaving in 10 mM sodium citrate buffer (pH 6.0) at 121°C for 2 min. 
BTG2 and PIK3IP1 were detected with rabbit polyclonal antibodies (BTG2, Sigma-
Aldrich, 1:1000 dilution; PIK3IP1, S-14, Santa Cruz Biotech., 1:300 dilution) using 
the PowerVision+TM Poly-HRP IHC Detection Kit (Immunovision Co.). The 
sections were counterstained with hematoxylin. The staining intensity was scored in 
a blinded fashion. 
1.5 Western blotting (I, III) 
Protein extract (20 µg) was used for Western blot analysis of TCEB1, RAD21, 
BTG1, PIK3IP3 and BIM. Proteins were separated by SDS-PAGE on 8% (RAD21), 
10% (PIK3IP1 and BIM) or 12% (BTG2 and TCEB1) polyacrylamide gels and 
transferred to PVDF membranes (Immobilon-P, Millipore Corp., Billerica, MA, 
USA). The membranes were incubated overnight with antibodies against RAD21 
(1:500 dilution, Novus Biologicals, Littleton, CO, USA), TCEB1 (1:2050 dilution, 
anti-SIII p15, BD Transduction Laboratories, San Jose, CA, USA), BTG2 (1:500 
dilution, Sigma-Aldrich, Saint Louis, MO, USA), PIK3IP1 (1:500 dilution, H-180, 
Santa Cruz Biotechnology Inc.), actin (1:400 dilution, pan AB-5 clone ACTN05, 
Lab Vision Corp, Fremont, CA, USA), or BIM (1:500 dilution, Cell Signaling 
Tech.). After washing and incubating with secondary antibodies (RAD21, BTG2, 
PIK3IP1 and BIM: anti-rabbit IgG horseradish peroxidase-conjugated antibody, 
Dako; TCEB1 and actin: anti-mouse IgG horseradish peroxidase-conjugated 
antibody, Dako), protein bands were visualized by autoradiography. 
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1.6 Chromatin immunoprecipitation (III) 
LNCaP-pcDNA3.1, LNCaP-ARmo and LNCaP-ARhi cells were analyzed for AR 
binding sites (ARBS). Cells were treated with various DHT concentrations, fixed 
(Merck KGaA, Darmstadt, Germany), pelleted and lysed. Chromatin was 
immunoprecipitated with 10 µg rabbit IgG (Santa Cruz Inc., Santa Cruz, California, 
USA) or 10 µl AR antibody (provided by Professor Olli Jänne, Helsinki University, 
Finland). ChIP DNA was sequenced with a Genome Analyzer II (Illumina Inc., San 
Diego, California, USA) according to the manufacturer’s protocol. Raw reads were 
aligned with Bowtie (Langmead et al. 2009) and the reads were mapped onto the 
human genome version 19 (hg19). Peak detection was performed with the tool 
MACS (Zhang et al. 2008a). ARBS were searched for upstream of a miRNA start 
site or, in the case of an intragenic miRNA, upstream of a host gene start site. If 
ARBS were identified and found to be closer to a miRNA than any other gene, they 
were determined to belong to the miRNA.  
1.7 Transfections and transductions 
1.7.1 Lentiviral-mediated gene silencing and overexpression (I) 
Lentiviruses were used to generate cell lines stably expressing either shRNAs 
targeting RAD21, KIAA0196, EIF3S3, or TCEB1 or cDNAs of the same genes. 
shRNA oligos were purchased from Sigma-Proligo (The Woodlands, TX) and 
cloned into the lentiviral plasmid Lentilox3.7 (pLL3.7, kindly provided by Dr. Kalle 
Saksela, University of Helsinki, Finland). cDNA clones were obtained from 
Geneservice (Cambridge, UK) and the coding regions of RAD21, KIAA0196, 
EIF3S3 and TCEB1 were cloned into the lentiviral plasmid WPI (kindly provided 
by Dr. Jarmo Wahlfors, University of Tampere, Finland). 
Lentiviral particles were produced by the calcium phosphate precipitation 
technique. The pLL3.7 vectors containing the shRNA sequences and the pWPI 
vectors containing the coding regions were cotransfected with the packaging 
plasmids pCMVD8.9 and pVSV-G (System Biosciences, Mountain View, CA) into 
HEK 293T/17 cells. Titers were measured by transducing PC-3 cells with serial 
dilutions of virus and analyzing the percentage of GFP-positive cells on an Agilent 
2100 Bioanalyzer (Agilent Techn.). A multiplicity of infection (MOI) of 10 was 
used to obtain >90% transduction efficiency (Figure 7). To enhance viral 
transduction, 8µg/ml of polybrene (Sigma-Aldrich, Milwaukee, WI) was added to 
each transduction. 
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Figure 7: An example of the percentage of GFP positive PC-3 cells after transduction with 
MOI 10. GFP, green fluorescein protein; MOI, multiplicity of infection. 
1.7.2 Transfections of pre- and anti-miRs (III) 
LNCaP cells were transiently transfected either with Pre-miR™ (Applied 
Biosystems, Foster City, CA, USA) precursor miRNAs (miR-32, miR-590-5p, miR-
148a and miR-99b) or an Anti-miR™ (Applied Biosystems) miRNA inhibitor (miR-
99a) to study the functional significance of these miRNAs in prostate cancer cells. 
LNCaP cells were transfected with 10 nM Pre-miR™ or Anti-miR™ using 
INTERFERin (Polyplus-transfection, Illkirch, France) according to the 
manufacturer’s protocol. The scramble Pre- or Anti-miR™ negative controls 
(Applied Biosystems) were used as reference treatments.  
1.8 Functional assays 
1.8.1 DHT treatment prior to functional assays (III) 
Before hormone exposure, LNCaP cells were cultured in 5% or 10% charcoal-
stripped serum (CSS; HyClone, Inc., South Logan, UT, USA) for 3 days. The 
medium was subsequently replaced with medium containing 0, 1, 10 or 100 nM 5α-
dihydrotestosterone (DHT) (Steraloids Inc., Newport, RI, USA), and RNA was 
extracted 6 hours later for expression analysis. When appropriate, cells were 
transfected with pre-miR constructs after 3 days of starvation in charcoal-stripped 
serum, and 15 nM DHT was added to the medium at the time of transfection. 
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1.8.2 Proliferation assays (I, III) 
PC-3 and NIH 3T3 cells were transduced with lentiviruses and LNCaP cells were 
transfected with pre- or anti-miRNA constructs. Cells were plated in 24-well plates, 
and Alamar Blue (Trek Diagnostic Systems, Cleveland, OH, USA) or Resazurin 
(R&D systems, Minneapolis, MN, USA) reagents were used to assess cell growth. 
Luminescence was detected with a fluorometer (Wallac 1420 Victor; Perkin-Elmer, 
Fremont, CA, USA). The number of cells on each day was calculated relative to day 
one.  
1.8.3 Cell cycle analysis (I, III) 
Propidium iodide staining followed by flow cytometric analysis was performed to 
determine the number of cells in each phase of the cell cycle. PC-3 and LNCaP cells 
were stained according to published guidelines (Prather et al, 1999). Briefly, PC-3 
cells transduced with shRNA were stained with a propidium iodide-containing 
hypotonic staining buffer and analyzed by flow cytometry (Coulter® EPICS XL-
MCL, Beckman Coulter Inc). LNCaP cells transfected with pre-miRNAs were 
resuspended in GM buffer and fixed in ethanol for 24 hours. After fixation, cells 
were stained with propidium iodide (Sigma) and analyzed by flow cytometry 
(Accuri® C6). The proportion of cells in each phase of the cell cycle was 
determined using EXPO32 ADC or ModFitLT 3.2 software (Becton Dickinson, 
Mountain View, CA). 
1.8.4 Apoptosis assay (III) 
The number of apoptotic LNCaP cells was determined by cleaved caspase-3 
staining. Three days after Pre-miR™ transfections, LNCaP cells were harvested and 
placed onto objective slides. Cells were fixed in ice-cold methanol and acetone and 
incubated with an anti-cleaved caspase-3 antibody (dilution 1:1000, Cell Signaling 
Technology, Beverly, MA, USA). The staining was visualized with the 
PowerVision+TM Poly-HRP IHC Detection Kit (ImmunoVision Technologies 
Corporation, Brisbane, CA). Counterstaining was performed with methyl green and 
cleaved caspase-3-positive cells were counted under a light microscope.  
1.8.5 Soft agar assay (I) 
Colony formation assays were utilized to evaluate the anchorage-independent 
growth of TCEB1-, EIF3S3-, RAD21- or KIAA0196-knockdown PC-3 cells and 
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TCEB1-overexpressing NIH 3T3 cells. In a 6-well plate, 5000 cells/well were 
seeded in 0.35% agarose on top of a 0.5% agarose base. The plates were incubated 
at 37°C and fed twice per week with culture medium. Colonies were photographed 
and counted after two weeks. 
1.8.6 Invasion assay (I) 
The invasive potential of TCEB1-, EIF3S3-, RAD21- or KIAA0196-silenced cells 
was determined using Matrigel™ Invasion Chambers (BD Biosciences, Bedford, 
MA). PC-3 or DU145 cells were plated in the chamber under serum starvation 
conditions (1% FBS) and incubated at 37°C for 22 hours. Culture medium 
containing 10% FBS was used as the chemoattractant. After incubation, cells that 
had invaded to the other side of the chamber were fixed with methanol, stained with 
hematoxylin and photographed. The relative area of invaded cells was measured 
using the image analysis software program ImageJ (Abramoff et al. 2004). 
1.8.7 Migration assay (I) 
The migration of EIF3S3-, RAD21- or KIAA0196-silenced PC-3 cells was 
evaluated with a wound-healing assay. Cells were plated in 6-well plates and grown 
to confluency. Wounds were made with a pipet tip, and movement was tracked by 
photographing the cells under a microscope after 0 and 15 hours. The relative size of 
the wound was determined by analysis with ImageJ (Abramoff et al. 2004). 
1.8.8 Luciferase assay (III) 
For luciferase assays, LNCaP cells were cotransfected with pSGG-3UTR (3´UTR of 
BTG2 or PIK3IP1) and pre-miRNA (pre-miR-control, pre-miR-32 or pre-miR-148a) 
using DreamFect (Oz Biosciences, Marseille, France) according to the 
manufacturer’s recommendations. Plasmids were purchased from Switchgear 
Genomics (Menlo Park, CA, USA). Cells were lysed 24 hours after transfection in 
reporter lysis buffer (Promega, Madison, WI, USA). Luciferase activity was 
analyzed using the Luciferase Assay System (Promega). For normalization, the 
protein concentration of each cell lysate was measured using the BioRad LC protein 
assay (BioRad). 
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1.8.9 Rescue experiment (III) 
A rescue experiment was performed to determine if the growth advantage provided 
by Pre-miR-32™ (Applied Biosystems) was abolished by BTG2 addition. 
Excluding the 3´UTR, the coding sequence of human BTG2 from cDNA clone 
SC115914 (OriGene, Rockville, MD, USA) was cloned into the pSG5 expression 
vector. Cells were counted, seeded at 50,000 cells/well in 24-well plates and reverse 
transfected with 10 nM pre-miRNA and 150 ng of plasmid/well using 
LipofectamineTM 2000 (Invitrogen) according to the manufacturer´s protocol. 
Growth curves were established as described above. 
1.9 Statistical analysis (I, II, III) 
The following tests were utilized to determine statistical significance for the data 
described in the Results section: in original communication I, two-tailed Mann-
Whitney U-test used was to determine statistical difference of expression of TCEB1 
in clinical samples and  in growth curves in experimental versus control groups  and 
unpaired t-test with Welch’s correction was used to determine statistical difference 
in various cell base assays (Matrigel invasion assay, soft agar assay, cell cycle 
analysis and in wound-healing assay. In original communication II, Welch t-test 
followed by Benjamini and Hochberg correction with p-value cut-off 0.05 and fold 
change cut of > 1.5 were used for the identification of differentially expressed 
miRNAs in microarray. Two-tailed nested t-test with Pearson’s correlation was used 
to evaluate possible correlation between clinical groups and Kaplan-Meier survival 
curves and log-rank tests were used to assess the predictive values of prognostic 
approaches. The random variance t-test was used in miR-predictor construction. In 
original communication III, Welch t-test followed by Benjamini and Hochberg 
correction with p-value cut-off 0.05 and fold change cut of > 1.5 were used for the 
identification of differentially expressed miRNAs in microarray. Mann-Whitney U-
test was assessed to determine the statistical significance in different growth curves 
between experimental and control groups. Welch t-test was used to assess statistical 
significance of cell cycle analysis and apoptosis assay. Kaplan-Meier survival 
curves with Mantel-Cox tests were employed to evaluate the prognostic value of the 
immunostaining.  
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RESULTS AND DISCUSSION 
1.1 Functional evaluation of putative 8q target genes 
(I) 
In this study, four putative target genes of 8q ampliﬁcation, TCEB1, EIF3H, RAD21 
and KIAA0196, were functionally examined to evaluate their influence on the 
tumorigenic properties of cancer cell lines. Silencing or overexpressing RAD21 or 
KIAA0196 in cell lines did not produce a phenotype, indicating that they are 
unlikely to be targets of 8q ampliﬁcation. The results for TCEB1 and EIF3H are 
discussed below.  
1.1.1 TCEB1  
TCEB1 (also known as Elongin C) was initially discovered by cDNA microarray to 
be highly expressed in the PC-3 cell line, which harbors an 8q gain. By fluorescent 
in-situ hybridization, TCEB1 was determined to be amplified in 23% of castration-
resistant tumors, but not in any of the primary tumors (Porkka et al. 2002). 
Expression analysis of TCEB1 in clinical tumors demonstrated a significantly higher 
expression level in CRPC compared with benign tissue (original communication I). 
In addition to prostate cancer, TCEB1 amplification has been reported in breast 
cancer, which also exhibits 8q gains (Choschzick et al. 2010). 
 TCEB1 has two known biochemical functions. Together with Elongin A and 
Elongin B, TCEB1 regulates transcription via a direct interaction with RNA 
polymerase II (Aso et al. 1995). In addition, TCEB1 binds along with Elongin B 
(forming an Elongin B/C complex) to a number of proteins that contain a BC-box, 
including von Hippel-Lindau (VHL) protein and SOCS-box containing proteins. 
Cullin-dependent ubiquitin ligases are multisubunit enzymes, and Elongin B/C 
functions as an adapter to link SOCS-box proteins to the Cullin-Rbx module. These 
multiprotein complexes ubiquitinate their substrates and target them for degradation 
(Kibel et al. 1995; Stebbins et al. 1999; Kamura et al. 1998 & 2004; Zhang et al. 
1999). 
Lentiviral-mediated TCEB1 silencing was utilized to investigate TCEB1 function 
in PC-3 cells. Several cell-based assays were performed. According to growth curve 
and flow cytometric cell cycle analyses, TCEB1 silencing did not alter the 
proliferation or apoptosis of PC-3 cells compared with shLUC-transduced controls. 
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Anchorage-independent growth was assessed by colony formation in soft agar. 
TCEB1-silenced PC-3 cells formed significantly fewer colonies in soft agar than 
control shLUC-transduced cells (Table 4). TCEB1 silencing dramatically reduced 
the invasion of PC-3 cells as demonstrated by Matrigel invasion assays. A similar 
result was obtained when DU145 cells were evaluated (Table 4). In contrast, no 
effect on the migration of PC-3 cells was apparent in wound-healing assays. DU145 
cells do not harbor an 8q gain and have lower TCEB1 expression than PC-3 cells 
(Porkka et al. 2002). These results indicate that TCEB1 promotes invasion with and 
without amplification.  Taken together these results, TCEB1 silencing reduced 
cellular invasion of PC-3 and DU145 cells and anchorage-independent growth of 
PC-3 cells.  
When TCEB1 was overexpressed in NIH 3T3 cells, cell growth was significantly 
increased compared with empty vector control (Table 4). However, NIH 3T3 cells 
overexpressing TCEB1 did not form colonies in soft agar. These data indicate that 
TCEB1 is not a transforming oncogene.  
In this study, TCEB1 functions were only studied in vitro and in a limited 
number of cell lines. PC-3 is the only prostate cancer cell line that has an 8q 
amplification and therefore is the best model for studying 8q target genes. NIH 3T3 
cells were used as a model for TCEB1 overexpression. The advantage of the use of 
mouse cell line is that murine cells can be transformed by single step. However, 
TCEB1 overexpression did not induce transformation of NIH 3T3 cells. Better 
model to study TCEB1 overexpression would have been a prostate cancer cell line 
witch do no harbor an 8q gain. It seems that as 8q amplification occurs late in 
prostate cancer tumorigenesis, target genes for the amplification do not initiate 
cancer, but are rather involved in late stage changes, such as metastatic processes. 
Thus, normal cells may not be the best model to study 8q target genes. So far, the in 
vivo functions of TCEB1 in prostate cancer have not been determined, and TCEB1 
has not been studied in other cancer types.  
Table 4: Results of TCEB1 and EIF3H overexpression and silencing in cell lines. 
Significance is assessed by Welch t-test.  
NIH 3T3 pWPI pWPI-TCEB1 pWPI-EIH3H 
Relative growth (relative to day  1)          
+4d 4.33 6.15 5.6 
    p=0.0055 p=0.0364 
 shLUC shTCEB1 shEIF3S3 
Number of colonies in soft agar    
PC-3 157 110 151 
     p=0.0052 n.s. 
% of cells invaded through Matrigel (relative to control)  
PC-3 100 51.5 p=0.0317   
DU145 100 60.8 p=0.0036     
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The gene expression profile of TCEB1-silenced PC-3 cells was determined by 
Agilent Whole Human Genome microarray. Genes known to be involved in 
invasion were among the 10 most down-regulated genes. For example, the 
extracellular matrix components ankyrin G (ANK3) and CHRDL2 (chordin-like 2) 
were down-regulated by TCEB1 silencing. In addition, proteinase domain-
containing ADAMTS12 (ADAM metallopeptidase with thrombospondin type 1 
motif, 12) was down-regulated. However, the role of ADAMTS12 in invasion is 
controversial because a recent mouse study suggested that ADAMTS12 has 
antiangiogenic properties and that when overexpressed in cells, it protects from in 
vivo tumor growth (El Hour et al. 2010). Angiopoietin like-4 (ANGPTL4) was up-
regulated in TCEB1-silenced cells. ANGPTL4 appears to play a pivotal role in 
cancer because previous studies reported that ANGPTL4 inhibits the invasion and 
motility of epithelial cancer cells (Galaup et al. 2006). More recent studies suggest 
that the suppression of ANGPTL4 impairs tumor growth through enhanced 
apoptosis (Zhu et al. 2011). Because TCEB1 is in a complex with ubiquitin ligases 
that target substrate proteins for degradation, it is possible that transcriptional 
profiling will not reveal the real targets responsible for the phenotype in TCEB1-
silenced cells. Thus, more comprehensive analyses of TCEB1 should be performed 
at the protein level. Novel proteins interacting with TCEB1 could be identified by 
pull-down assays and by this approach novel regulatory functions of TCEB1 could 
be revealed. In addition, it should be studied whether TCEB1 overexpression have 
an effect on transcription and especially to the transcription of known oncogenes. To 
summarize, TCEB1 promotes invasion by unknown mechanisms and therefore is a 
potential target gene of 8q21 amplification.  
TPD52 has been suggested to be the target gene for the minimal amplification 
region of 8q21. It is coamplified with TCEB1 and overexpressed in prostate cancer 
(Rubin et al. 2004; Wang et al. 2004). TPD52 enhances proliferation, decreases 
apoptosis and increases migration (Wang et al. 2007; Ummanni et al. 2008). In 
addition, TPD52 is androgen-regulated and enhances colony formation and 
proliferation under androgen-depleted conditions. One hypothesis is that TPD52 is 
involved in the development of castration-resistant disease by inhibiting the 
apoptosis caused by androgen deprivation therapy (Zhang et al. 2007a & 2011). In 
contrast to TCEB1, which is overexpressed only in advanced tumors, TPD52 is 
highly overexpressed in localized primary tumors and in PIN lesions. Because 8q 
gains occur late in prostate cancer progression, other mechanisms must exist that 
regulate TPD52 expression (Rubin et al. 2004; Wang et al. 2004). 
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1.1.2 EIF3H 
High-level amplification of EIF3H (also known as EIF3S3 and EIF3-p40) was 
found in one-third of CRPC, where it was typically coamplified with MYC. 
Amplification leads to EIF3H overexpression and is associated with poor prognosis 
after radical prostatectomy (Nupponen et al. 1999, Saramäki et al. 2001, Savinainen 
et al. 2004). We previously demonstrated that overexpression of EIF3H in NIH 3T3 
cells enhanced cell proliferation and that inhibition of EIF3H by siRNA in prostate 
cancer cells inhibited cell growth. These data provide strong evidence that EIF3H is 
a candidate target gene of 8q24 gains (Savinainen et al. 2006). 
EIF3H is a subunit of eukaryotic translation initiation factor 3 (EIF3). Several 
components of EIF3 have been implicated in cancer; in one study, 5 of the 13 
subunits of EIF3 caused malignant transformation of immortal NIH-3T3 cells 
(Zhang et al. 2007b). Chromosomal aberrations in EIF3H have been reported in 
breast, prostate and hepatocellular carcinoma. In addition, genome wide association 
studies identified EIF3H as a putative causative factor in hereditary colorectal 
cancer (Tomlinson et al. 2008). 
When EIF3H was overexpressed in NIH 3T3 cells, the cellular growth rate was 
significantly enhanced (Table 4), which we have previously demonstrated 
(Savinainen et al. 2006). However, when EIF3H was silenced in PC-3 cells, no 
effects were seen on growth, invasion or anchorage-independent growth. This 
contradicts our previous result that EIF3H silencing by siRNA reduced the growth 
of several prostate cancer cell lines. Also Zhang and colleques have shown that 
knockdown of EIF3H expression in PC-3 cells affects to proliferation rate and 
colony formation on soft agar. In addition, enhanced proliferation and colony 
formation was seen in normal primary prostate (PrEC) cells overexpressing EIF3H 
(Zhang et al. 2008b). It is possible that lentiviral-mediated silencing with shRNAs 
was not sufficiently effective to observe a growth reduction in PC-3 cells. Silencing 
efficiency of EIF3H siRNA was up to 96% in PC-3 cell line, however, with shRNA 
using the same sequence the efficiency was approximately 80% (Savinainen et al. 
2006). Off-target effects are difficult to exclude totally, siRNA sequence that was 
used was designed not to target any other gene. However, most efficient siRNA 
sequence was selected and all the experiments were done with the same 
siRNA/shRNA. Use of several siRNAs/shRNAs that target the same gene would 
diminish the fear of off-target effects.  
In addition to prostate cancer cells, we studied EIF3H in two colorectal cell lines, 
LoVo and HT-29, of which HT-29 has high expression and gene amplification of 
EIF3H. In LoVo cells, EIF3H silencing reduced and overexpression enhanced cell 
growth. In HT-29 cells, silencing EIF3H reduced anchorage-independent growth 
(Pittman et al. 2010). Taken together these results, EIF3H overexpression in NIH 
3T3 cells enhanced the growth rate. However, silencing EIF3H in PC-3 did not 
cause any phenotype.  
57 
As mentioned earlier, EIF3H is a subunit of translation initiation factor complex. 
Cancer cells have increased metabolic activity and enhanced proliferation, which 
requires enhanced protein synthesis (Rosenwald, 2004). Ratelimiting step in protein 
translation is the initiation step. Alteration in the expression and activity of specific 
translation factors are common feature of human cancer (Silvera et al. 2010). It has 
been shown that overexpression of EIF3H leads to enhanced rate of protein 
synthesis and also selectively enhances translation of several oncogenic mRNAs. 
Mechanism how EIF3H affects to the rate of protein synthesis is not known. EIF3H 
overexpression does not couse an increase in EIF3 levels, however its activity may 
be enhanced (Zhang et al. 2007b; Zhang et al. 2008b). These mechanisms could be 
studied in more detail to understand the oncogenic properties of EIF3H. According 
to previous studies and those in original communication I, EIF3H is considered a 
putative target gene for 8q gains.  
No functional studies have been performed on the synergistic effects of 8q target 
genes. Often the entire arm of 8q is gained, triggering the up-regulation of several 
putative target genes. It is also possible that these genes have synergistic effects that 
are not observed when analyzing the genes individually. 
1.2 miRNA expression studies on clinical prostate 
cancer (II, III) 
Agilent miRNA microarrays were utilized to study miRNA expression in the 
clinical prostate cancers in original communications II and III. In original 
communication II, 102 clinical samples were obtained from Erasmus University 
Medical Center, Rotterdam, The Netherlands. The samples consisted of 11 normal 
adjacent tumors (NAP), 50 primary tumors (PCa), 4 non-malignant samples 
obtained by TURP (TURP-normal), 22 malignant TURP (TURP-PCa), 3 normal 
lymph nodes (LN-normal) and 12 metastatic lymph nodes (PC-lymph). The same 
study platform was used in original communication III to determine the miRNA 
expression profiles of 54 clinical samples from Tampere University Hospital, 
encompassing 5 benign hyperplasia (BPH), 28 primary tumors (PC), 7 benign 
prostatic hyperplasia obtained by TURP (BPH-TURP) and 22 castration-resistant 
tumors (CRPC). In both studies, microarray results were normalized by quantile 
normalization, and pairwise Welch t-tests were employed to obtain differentially 
expressed miRNAs in each group. In the Rotterdam sample set, a total of 513 (71%) 
miRNAs from the 723 human miRNAs included in the array were considered 
significantly expressed, whereas 411 (57%) miRNAs in the Tampere sample set 
were significantly expressed over background.  
Altogether, 80 miRNAs were differentially expressed in the Rotterdam sample 
set that contained three types of malignant samples and the corresponding benign 
controls (primary tumors, TURPs and lymph nodes). In the Tampere clinical 
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samples, there were 65 differentially expressed miRNAs in the primary tumors and 
88 differentially expressed miRNAs in the CRPCs compared with the benign 
controls (Figure 8).   
 
 
Figure 8: Venn diagram of differentially expressed miRNAs in Tampere samples and in 
Rotterdam samples. PC, primary prostate tumor; BPH, benign prostatic 
hyperplasia; CRPC, castration resistant prostate cancer 
When the expression profiles of the primary tumors from the Tampere and 
Rotterdam clinical samples were compared, 29 miRNAs were differentially 
expressed. The results are summarized in Table 5. In total, 19/29 miRNAs were 
previously reported to be deregulated in prostate cancer (Volinia et al. 2006; Ambs 
et al.  2008; Ozen et al. 2008;  Tong et al. 2009; Schaefer et al. 2010;  Carlsson et 
al. 2011; Wach et al. 2012). Only miR-7 had discrepant results; Ambs et al. reported 
down-regulation of miR-7 whereas we observed up-regulation.  
Discrepancies are very common in published miRNA expression profiles; several 
miRNAs have been reported to be up-regulated in certain studies and down-
regulated in others. One explanation stems from the use of different platforms, 
particularly in the earliest profiling studies when the arrays were custom-made. The 
array platform used by Volinia et al. also detected precursor molecules, and 
Carlsson et al. used a qPCR-based method. The data reported by Ozen et al. appears 
to be distorted because all of the miRNAs (76) with differential expression were 
down-regulated. The number of miRNA probes in different platforms varies. In 
addition, controls, normalization, sample selection and preparation can significantly 
affect the results. 
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Table 5: Combined results deregulated miRNAs in primary prostate cancer 
according to the two different data sets analyzed 
miRNA ID Regulation Implicated in previous studies 
miR-130b up Schaefer, up 
miR-182 up Ambs, Schaefer, Wach,  up 
miR-182* up Schaefer, up 
miR-183 up Schaefer, up 
miR-183* up  
miR-200b* up  
miR-25 up Tong, Ambs, Volinia, up 
miR-375 up Ambs, Schaefer, Wach,  up 
miR-425 up Ambs, up 
miR-512-3p up  
miR-615-3p up  
miR-7 up Ambs, down 
miR-93 up Ambs, Volinia, Carlsson, Wach, up 
miR-96 up Schaefer, up 
miR-1 down Ambs, down 
miR-133a down Ambs, down 
miR-133b down  
miR-145 down Tong, Ambs, Wach, down 
miR-145* down Carlsson, down 
miR-149 down Volinia, Schaefer, down 
miR-150 down  
miR-204 down  
miR-205 down Tong, Ambs, Schaefer, down 
miR-221 down Tong, Ambs, Schaefer, Wach, down 
miR-221* down Carlsson, down 
miR-222 down Tong, Schaefer, Wach, down 
miR-455-3p down  
miR-455-5p down  
miR-551b down   
 
Here, when Agilent microarrays were used for two different sample sets, there 
was much less discrepancy. Still, many of the significantly deregulated miRNAs 
differed, which is most likely a function of using different data sets and controls. In 
the Rotterdam clinical sample set, normal adjacent tissue was used as a control, 
whereas BPH was the control for the Tampere clinical samples. Metastatic lymph 
nodes were included in the Rotterdam set. TURP-PCa covers a heterogeneous group 
of primarily advanced diseases; however, for half of the TURP-PCa samples, it was 
unknown whether they represented castration-resistant disease. It was impossible to 
draw any conclusions from the miRNA expression profile of the CRPC samples in 
the Rotterdam clinical sample set.  
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Many of the miRNAs that were differentially expressed in these two clinical 
datasets have been mechanistically implicated in prostate cancer. For example, the 
expression of miR-205 in prostate cancer cells impairs migration and invasion, and 
miR-145 expression leads to cell cycle arrest and apoptosis (Gandellini et al. 2009; 
Zaman et al. 2010). miR-93 and miR-25 target the tumor suppressor PTEN, and 
miR-221 has been reported to be androgen-regulated (Poliseno et al. 2010; Ambs et 
al. 2008). These data indicate that expression profiling is a useful tool to identify 
miRNAs that are potentially involved in cancer progression. In the case of several of 
the differentially expressed miRNAs, further studies are necessary to address 
whether they are functionally relevant in prostate cancer. In addition, the 
mechanisms for the deregulation of individual miRNAs are not well understood, but 
it appears that gene amplifications and deletions of miRNAs are rare (Porkka et al. 
2010).  
1.2.1 Prognostic miRNA signature (II) 
The 80 miRNAs that were differentially expressed in the Rotterdam clinical samples 
were used for hierarchical clustering of all 102 samples. These miRNAs divided 
primary tumors (n= 50) into two different subgroups: group I contained 34 samples 
that clustered closely to the non-malignant tissues (NAP, TURP-normal and LN-
normal), whereas group II, consisting of 16 samples, clustered with samples from 
more advanced disease (LN-PC, TURP-PCa). Group II tumors were significantly 
associated with an increased rate of metastasis after radical prostatectomy and with 
cancer-related deaths. Twenty-two miRNAs contributed to the separation of these 
groups, of which several were down-regulated in metastatic lymph nodes (original 
communication II).  
Twenty miRNAs from the panel that separated the two groups together with 5 
other miRNAs best separated group I from group II by the Bayesian Covariate 
Compound Predictor Algorithm (Table 6). This miR-predictor correctly classified 
40 out of 50 samples. Ten samples were not assigned to either group. In this dataset, 
the miR-predictor was superior in predicting prognosis to pathological grade or 
stage and to preoperative PSA (original communication II). 
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Table 6: 25 miRNAs that were best in separating prognostic groups I and II in 
Rotterdam clinical data set. Regulation shown in worse prognosis group (group II) 
miRNA ID 
Up-
regulated 
Down-
regulated 
miR-25 miR-133a 
miR-32 miR-133b 
miR-106b miR-143* 
miR-93 miR-143 
miR-96 miR-145 
miR-183* miR-145* 
miR-183 miR-221 
miR-425 miR-222 
let-7b miR-378 
miR-663 miR-204 
miR-301b miR-27b 
miR-141* miR-139-5p 
  miR-1 
 
The weakness of this predictor is that it was not tested on additional datasets. 
Only a few studies have reported on miRNA expression as prognostic indicators in 
prostate cancer. Certain studies arrived at the conclusion that there are no 
differences in miRNA expression between favorable and unfavorable prognoses 
(Leite et al. 2011). Tong et al. demonstrated that the expression of 16 miRNAs 
classified relapse patients from non-relapse patients. Of those 16 miRNAs, only 
miR-96 is on our list. In the study by Schaefer et al., miR-96 was found to be a 
prognostic indicator. Also miR-221 expression has been associated with tumor 
progression and clinical recurrence (Spahn et al. 2010). Again, there are several 
reasons for the discrepancies, many of them have been discussed previously (in 
example: different platforms, sample selection and handling). In addition to these, 
definition of progression is varies in different studies. In our study, group II tumors 
were associated with metastasis and prostate cancer related death, not with PSA 
progression. In many studies, PSA progression (biochemical relapse) is used to 
devide progressors from non-progressors (Tong et al. 2008; Schaefer et al. 2010). It 
is difficult to compare such results, since increase of PSA following surgery is 
associated with prostate cancer specific death, but still the majority of men with 
PSA progression die of other causes. Carver et al. reported that 36% of men with 
PSA progression after surgery eventually developed clinically relevant disease 
(Carver et al. 2006). Porter et al. observed that almost 50% of patient had PSA 
progression after radical prostatectomy, but prostate cancer specific death occurred 
in only 19% of the population (Porter et al. 2006). Against these observations, there 
might be too much background noise when PSA progression is used as an end-point 
and the real prognostic indicators are not found.  
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 Our results indicate that miRNA expression can be used to determine the 
prognosis of prostate cancer patients. Still, discrepancy exists among individual 
studies in terms of which miRNAs have prognostic value. More detailed studies on 
individual miRNAs are necessary to determine if a single miRNA or a small panel 
miRNAs can function as a clinically relevant prognostic marker. In addition, more 
reliable tools to study miRNA expression are required if miRNA expression is to be 
used in large-scale clinical tests.  
1.3 Putative AR regulated miRNAs (III) 
To select interesting miRNAs for further functional analysis, miRNA expression 
profiling on CRPC was combined with the knowledge of AR binding sites (ARBS). 
AR signaling is reactivated in CRPC, but the critical target genes for the emergence 
of CRPC are unknown (Chen et al. 2004; Linja et al. 2001). ARBS were profiled by 
chromatin immunoprecipitation and sequencing (Chip-seq) in LNCaP-derived cell 
line models that express different levels of AR. Altogether, 414 miRNAs were 
identified with proximal ARBS. In a miRNA microarray, 88 miRNAs were 
differentially expressed in CRPC compared with benign controls. miRNAs that are 
deregulated in CRPC and contain ARBS are listed in Table 7. Of these, miR-125b, 
miR-21 and miR-221 have previously been demonstrated to be regulated by AR 
(Ribas et al. 2009: Shi et al. 2007; Ambs et al. 2008). From an initial screen for a 
growth effect of miRNA-transfected LNCaP cells, miR-32 and miR-148a were 
selected for further studies and will be discussed below.  
miRNAs are widely distributed in the human genome, with some miRNAs 
located in intergenic regions, having their own transcriptional regulatory elements. 
Approximately 50% of miRNAs are intragenic, located in the introns of a host gene 
(Saini et al. 2008; Rodriguez et al. 2004). Intragenic miRNAs can be co-expressed 
with the host gene, or they can utilize their own promoter (Ozsolak et al. 2008; 
Monteys et al. 2010). ARBS were searched for upstream of the miRNA start site 
and, in the case of intragenic miRNAs, upstream of the host gene. If ARBS were 
identified without a proximal gene, the ARBS were determined to belong to the 
miRNA. However, it is challenging to conclusively associate gene to certain ARBS. 
It is possible that the identified ARBS regulate distal gene through DNA looping.  
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Table 7: Differentially expressed miRNAs in castration-resistant prostate cancer 
which have AR binding site according to the Chip-seq analysis 
miRNA ID regulation miRNA ID regulation 
let-7a up miR-100 down 
miR-148a up miR-101* down 
miR-17 up miR-125b down 
miR-18a up miR-125b-2* down 
miR-19a up miR-181a down 
miR-20a up miR-181b down 
miR-20a* up miR-221 down 
miR-21 up miR-222 down 
miR-30b up miR-24 down 
miR-30b* up miR-26a down 
miR-32 up miR-28-3p down 
miR-340* up miR-498 down 
miR-625 up miR-584 down 
  miR-873 down 
    miR-99a down 
 
1.3.1 miR-32 and miR148a 
miR-32 and miR-148a were up-regulated in CRPC according to the microarray 
analysis, and both were demonstrated to possess an AR binding site (Table 7 and 
Figure 9). Precursor molecules for miR-32 and miR-148a and a control scramble 
precursor were transfected into the AR-responsive cell line, LNCaP. As 
demonstrated by growth curves, both miRNAs significantly enhanced cell growth 
compared with control-transfected cells. Cell cycle analysis by flow cytometry 
revealed fewer apoptotic cells in miR-32-transfected LNCaPs and more cells in S-
phase in miR-148a-transfected LNCaPs. The ability of miR-32 to reduce apoptosis 
was verified by cleaved caspase-3 staining; miR-32 transfection significantly 
reduced the number of stained LNCaP cells (Table 8). The up-regulation of miR-32 
and miR-148a by androgens was confirmed and the AR binding sites in close 
proximity to both miRNAs were validated by ChIP-PCR (original communication 
III). 
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Figure 9: miR-32 and miR-148a expression in clinical samples according to miRNA     
microarray. Significance is assessed by Mann-Whitney U-test, between samples 
BPH turp and CRPC. (Jalava et al. 2012) 
Table 8: Functional analysis of pre-miR-32 and pre-miR-148a transfected LNCaP 
cells. Significance is assessed by Welch t-test. 
  pre-miR-ctrl pre-miR-32 pre-miR-148a 
Relative growth (relative to day 1)    
+5d 2.467 3.363 3.573 
  p=0.0002 p=0.0022 
Cell cycle analysis (fold change compared to pre-miR-ctrl)   
G1 1 1.059 n.s 0.92 n.s 
G2 1 0.672 n.s 1.202 n.s 
S 1 0.856 n.s 4.829 p= 0.0257 
apoptosis 1 0.359 p=0.0353 1.43 n.s 
Caspase 3 staining    
 % of positive 7.17 4.01     
  p=0.0037   
 
Agilent mRNA microarrays were utilized to identify putative targets of miR-32 
and miR148a. Even though miRNAs can repress the translation of target genes, it 
has been shown that miRNAs predominantly act by decreasing the mRNA level of 
their targets (Guo et al. 2010). This makes mRNA microarrays an efficient tool for 
identifying putative target genes. Of the genes that were down-regulated by pre-
miR-32 or pre-miR148a transfection in LNCaP cells, BTG2 (B-cell translocation 
gene 2) and PIK3IP1 (phosphoinositide-3-kinase interacting protein 1) were selected 
for further study as putative target genes of miR-32 and miR-148a, respectively. 
Down-regulation of BTG2 and PIK3IP1 by transfection of miR-32 and miR-148a 
was confirmed at both the protein and the mRNA level. Luciferase reporter assays 
indicated direct binding of miR-32 to the BTG2 3’UTR and of miR-148a to the 
PIK3IP1 3’UTR (original communication III). Taken together these results, miR-32 
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and miR-148a were discovered to be up-regulated in CRPC. Both of the miRNAs 
enhanced the growth of LNCaP cells, miR-32 by reducing apoptosis. These 
miRNAs were shown to be regulated by androgens, and BTG2 and PIK3IP1 were 
found to be the target genes for miR-32 and miR-148a, respectively.  
BTG2 is tumor suppressor, which is involved in many cellular processes, 
including cell cycle control and apoptosis (Hong et al, 2005; Winkler, 2010). It has 
been previously been reported to be down-regulated in primary prostate tumors, 
however in the study CRPCs were not evaluated (Ficazzola et al. 2001). PIK3IP1 
interacts with PI3K and negatively regulates its activity (Zhu et al. 2007).  
BTG2 and PIK3IP1 expression was analyzed by immunohistochemistry in 264 
primary tumors (PC) and CRPCs. The expression of PIK3IP1 was reduced in 
malignant tissue compared with non-malignant tissue, but there was no significant 
difference in staining intensity between PC and CRPC. In contrast, BTG2 staining 
intensity was significantly lower in CRPC compared with PC. In prostatectomy 
specimens, low BTG2 staining was significantly associated with a higher pT stage 
(pT3 vs. pT2), but was not associated with Gleason score or PSA progression (Table 
9). In addition, loss of BTG2 expression was significantly associated with a shorter 
progression-free period (original communication III). 
Table 9: BTG2 and PIK3IP1 protein expression in clinical prostate cancer samples. 
Significance is assessed by chi-square test.  
  BTG2 PIK3IP1 
 PC  CRPC PC CRPC 
  n=168 n=85 n=170 n=94 
IHC 0 (%) 10 27 4 3 
IHC 1 (%) 38 54 29 29 
IHC 2 (%) 46 19 56 66 
IHC 3 (%) 6 0 11 2 
p-value   <0.0001   n.s 
 pT2 pT3 pT2 pT3 
  n=115 n=50 n=116 n=52 
IHC 0 (%) 6 20 3 4 
IHC 1 (%) 39 34 27 34 
IHC 2 (%) 45 43 57 25 
IHC 3 (%) 10 0 13 8 
p-value   0.009   n.s. 
 
 
We have previously shown that miR-32 is up-regulated by androgens (Waltering 
et al. 2010). Also the androgen responsiveness of miR-148a has been suggested 
(Murata et al. 2010). However, several studies failed to observe androgen regulation 
of miR-32 and miR-148a (Ambs et al. 2008; Shi et al. 2007 and Ribas et al. 2009). 
There are several reasons for the contradictory results. Ambs et al., Shi et al. and 
Ribas et al. used the synthetic androgen R1881, whereas we treated cells with DHT. 
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All of the other studies treated with androgens for longer times, ranging from 12 h-
72 h; we detected the best induction of miR-32 and miR-148a at 6 h (original 
communication III). In addition, the platforms differed in all studies (Agilent 
microarrays in our study, custom-made array platforms in Ambs et al. and Ribas 
etnd Northern blots in Shi et al.). 
There are two published targets for miR-148a in prostate cancer, CAND1 (cullin-
associated and neddylation-dissociated 1) and MSK1 (antigen identified by 
monoclonal antibody AJ9) (Murata et al. 2010; Fujita et al. 2010). Neither of these 
genes was down-regulated in the mRNA array of miR-148a-overexpressing LNCaP 
cells, therefore they were not further studied.  
In the study of Murata et al., CAND1 was found to be miR-148a target in the 
same cell line that we used, LNCaP. miR-148a targets were searched from Sagner 
miRBase Target database, and CAND1 was selected for further study. They saw 
CAND1 downregulation by miR-148a transfection, in both mRNA and protein 
level, which contradictories with our microarray data. In addition, in luciferase 
reporter assay where CAND1 3´ÚTR was used, miR-148a transfection reduced 
luciferase activity. These discrepancies are difficult to explain, it could be useful to 
study in our LNCaP cells whether CAND1 downregulation by miR-148a could be 
seen in protein level by Western blot analysis.  
The study by Fujita et al. is one of the examples how the use of different cell 
lines can produce conflicting data. They selected miR-148a for further studies 
because in DU145 and PC-3 cells have lower expression of miR-148a than 
androgen responsive cell lines and in PrEC cell line. They come to conclusion that 
miR-148a is tumor suppressor in prostate cancer, and that it targets MSK1 in PC-3 
cells. Here we show that miR-148a is up-regulated in castration-resistant prostate 
cancer. However, sometimes even when expression in clinical samples is studied, 
different research groups get opposite results.  One example is miR-221 and miR-
222, which have been suggested to be both, oncogenic and tumor suppressors in 
prostate cancer. They have been suggested to be overexpressed in androgen 
independent cells and possess oncogenic functions in prostate cancer (Sun et al. 
2009). However, we and others have seen that these miRNAs are down-regulated in 
primary tumors and in CRPC (Schaefer et al. 2010; Spahn et al. 2010). In one study, 
up-regulation of miR-221 and 222 was demonstrated in CRPC bone metastasis. In 
contrast, they do see downregulation of these miRNAs in primary tumors (Sun et al. 
2011). These might represent a real situation, where miRNA expression is under 
complex and flexible regulation, and they function differentially in different stages 
of prostate cancer. On the other hand, these results may be due to the differential 
sample preparation and different study platforms.  
 PIK3IP1 was identified as a target gene of miR-148a, despite the fact that none 
of the target prediction programs selected it as a predicted target. Luciferase assays 
indicated direct binding of miR-148a to the PIK3IP1 3’UTR. Target predictions are 
based on the idea that the six nucleotide long seed sequence of a miRNA (positions 
2-7) must be fully complementary to the target sequence (Lewis et al. 2005). 
However, predictions suffer from both false positives and false negatives results 
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(Min & Yoon, 2010). There is evidence that noncanonical target sites exist, with 
bulges in the seed region. So far, it is not known which general rules could be used 
for predicting such sites (Chi et al. 2012) 
In further studies, PIK3IP1 expression did not correlate with miR-148a 
expression because PIK3IP1 expression was not down-regulated in CRPC compared 
to primary tumors. It is possible that we failed to correctly identify miR-148a targets 
by mRNA array or that the targets differ in LNCaP cells versus clinical samples. In 
cell lines, mRNAs often have truncated 3’ UTRs, and therefore miRNA target genes 
might be different in vitro than in vivo (Sandberg et al. 2008). 
Ambs and colleagues (2008) reported the up-regulation of miR-32 in prostate 
cancer. In the Rotterdam clinical samples, we observed miR-32 up-regulation in 
primary tumors (original communication II), but in the Tampere clinical sample set, 
miR-32 was only up-regulated in a subset of the primary tumors. However, the most 
dramatic up-regulation of miR-32 in the Tampere clinical sample set was detected in 
castration-resistant disease (Figure 9, original communication III). Ambs et al. 
reported that BCL2L11 (also known as Bim) is a target gene of miR-32. We did not 
find down-regulation of Bim by transfecting miR-32 into LNCaP cells (original 
communication III). In contrast, we identified BTG2 as a target of miR-32. It is 
possible, as miRNAs often have several target genes, that both genes are targeted by 
miR-32 in different cellular environments. BTG2 expression is reduced in CRPC, 
and loss of BTG2 correlates with reduced progression-free survival. In the 
Rotterdam clinical sample set, miR-32 was one of the 25 miRNAs that predicted the 
prognosis of prostatectomy-treated patients (original communication II).  
Further studies are required to address whether either miR-32 or BTG2 can be 
used as a prognostic marker in prostate cancer. Prognostic factors in clinical use are 
Gleason score, pT-stage (pathological tumor stage) and the level of PSA (Partin et 
al. 2001; Graff et al. 2007). Careful evaluation of BTG2 staining alone and in 
combination with these existing markers is needed to address the question whether 
BTG2 staining is usable as a prognostic marker, independently or in combination 
with other markers. The same studies should be done with miR-32, but there are 
technical issues that are needed to overcome before miRNA expression can be 
analyzed in efficient way from clinical tumor samples. In addition, it should be 
evaluated if miR-32 could be detected from the blood or from the urine of the 
prostate cancer patients, which would make the detection easier. 
Here we suggest a mechanism how the expression of tumor suppressor BTG2 is 
down-regulated in advanced tumors by miR-32. Expression of miR-32 on the other 
hand, seems to be regulated by AR binding to the miR-32 promoter. However, there 
might be other mechanisms for miR-32 overexpression, like epigenetic regulation 
that needs to be studied. If AR is responsible for miR-32 up-regulation there must be 
reason why this is occurring only in cancer and not in normal prostate epithelium. 
There might be other collaborating factors that enhance AR binding to miR-32 
promoter.  
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CONCLUSIONS 
The primary findings and conclusions of this thesis are as follows: 
 
Of the four putative 8q target genes studied, EIF3H and TCEB1 had functional 
effects on prostate cancer cells. TCEB1 silencing reduced the invasion and colony 
formation of cancer cell lines. In addition, overexpression of TCEB1 enhanced the 
growth of murine fibroblast cells. Overexpressed EIF3H enhanced cellular growth. 
The increased expression of TCEB1 in castration-resistant disease was confirmed. 
These data indicate that TCEB1 and EIF3H are putative target genes of 8q21 and 
8q24 amplifications, respectively. 
miRNA expression in prostate cancer was profiled in a large clinical dataset. 
Altogether, 80 miRNAs were differentially expressed in malignant tissue compared 
with benign tissue. Of these, 25 miRNAs were able to separate primary tumors into 
an aggressive group and a less aggressive group. In this dataset, these miRNAs 
predicted prognosis better than a Gleason score, pathological stage or preoperative 
PSA. 
miRNA expression was evaluated in castration-resistant prostate cancers. In total, 
88 miRNAs were differentially expressed. The LNCaP-derived cell line was used to 
map ARBS in the genome, from which 414 miRNAs with ARBS were identified. Of 
these, 28 miRNAs were de-regulated in CRPC.  
After initial screening, miR-32 and miR-148a were selected for follow-up 
studies. They are both up-regulated in CRPC, contain ARBS, and are up-regulated 
by androgens. In addition, when transfected into an androgen-responsive cell line, 
they each imparted a growth advantage to the cells; miR-32 accomplished this by 
inhibiting apoptosis.  
BTG2 and PIK3IP1 were identified as target genes for miR-32 and miR-148a, 
respectively. By immunohistochemistry, the expression of PIK3IP1 was decreased 
in prostate cancer compared with non-malignant tissue, but there were no 
differences in PIK3IP1 expression between CRPC and primary tumors. In contrast, 
the expression of BTG2 was decreased in CRPC compared with primary tumors. 
Low BTG2 staining in prostatectomy specimens was associated with higher pT 
stage and a shorter progression-free period.  These preliminary results indicate that 
either miR-32 or BTG2 could be potential therapeutic targets in advanced prostate 
cancer.  
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TCEB1 promotes invasion of prostate cancer cells
Sanni E. Jalava1, Kati P. Porkka1, Hanna E. Rauhala1, Jarkko Isotalo1, Teuvo L. Tammela2 and Tapio Visakorpi1*
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Ampliﬁcation of the long arm of chromosome 8 is one of the most
recurrent ﬁndings in prostate cancer and it is associated with poor
prognosis. Several minimal regions of ampliﬁcation suggest multi-
ple target genes which are yet to be identiﬁed. We have previously
shown that TCEB1, EIF3S3, KIAA0196 and RAD21 are ampliﬁed
and overexpressed in prostate cancer and they are located in the
8q area. In this study, we examined the functional effects of these
genes to prostate cancer cell phenotype. We overexpressed and
inhibited the genes by lentivirus mediated overexpression and
RNA interference, respectively. shRNA mediated TCEB1 silencing
decreased signiﬁcantly cellular invasion of PC-3 and DU145 cells
through Matrigel. TCEB1 silencing reduced the anchorage-inde-
pendent growth of PC-3 cells. Similar effects were not seen with
any other genes. When overexpressed in NIH 3T3 cells, TCEB1
and EIF3S3 increased the growth rate of the cells. Transcriptional
proﬁling of TCEB1 silenced PC-3 cells revealed decrease of genes
involved in invasion and metastasis. Finally, we also conﬁrmed
here the overexpression of TCEB1 in hormone-refractory prostate
tumors. This study indicates that TCEB1 promotes invasion of
prostate cancer cells, is involved in development of hormone-
refractory prostate cancer and is thereby a strong candidate to
be one of the target genes for the 8q gain.
' 2008 Wiley-Liss, Inc.
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Prostate cancer is the most common male malignancy in West-
ern countries and the second most common cause of cancer related
deaths in males.1 Because of the intensive research in the past
years main chromosomal aberrations in prostate cancer have been
revealed, but hunting for many of the target genes is still in pro-
cess. Gain of the long arm of chromosome 8 (8q) is one of the
most recurrent ﬁndings in advanced prostate tumors and it is asso-
ciated with poor prognosis.2,3
Several minimal regions of ampliﬁcation of 8q have been iden-
tiﬁed by comparative genomic hybridization (CGH) and array-
CGH, suggesting several target genes. Two of these minimal
regions are 8q21 and 8q23-24.4–6 We have identiﬁed 4 genes that
are ampliﬁed and highly expressed in prostate cancer and located
in these regions. One of them, TCEB1 [transcription elongation
factor B (SIII), polypeptide 1 (15 kDa, elongin C)] is located in
8q21.11 and others RAD21 [RAD21 homolog (S. pombe)],
KIAA0196 and EIF3S3 (eukaryotic translation initiation factor 3,
subunit H) in 8q23-24.7–9
TCEB1 was found to be ampliﬁed in 20% of hormone-refrac-
tory prostate tumors. Although in untreated primary tumors no
gene ampliﬁcation was found, low-level gains were found in about
30% of the tumors. In PC-3 cell line, which contains the TCEB1
gene ampliﬁcation, the expression is 5 times higher compared to
cell lines with no ampliﬁcation.7 RAD21 is ampliﬁed in 30% of
hormone-refractory carcinomas and it is expressed signiﬁcantly
more in untreated prostate carcinomas than in benign prostate
hyperplasia (BPH). Also KIAA0196 is ampliﬁed in 30% of hor-
mone-refractory tumors and its expression is associated with the
ampliﬁcation.8 High-level ampliﬁcation of EIF3S3 has been found
in 30–50% of hormone-refractory cancers. The expression of
EIF3S3 is also higher in prostate carcinomas than in BPH.9–11
The RAD21 protein is one of the 4 subunits forming the cohesin
complex which holds sister chromatins together until the onset of
anaphase.12 In addition to this, RAD21 plays a role in apoptosis as
it is cleaved by caspases during the apoptosis signaling cascade.13
The expression of RAD21 has been reported to be upregulated in
metastatic breast cancer and it has been shown that silencing
RAD21 in breast cancer cells decreases cell growth and sensitizes
cells to chemotherapeutic drugs.14,15 EIF3S3 is one of the subunits
of a multiprotein complex that has a central role in translation ini-
tiation.16 Ampliﬁcation of EIF3S3 has been reported also in breast
and hepatocellular carcinomas.9,17 We have previously shown that
EIF3S3 promotes growth of prostate and breast cancer cells.18
Zhang et al.19 suggested that overexpression of any subunit of
EIF3 is enough to transform immortal ﬁbroblast cells. TCEB1 is
one of the 3 subunits of the Elongin complex (SIII) that activates
transcription.20 TCEB1 binds also to many proteins in cytoplasm,
namely von Hippel-Lindau (VHL) protein and SOCS-box contain-
ing proteins.21,22 TCEB1 has not been studied as a putative onco-
gene before. KIAA0196 is a poorly known gene, and its function
in cancer has not been studied before.
The aim of this study was to evaluate the roles of these 4 putative
target genes (TCEB1, RAD21, KIAA0196 and EIF3S3) of the 8q
ampliﬁcation in prostate cancer. We overexpressed and inhibited
the genes by lentivirus mediated overexpression and RNA interfer-
ence, respectively. Effects of gene silencing or overexpression were
evaluated using cell based assays such as proliferation assay,
anchorage-independent growth and Matrigel invasion assay.
Material and methods
Cell lines and tumor samples
All cell lines (PC-3, DU145, NIH 3T3, HEK 293T/17) were
purchased from ATCC (Rockville, MD) and cultured according to
the recommended protocols.
Freshly frozen samples of 9 benign prostatic hyperplasia
(BPH), 30 untreated primary and 12 locally recurrent hormone-
refractory prostate cancer specimens were obtained from Tampere
University Hospital and used for real time quantitative RT-PCR.
All the specimens were ﬁrst histologically examined to contain
more than 60% of cancerous or hyperplastic tissue. BPH samples
were obtained from prostatectomy specimens from cancer
patients, but the specimens were ﬁrst histologically analyzed not
to contain any cancer. Subsequently, cells were scratched from
frozen tumor blocks using a pre-cooled, sterile scalpel for RNA
extraction. The use of clinical material has been approved by Ethi-
cal Committee of the Tampere University Hospital.
Generation of the lentiviral constructs
Small interfering RNA (siRNA) sequences were designed
according to the public recommendations (http://www.rockefeller.
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edu/labheads/tuschl/sirna.html) and screened against the GenBank
database by BLAST (http://www.ncbi.nlm.nih.gov/blast/Blast.
cgi). Efﬁciency of the siRNA target sequences of RAD21,
KIAA0196, EIF3S3 and TCEB1 were ﬁrst tested in PC-3 cell line
using synthetic siRNA oligos (data not shown). Short hairpin
RNA (shRNA) sequences were created from the tested siRNA
sequence by adding XhoI restriction site and loop sequences (Ta-
ble I). shRNA oligos were purchased from Sigma-Proligo (The
Woodlands, TX). shRNAs were subsequently cloned into the len-
tiviral plasmid Lentilox3.7 (pLL3.7), kindly provided by Dr. Kalle
Saksela, (University of Helsinki, Finland). Sequence analysis was
performed to verify appropriate coding sequence. cDNA clones of
each of the 4 genes were obtained from Geneservice (Cambridge,
UK). Coding regions of RAD21, KIAA0196, EIF3S3 and TCEB1
were cloned into the lentiviral plasmid WPI (kindly provided by
Dr. Jarmo Wahlfors, University of Tampere, Finland), and appro-
priate sequence was veriﬁed by sequence analysis.
Virus production and transductions
VSVg pseudotyped lentiviral particles were produced in HEK
293T/17 cells by calsium phosphate precipitation technique.
pLL3.7 vector containing the shRNA sequences and pWPI con-
taining the coding regions were co-transfected with packaging
plasmids pCMVD8.9 and pVSV-G (System Biosciences, Moun-
tain View, CA).23 pLL3.7 contains green ﬂuorescence protein
(GFP) as a reporter gene. Titers were measured by transducing
PC-3 cells using serial dilution of viruses and analyzing the per-
centage of GFP positive cells by Agilent 2100 Bioanalyzer (Agi-
lent Technologies, Palo Alto, CA) after 72 hr incubation. In most
experiments, PC-3, DU145 and NIH 3T3 cells were transduced
with the multiplicity of infection (MOI) 10 to obtain >90% trans-
duction efﬁciency. To enhance the viral transduction, 8lg/ml of
polybrene (Sigma-Aldrich, Milwaukee, WI) was used in every
transduction. The cells showed overexpression or silencing of the
genes for several weeks after the transduction.
Quantitative real-time RT-PCR (q-RT-PCR)
Total RNA from the cell lines or tumor samples were extracted
using RNeasy Mini Kit (Qiagen, Valencia, CA), and was used for
the ﬁrst strand cDNA synthesis with AMV Reverse Transcriptase
(Finnzymes, Espoo, Finland) and Random primers (Promega, Madi-
son, WI) (cell lines) or Superscript II Reverse Transcriptase and
oligo d(T)12–18 primers (Invitrogen Life Technologies, Carlsbad,
CA) (tumor samples). The expression levels of RAD21, KIAA0196,
EIF3S3 and TCEB1 and a housekeeping gene TATA-box binding
protein (TBP) were analyzed according to the previously described
guidelines.8 Brieﬂy, PCR reactions were performed using the Light-
CyclerTM apparatus (Roche Diagnostics, Mannheim, Germany)
with the LC Fast Start DNA SYBR Green I Kit (Roche Diagnos-
tics). Melting curve analysis and agarose gel runs were performed
to ensure the formation of speciﬁc PCR products.
Western blot and antibodies
Cells growing on a 10-cm plate were harvested using scraper
and cytoplasmic and nuclear proteins were isolated, separately.
Brieﬂy, cells were ﬁrst suspended to Hypotonic buffer (10 mM
Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.2 mM PMSF, 0.5
mM DTT), and cytoplasmic proteins were collected from superna-
tant. Remaining pellet were then resuspended Low-salt buffer (20
mM Hepes, pH 7.9, 25% glycerol, 1.5 mM MgCl2, 20 mM KCl,
0.2 mM EDTA, 0.2 mM PMSF, 0.5 mM DTT), and nuclear pro-
teins were collected using High-salt buffer (as Low-salt buffer, but
1.2 M KCl). Protein concentration was measured using simpliﬁed
Bradford method (BioRad Laboratories, Hercules, CA). 20 lg of
proteins were separated by electrophoresis through 8% (RAD21)
or 12% (TCEB1) SDS-PAGE gels and transferred to PVDF mem-
branes (Immobilon-P, Millipore, Billerica, MA) using semi-dry
transfer technique. Membranes were incubated with primary anti-
body (RAD21: dilution 1:500 anti-RAD21 Novus Biologicals, Lit-
tleton, CO; TCEB1: dilution 1:250 anti-SIII p15, BD Transduction
laboratories, San Jose, CA; Actin: dilution 1:400 pan AB-5 clone
ACTN05, Lab Vision, Fremont, CA) for 1 hr in room temperature.
After washing and incubation with secondary antibodies, protein
bands were visualized on autoradiography ﬁlm by using the West-
ern Blotting Luminol Reagent (Santa Cruz, CA) according to the
manufacturer’s guidelines.
Growth curves
Cells transduced with lentiviruses were plated on a 24-well
plate at 20,000 cells/ml (PC-3) or 60,000 cells/ml (NIH 3T3) den-
sity. Alamar BlueTM (Trek Diagnostic Systems, Cleveland, OH,
USA) was added to the wells to ﬁnal concentration of 10%. Oxi-
dized form of Alamar Blue enters the cytosol of the cells and is
converted to reduced form by mitochondrial enzyme activity. This
redox reaction changes the color of Alamar Blue from blue to
pink. Fluorescence was measured after 2 hr of incubation using a
96-well ﬂuorometer (Wallac 1420 Victor, PerkinElmer, Fremont,
CA). Values were normalized against Day 1. Each experiment
was done in 5 replicates.
Cell cycle analysis by ﬂow cytometry
Propidium iodide-staining and ﬂow cytometric analysis was
used to determine the number of cells in S-phase fraction (SPF)
and apoptosis. Cells transduced with lentiviruses were harvested
and resuspended to the Hypotonic Staining Buffer (0.1 mg/ml so-
dium citrate dehydrate, 50 lg/ml propidium iodide, 2 lg/ml Ribo-
nuclease A and 0.003% Triton1 X-100) and the amount of propi-
dium iodide incorporated to the genome was measured using ﬂow
cytometry (Coulter1 EPICS XL-MCL, Beckman Coulter, Fuller-
ton, CA). Each experiment was done in triplicate. The relative
proportions of SPF and apoptotic/necrotic cells were analyzed
using the EXPO32 ADC software program.
Soft agar assay
Anchorage-independent growth was assessed by colony forma-
tion in soft agar. The 5% agarose solution (Low gelling tempera-
ture Agarose, Electran, BDH Chemiclas, Poole, UK) was mixed
with culture medium to make 0.5% agarose for lower layer. Cells
transduced with lentiviruses were trypsinized and dilution of
5,000 cells/well was mixed with 5% agarose to form 0.35% upper
layer, and allowed to solidify before incubation at 37C. Cells
were fed twice a week with culture medium. After 2 weeks, colo-
TABLE I – THE shRNA SEQUENCES USED
Name Sequence: (50–30direction)
shRAD21 TGTAGTTCGAATCTATCACATTCAAGAGATGTGATAGATTCGAACTACTTTTTTC
ACATCAAGCTTAGATAGTGTAAGTTCTCTACACTATCTAAGCTTGATGAAAAAAGAGCT
shKIAA0196 TGTCAGAGAGAGGATGCTGGTTCAAGAGACCAGCATCCTCTCTCTGACTTTTTTC
ACAGTCTCTCTCCTACGACCAAGTTCTCTGGTCGTAGGAGAGAGACTGAAAAAAGAGCT
shTCEB1 TGCATTAACATCAGGCACGATTCAAGAGATCGTGCCTGATGTTAATGCTTTTTTC
ACGTAATTGTAGTCCGTGCTAAGTTCTCTAGCACGGACTACAATTACGAAAAAAGAGCT
shEIF3S3 TGCAAGTGCAGATAGATGGCTTCAAGAGAGCCATCTATCTGCACTTGCTTTTTTC
ACGTTCACGTCTATCTACCGAAGTTCTCTCGGTAGATAGACGTGAACGAAAAAAGAGCT
shLUC TGATTTCGAGTCGTCTTAATTTCAAGAGAATTAAGACGACTCGAAATCTTTTTTC
ACTAAAGCTCAGCAGAATTAAAGTTCTCTTAATTCTGCTGAGCTTTAGAAAAAAGAGCT
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nies were photographed under UV-microscope and counted. All
experiments were done in triplicate and repeated at least twice.
Invasion assay
Invasion assay was done using the MatrigelTM Invasion Cham-
bers (BD Biosciences, Bedford, MA). The culture medium in the
wells contained 10% FBS as chemoattractant. 13 105 of lentiviral
transduced PC-3 or DU145 cells in culture medium containing 1%
FBS were plated onto an insert. Plates were incubated in 37C for
22 hr. Next, the cells inside the inserts were removed, and the
invaded cells were ﬁxed with methanol and stained with hematox-
ylin. Wells were photographed under microscope and the relative
area of cells as function of number of invading cells were meas-
ured using image analysis software program ImageJ.24 Each
experiment was done in triplicate and repeated at least twice.
Wound-healing assay
PC-3 cells transduced with lentiviruses were plated on a 6-well
plate and allowed to grow to conﬂuency. Three separate wounds
were drawn by pipet tip into the well. Cells were rinsed with PBS
and fresh medium was added to the wells. Pictures were taken by
microscope in 0 and 15 hr and the relative size of the wound was
analysed by ImageJ.24 Each experiment was done in triplicate.
Microarray
PC-3 shLUC -transduced and PC-3 shTCEB1-transduced cells
were used for gene expression analysis. shLUC transduced cells
were used as a control. Cells were harvested 7 days after transduc-
tion into Trizol RNA extraction reagent (Invitrogen) and total
RNA was extracted. Gene expression proﬁling was done using
Agilent Technologies’ (Santa Clara, CA) Dual-Mode Gene
Expression Platform. 500 ng of RNA was labeled using Low RNA
Input Linear Ampliﬁcation PLUS, Two-Color Kit. Ampliﬁed and
labelled samples were hybridized on Agilent’s Whole Human Ge-
nome Oligo Microarray (44k). Microarray was scanned using Agi-
lent’s DNA Microarray Scanner and data was extracted and nor-
malized using Agilent’s Feature Extraction software (v9.5.1). No
background signals were subtracted and data was normalized
using the ‘‘linear and lowess method’’. All low-quality data points
(low signal-to-noise ratio, saturated signals or nonuniform signals)
were excluded from further analysis. Genes were considered to be
differentially expressed if there was more than 2-fold difference in
expression between shTCEB1 and shLUC. Microarray data have
been deposited to ArrayExpress database (Accession number E-
MEXP-1627)
Gene ontology enrichment analysis
Enrichment of differentially expressed genes in TCEB1 silenced
cells into speciﬁc gene ontologies was studied using statistical
computing environment R with topGO package from Bioconduc-
tor software project.25
Statistical analysis
Two-tailed Mann-Whitney U-test or Unpaired t-test with Welch
correction was used to determine statistical difference between ex-
perimental and control groups. p-value of <0.05 was considered
signiﬁcant.
Results
TCEB1 expression in clinical samples
The data on the expression of EIF3S3, RAD21 and KIAA0196
in clinical prostate cancer have been published before.8,11 Here,
we analyzed the TCEB1 expression in clinical samples of BPH,
untreated primary, and hormone-refractory prostate carcinomas by
using q-RT-PCR. As shown in Figure 1, expression of TCEB1 was
signiﬁcantly increased in hormone-refractory prostate carcinomas,
compared to the untreated primary tumors (p 5 0.0184).
Generation of cell lines
PC-3 cell line was used as a model to examine the role of
RAD21, TCEB1, EIF3S3 and KIAA0196 in prostate cancer. PC-3
cell line contains the ampliﬁcation of 8q and the genes are all
expressed in PC-3.7,8,11 Lentivirus mediated shRNA system was
set up for each of these genes. shRNAs were subcloned into a plas-
mid Lentilox3.7 which express shRNA under human U6 promoter
and reporter gene EGFP under a control of cytomegalovirus (CMV)
promoter. Cells were ﬁrst transduced with different multiplicity of
infections (MOIs) and the expression of the target genes were eval-
uated using the Q-RT-PCR (data not shown). Transducing cells with
MOI 10 led to 65–85% speciﬁc inhibition of target gene at mRNA
level (Fig. 2a). Effects of gene silencing were seen also at the pro-
tein level with RAD21 and TCEB1 (Figs. 2c and 2d). No reliable
antibodies are available against KIAA0196 or EIF3S3, which is why
silencing of these genes was only demonstrated at the mRNA level.
Fireﬂy luciferase shRNA was used as a negative control in each
experiment. The same shRNA system was used in DU145 cell line,
where TCEB1 was 70% silenced using MOI 10 (Fig. 2b).
NIH 3T3 cells were used to set up an overexpression model of
RAD21, KIAA0196, EIF3S3 and TCEB1. Coding regions of the
genes were subcloned into lentiviral plasmid WPI in which the
transgene and GFP are bicistronically expressed under EF1-alpha
promoter. GFP expression was used to determine the transduction
efﬁciency by ﬂuorescence microscope and Bioanalyzer. After
transduction, transgene expression was evaluated at the mRNA
level. The expression of the transgene was 30–600 times higher in
transduced cell line than in empty vector control (Fig. 2e). In the
case of TCEB1 and RAD21, for which speciﬁc antibodies were
available, upregulation was seen also at the protein level (Figs. 2f–
2g).
The effect of gene silencing and overexpression on the growth
of the cells was assessed using growth curves. Silencing RAD21,
KIAA0196, TCEB1 or EIF3S3 in PC-3 cell line did not cause any
affects on the cell growth compared to shLUC transduced cells
(Fig. 3a). Results were conﬁrmed by determination of SPF by
ﬂow cytometry, the mean 6 SD of SPF were: shLUC 15.1 6
2.3%, shRAD21 14.9 6 0.3%, shEIF3S3 13.8 6 1.0%,
shKIAA0196 14.4 6 1.2% and shTCEB1 13.4 6 0.8%. No effects
were seen on the apoptotic/necrotic cell populations either in the
ﬂow cytometric analysis (data not shown).
Overexpressing RAD21 or KIAA0196 in NIH 3T3 cells did not
have any effects on the cell growth, whereas overexpressing
EIF3S3 or TCEB1 increased signiﬁcantly cell growth compared to
FIGURE 1 – Mean (6SEM) relative expression level of TCEB1 in
BPH (n 5 9), untreated primary (n 5 30) and hormone-refractory (n
5 12) prostate carcinomas analyzed by q-RT-PCR. Error bars indicate
standard error of the mean. TCEB1 expression was signiﬁcantly higher
in hormone-refractory tumors compared to BPH (p 5 0.0184, Mann-
Whitney U-test).
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cells tranduced with empty vector (p 5 0.0317, p 5 0.0079,
respectively) (Fig. 3b).
Invasion and anchorage-independent growth
We used the highly invasive PC-3 cells to assess the inﬂuence
of RAD21, EIF3S3, KIAA0196 and TCEB1 on invasion by using
the Matrigel invasion assay. Silencing of EIF3S3, KIAA0196 and
RAD21 had no signiﬁcant effects on the ability of the cells to
invade. Whereas, TCEB1 silencing signiﬁcantly reduced invasion
(p 5 0.042) as shown in Figure 4a. Similar reduction on invasion
(p 5 0.0036) was also seen with the other invasive prostate cancer
cell line DU145 (Fig. 4b). No effect was seen on the migration of
TCEB1 silenced PC-3 cells, studied by the wound healing assay
(Supp. Fig. 1).
Next we wanted to study the effects of gene silencing on the
colony formation using soft agar assay. After 14 days of incuba-
tion RAD21, EIF3S3 or KIAA0196 silenced PC-3 cells formed col-
onies as much as the control cells. Whereas, PC-3 cells where
TCEB1 was silenced formed about one third less colonies than
control cells (p 5 0.005). (Fig. 4c). However, NIH 3T3 cells over-
expressing TCEB1 did not form colonies on soft agar, indicating
that the TCEB1 is not able to transform the cells (data not shown).
Gene expression proﬁle of TCEB1 suppressed PC-3 cells
To examine which genes are associated with TCEB1 expres-
sion, we analyzed gene expression in TCEB1 silenced PC-3 cells
compared to control (shLUC transduced) cells by using Agilent’s
Whole Human Genome Oligo Microarray (44k). Both copies of
FIGURE 2 – (a) Mean (6SD) relative expression of the genes in shRNA silenced PC-3 cells according to q-RT-PCR. Expression was normal-
ized using housekeeping gene TBP and compared to the expression of the control, shLUC. (b) Mean (6SD) relative expression of TCEB1
silenced DU145 cells according to q-RT-PCR. Expression is normalized to TBP and compared to the expression of the control, shLUC. (c–d)
Western blot analysis of shRNA effects on TCEB1 or RAD21 expression in PC-3 cells. b-actin was used as a loading control. (e) Mean (6SD)
expression of pWPI-cDNA transduced NIH 3T3 cells according to q-RT-PCR. Expression was normalized to TBP and levels are compared to
the empty vector transduced cells. (f–g) Western blot analysis of pWPI-cDNA transduction effects on TCEB1 or RAD21 expression in NIH 3T3
cells. Actin was used as a loading control.
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TCEB1 probes on the array were among the 11 most downregulated
genes, which indicate successful gene silencing. Altogether 361
genes were found to be changed at least 2-fold (Supp. Table 1).
Among the 10 most downregulated genes were cytoskeleton
protein ankyrin G (ANK3), putative extracellular matrix protein
chordin-like 2 (CHRDL2) and protease ADAM metallopeptidase
with thrombospondin type 1 motif, 12 (ADAMTS12). One of the
most upregulated gene was angiopoietin/angiopoietin-like gene
family member, angiopoietin-like 4 (ANGPTL4). Table II shows
25 most downregulated or upregulated genes with existing annota-
tions. All 369 at least 2-fold changed genes were included in gene
ontology analysis, and of those, 181 had existing GO-annotation.
Enriched pathways are found in Supp. Table 2.
Discussion
Gain of 8q is one of the most common chromosomal aberrations
in advanced prostate cancers. It is also found in breast, bladder
and ovarian cancers. In prostate cancer, there are several minimal
regions of ampliﬁcation indicating more than one target gene. Our
group has identiﬁed 4 genes that are ampliﬁed in prostate cancer
and whose overexpression is associated with the ampliﬁcation.7,8,9
Three of the genes, RAD21, EIF3S3 and KIAA0196 are located in
the minimal ampliﬁcation region 8q23-24 and one of the genes,
TCEB1, is in the minimal ampliﬁcation region 8q21.
Originally, we identiﬁed TCEB1 as a candidate target gene as
its ampliﬁcation was associated with the expression in prostate
FIGURE 3 – (a) Growth curve of shRNA silenced PC-3 cells. Cells
transduced with lentiviruses were seeded on a 24-well plate and Ala-
mar Blue was added to the wells at each day of measurement (1, 3 and
5). Data are shown as mean 6 SD of each day of measurement nor-
malized against Day 1. Each experiment was done in ﬁve replicates.
(b) Growth curve of pWPI-cDNA transduced NIH 3T3 cells. Alamar
Blue assay was done as described in Figure 2a. pWPI-EIF3S3 and
pWPI-TCEB1 transduced cells grew signiﬁcantly (p 5 0.0317, p 5
0.0079, respectively) faster than control cells (empty pWPI vector).
Each experiment was done in ﬁve replicates and p-values were calcu-
lated by Mann-Whitney U-test.
FIGURE 4 – (a) shRNA silenced PC-3 cells were seeded into Matri-
gel invasion chambers and photographed after 22 hr incubation. The
mean (6SD) of relative area of invaded cells was counted with imageJ
from the photographs. TCEB1 silencing reduced signiﬁcantly invasion
(p 5 0.0422). Each experiment was done in triplicate and p-value was
calculated by Unpaired t-test with Welch correction. (b) DU145 cells
were treated with shTCEB1 and Matrigel invasion assay was done as
described in Figure 3a. Silencing TCEB1 reduced signiﬁcantly (p 5
0.0036) invasion of DU145 cells through Matrigel. (c) Effects of gene
silencing on colony formation of PC-3 cells in soft agar. TCEB1
silenced cells formed signiﬁcantly (p 5 0.0052) less colonies in soft
agar than control cells. After two weeks of incubation, plates were
photographed and colonies were count from the image with imageJ. In
the black and white photograph, the white color indicates green
colonies.
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cancer cell lines.7 Here, we conﬁrmed the increased expression
also in hormone-refractory tumors. We showed also that silencing
of TCEB1 in PC-3 cells reduced invasion. The role of TCEB1 in
invasion is in agreement with the expression as invasion and me-
tastasis are late stage events in tumorigenesis. We also wanted to
explore if the effects on invasion were seen in a cell line which
does not have an ampliﬁcation of TCEB1. TCEB1 was silenced in
DU145 prostate cancer cell line, which is aggressive and capable
of invasion through Matrigel but does not carry 8q gain. We
showed that in DU145 cells, TCEB1 silencing reduce invasion.
This indicates that TCEB1 promotes invasion with or without
ampliﬁcation. TCEB1 silencing also suppressed anchorage-inde-
pendent growth. However, TCEB1 expression alone was not
enough to transform NIH 3T3 cells. This indicates that TCEB1 is
not classical transforming oncogene.
TCEB1 has not previously been studied as a putative oncogene
and the link between its function and invasion is not known.
TCEB1 has several functions in cell. It is part of the Elongin com-
plex (SIII) that works as a transcription activator.20 TCEB1 inva-
sion promoting capability could be due to the enhancing expres-
sion of invasion related genes. TCEB1 has also functions in cyto-
plasm. There it is part of the von Hippel-Lindau (VHL) protein
complex. VHL targets the oncogene HIF1a for degradation selec-
tively in the presence of oxygen.26 Inherited VHL-disease is
caused by inactivating mutations in VHL which causes multiple
tumors in different organs. Mutations in VHL are frequently found
also from kidney cancers.27 VHL is not the only protein TCEB1
binds to. It has been shown that many SOCS-box proteins assem-
ble with Elongin C, Elongin B and the additional components Cul-
5 and Rbx2.28 This means that TCEB1 has a role in various com-
plexes that involve targeting proteins for degradation.
To study the transcriptional mechanisms how TCEB1 is
involved in invasion and metastasis, we proﬁled TCEB1 silenced
PC-3 cells with whole genome microarray. More than 300 genes
TABLE II – THE 25 MOST DOWNREGULATED OR UPREGULATED GENES IN THE TCEB1 SILENCED PC-3 CELLS
ACCORDING TO THE MICROARRAY ANALYSIS
Gene name Description Ratio
Downregulated
1 PAP2D Phosphatidic acid phosphatase type 2 0.15
2 ANK3 Ankyrin 3, epithelial 0.17
3 CHRDL2 Chordin-like 2 0.18
4 LUM Lumican 0.19
5 TCEB1 Transcription elongation factor B, polypeptide 1 0.20
6 RSHL3 Radial spokehead-like 3 0.20
7 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 0.22
8 FABP4 Fatty acid binding protein 4, adipocyte 0.22
9 TCEB1 Transcription elongation factor B polypeptide 1 0.25
10 DSEL Dermatan sulfate epimerase-like 0.27
11 SPATA4 Spermatogenesis associated 4 0.28
12 PAG1 Phosphoprotein associated with glycosphingolipid microdomains 1 0.30
13 GDF6 Growth differentiation factor 6 0.30
14 RNU12 RNA, U12 small nuclear 0.31
15 BC069749 STAM binding protein-like 1 0.33
16 IGFBP5 Insulin-like growth factor binding protein 5 0.33
17 GCK Glucokinase 0.34
18 AW377662 Keratin associated protein 4–7 0.35
19 IL23A Interleukin 23, alpha subunit p19 0.36
20 CXCL6 Chemokine (C-X-C motif) ligand 6 0.36
21 TGM2 Transglutaminase 2 0.36
22 ARSB Arylsulfatase B 0.37
23 LOC204010 Similar to 40S ribosomal protein SA (P40) 0.37
24 IL13RA2 Interleukin 13 receptor, alpha 2 0.37
25 DMD Dystrophin 0.38
Upregulated
1 THC2780053 50S ribosomal protein L16 9.32
2 ANGPTL4 Angiopoietin-like 4 6.15
3 PPFIA4 Protein tyrosine phosphatase, receptor type, f polypeptide 4.58
4 STC1 Stanniocalsin 1 3.69
5 IGF2 Insulin-like growth factor 2 3.47
6 LTB Lymphotoxin beta (TNF superfamily, member 3) 3.41
7 KRT37 Keratin 37 3.32
8 CA9 Carbonic anhydrase IX 3.13
9 RDH12 Retinol dehydrogenase 12 3.11
10 EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1 3.08
11 SEC14L1 SEC14-like 1 3.06
12 NDRG1 N-myc downstream regulated gene 1 2.97
13 TLE1 Transducin-like enhancer of split 1 2.97
14 LCN2 Lipocalin 2 2.96
15 CFLP1 Coﬁlin pseudogene 1 2.95
16 MDK Midkine (neurite growth-promoting factor 2) 2.94
17 H1F0 H1 histone family, member 0 2.87
18 ZNF580 Zinc ﬁnger protein 580 2.87
19 ALDH1A3 Aldehyde dehydrogenase 1 family, member A3 2.87
20 WFDC5 WAP four-disulﬁde core domain 5 2.86
21 S100A11 S100 calcium binding protein A11 2.82
22 VIPR1 Vasoactive intestinal peptide receptor 1 2.69
23 FAM100A Family with sequence similarity 100, member A 2.66
24 MRPL2 Mitochondrial ribosomal protein L2 2.64
25 SORBS3 Sorbin and SH3 domain containing 3 2.56
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were found to be at least 2-fold changed, and of those less than
200 had existing annotation. Proﬁling revealed downregulation of
extracellular matrix components ANK3 and CHRDL2, and metal-
loproteinase domain containing ADAMTS12, which were all
among top 10 of most downregulated genes in the array. Ankyrins
are a family of proteins that link the integral membrane proteins to
the underlying spectrin-actin cytoskeleton. In one study ANK3
was one of the genes in 11 gene signature which associated with
prognosis of several cancers, including prostate cancer. Decreased
expression of ANK3 was associated with good prognosis pheno-
type.29 Another extracellular matrix component, CHRDL2, also
known as BNF-1, is found to be upregulated in tumors.30 Disinte-
grin and metalloproteinases ADAMS and ADAMTS are involved
in various biological events and many of them are expressed in
malignant tumors. For example ADAM12 has been shown to
digest extracellular matrix compounds, gelatin, Type IV collagen
and ﬁbronectin.31 ADAMTS12 is known to be proteinase type, but
detailed information about its substrates and biological functions
is not known.32 One of the most upregulated gene in the array was
ANGPTL4 which is suggested to inhibit invasion and motility.33,34
Thus, the association of TCEB1 with the expression of these genes
could, at least partly, explain the mechanisms how TCEB1 is pro-
moting invasiveness of prostate cancer cells.
Another suggested target gene for the ampliﬁcation of 8q21 in
prostate cancer is a TPD52 family member, hD52 (also known as
PrLZ).35 When expressed in NIH 3T3 cells, the murine orthologue
of TPD52 (mD52) was able to transform the cell line and form
metastatic tumors in mice. However, no human cell lines and
human hD52 were included in the study.36
The most studied candidate target gene for 8q24 ampliﬁcation
is the well-known oncogene MYC.37 In some studies, ampliﬁca-
tion of MYC has been shown to correlate with its overexpres-
sion and poor prognosis of prostate cancer.38,39 We have also
demonstrated ampliﬁcation of MYC in prostate cancer.6,9,11
However, the expression was not associated with ampliﬁcation.
In addition, the MYC expression was not found to be increased in
prostate cancer in general.11 Here, EIF3S3 located in 8q23-24 had a
minor positive effect on the growth of the NIH 3T3 cells, which we
have also previously reported.6 Whereas, RAD21 and KIAA0196
did not seem to have any signiﬁcant role in growth, anchorage-inde-
pendent growth or invasion in vitro. Altogether the functional data
do not support the hypothesis that RAD21 or KIAA0196 would be
the target genes, instead the may be conincidentially ampliﬁed. One
shortcoming of this study is that the effects of the genes were ana-
lyzed one gene at the time. Since the gain of 8q most often com-
prises the whole long arm of the chromosome,2,4 it is possible that
the target genes of the gain have synergistic effects. Thus, also the
combined effects of the putative target genes should be studied in
the future.
Taken together, the data suggest that TCEB1 is an invasion and
metastasis promoting gene, and therefore a strong candidate target
gene for the ampliﬁcation of 8q21.
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ABSTRACT 
Prostate cancer is the most frequent male malignancy and the second most common cause of 
cancer-related death in Western countries. Current clinical and pathological methods are limited 
in the prediction of postoperative outcome. It is becoming increasingly evident that small non-
coding RNA (ncRNA) species are associated with the development and progression of this 
malignancy. To assess the diversity and abundance of small ncRNAs in prostate cancer we 
analyzed the composition of the entire small transcriptome by Illumina/Solexa deep sequencing. 
We further analyzed the microRNA (miRNA) expression signatures of 102 fresh-frozen patient 
samples during prostate cancer progression by miRNA microarrays. Both platforms were cross-
validated by quantitative RT-PCR. Besides the altered expression of several miRNAs, our deep 
sequencing analyses revealed strong differential expression of small nucleolar RNAs and tRNAs. 
From microarray analysis, we derived a miRNA diagnostic classifier that accurately distinguishes 
normal from cancer samples. Furthermore, we were able to construct a prostate cancer prognostic 
predictor that independently forecasts postoperative outcome. Importantly, the majority of 
miRNAs included in the predictor also exhibit high sequence counts and concordant differential 
expression in Illumina PCa samples, supported by quantitative RT-PCR. Our findings provide 
miRNA expression signatures that may serve as an accurate tool for the diagnosis and prognosis 
of prostate cancer. 
 
Key words: prostate cancer; microRNA; snoRNA; microarray; deep sequencing; Q-PCR 
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INTRODUCTION  
Prostate cancer is the most common malignancy and the second cancer-related cause of death 
among Western men (Ferlay et al., 2007). Fatal outcome from prostate cancer is generally 
preceded by local tumor infiltration beyond the prostate and metastasis to lymph nodes.  
Although the majority of prostate cancer patients are diagnosed with curable, organ-confined 
disease, more than a quarter of them experience a relapse within five years after surgery (Wright 
and Simon, 2003). Due to their heterogeneous character, it is difficult to distinguish indolent from 
more-aggressive prostate neoplasms (Marberger, 2009). Accurate identification of patients with 
an increased risk of postsurgical prostate cancer recurrence is of major importance for the 
determination of adequate adjuvant therapy. Current prediction models are based on standard 
clinical variables like preoperative prostate specific antigen (PSA), Gleason score, and pathologic 
stage. However, their performance is unsatisfactory regarding preoperative evaluation of 
treatment choice and postsurgical clinical outcome. A better understanding of the biologic 
mechanisms of prostate cancer formation and progression is crucial for the discovery of new 
markers for this disease.  
In recent years, it has become apparent that different non-coding RNAs (ncRNAs) are also 
implicated in prostate cancer. Several microRNAs (miRNAs) are now associated with the 
progression and classification of this and other malignancies (Lu et al., 2005; Ozen et al., 2008; 
Porkka et al., 2007; Prueitt et al., 2008; Shi et al., 2007; Tong et al., 2009; Volinia et al., 2006). 
Evidence is accumulating that small nuclear RNA (snRNA) and small nucleolar RNA (snoRNA) 
are also employed in cis and trans gene regulation and alternative splicing besides their 
established function in rRNA modification (Dong et al., 2008; Ender et al., 2008; Mattick and 
Makunin, 2006; Reis et al., 2004). Nevertheless, the assessment of the complete small ncRNA 
transcriptome involved in the formation and differentiation of different types and subtypes of PCa 
has remained a challenge.  
In this study, we examined the expression of the entire small transcriptome in prostate cancer 
using Illumina/Solexa deep sequencing. We further analyzed the expression signature of more 
than 700 mature miRNA species during progression of prostate cancer disease by Agilent 
microarrays and were able to derive differential miRNA expression profiles strongly associated 
with prostate cancer diagnosis and clinical outcome. A selected subset of miRNAs was further 
used to cross-validate both platforms by quantitative real-time-PCR (Q-PCR). 
 
RESULTS 
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Dynamics of the small transcriptome in prostate cancer 
We used Illumina/Solexa deep sequencing to examine the ncRNA content in two prostate cancer 
small RNA libraries: organ-confined prostate cancer (PCa) and metastatic lymph node PCa (LN-
PCa).  
Both sequencing reactions yielded 5 547 066 unfiltered sequence reads, for PCa and 4 915 053 
for LN-PCa. For PCa, 4 517 214 (81%) reads were mapped to 545 900 individual loci in the 
Human genome. For LN-PCa, 3 524 014 (78%) reads were mapped to 395 281 individual loci.  
Identified loci were further classified as known miRNA, snoRNA, snRNA, rRNA, tRNA,  
fragments of large ncRNA, genomic repeats, mRNA, and other hairpins originating from yet un-
annotated genomic regions (Table S1). MiRNAs were the most abundant RNA detected, 
comprising approximately 95% of the total RNA pool. We were able to identify 725 mature 
miRNA species deriving from 427 known human stem-loop sequences (miRBase 12.0). 
Furthermore, 20 candidate miRNA sequences originating from novel genomic miRNA-loci were 
discovered (Table S2). These loci correspond to novel miRNAs with very low sequence counts. 
In addition, two miRNAs homologous to the known rat rno-mir-320 and mouse mmu-mir-449c 
were detected. 
The overall expression of miRNA species was relatively decreased in LN-PCa as demonstrated 
by the noticeably lower total sequence count of miRNAs in LN-PCA (3 278 482) compared to 
PCa (4 232 318) (Table S1). Strikingly, the opposite tendency was observed for sequenced 
fragments mapped to tRNA and snoRNA loci. The total count of tRNA and snoRNA fragments 
was increased more than 20% in LN-PCa compared to PCa. tRNA fragment levels were elevated 
from 58 224 to 84 709 total sequence counts, while snoRNA fragments had corresponding total 
sequence counts of 16 762, and 20 569, in the PCa, and LN-PCa samples, respectively. Similarly, 
the diversity of detected snoRNA species was increased in the LN-PCa library. A search with the 
mapped sequences from both sample libraries against known snoRNAs identified 112, and 158 
unique snoRNA loci encoding either C/D-box or H/ACA box snoRNAs (Fig 1A). This global 
pattern of differential expression was also observed on the level of individual small ncRNAs. 
Only 19 miRNAs were found to be up-regulated in metastatic lymph node compared to PCa, 
while 69 were down-regulated. While the majority of differentially expressed ncRNAs species in 
PCa were miRNA, in the LN-PCa the most abundant ncRNA species were sno- and tRNAs (Fig 
1B, Table S3).  
Mature tRNA have a size of approximately 75 nucleotides (nt), while snoRNAs range in size 
from 70 to200 nt depending of their class (C/D box or H/ACA box) and cellular function 
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(guiding of RNA methylation or pseudourydilation). The majority of sequence reads mapped to 
snoRNA in both sequencing libraries had a size of 22-23 nt similarly to miRNA (Supplementary 
Figure S1). Most tRNA derived fragments identified in the PCa library had a size of ~18nt, while 
in LN-PCa library a peak in the size range of 27 nt was observed, indicating different processing 
of tRNA in LN-PCa (Supplementary Figure S1).  
To assess whether the relative down-regulation of miRNAs observed in the LN-PCa sample is 
mediated by alterations in the miRNA processing pathways, we examined the expression of the 
miRNA processing enzymes Drosha and Dicer in each one of the samples used for the generation 
of our deep sequencing libraries by Q-PCR. No significant change in the expression levels of 
these enzymes was found between PCa and LN-PCa (Supplementary Figure S2a and S2b). This 
result was further confirmed by the analysis of an extended sample cohort consisting of 60 PCa 
and 16 LN-PCa samples (Supplementary Figure S2c and S2d).  
Transcriptional profiling of the miRNA transcriptome 
Class discovery of miRNAs associated with prostate cancer  
To examine changes in expression of individual miRNAs that may be relevant to the occurrence 
and progression of clinically significant prostate cancer, we performed miRNA microarray 
analysis on a patient cohort consisting from 102 clinical tissue samples divided over six sample 
groups (Table 1).  
Using a class discovery approach, we investigated whether miRNA expression profiles can 
distinguish normal from malignant tissue and further discriminate different prostate cancer 
subtypes. 513 from the 723 human microRNAs included on the chip, displaying significant 
hybridisation signal levels were tested for differential expression between the normal and the 
corresponding cancer group in a pairwise fashion. From these, 80 miRNAs were identified as 
significantly changing between normal and malignant tissues (Figure 2a and Table S4). These 80 
miRNAs were used for the hierarchical clustering of all samples, which clearly separated non-
malignant from advanced prostate cancer specimens and further divided organ-confined PCa 
samples into two groups (Figure 2a). Group I, clustering with normal adjacent prostate (NAP), 
normal lymph node (LN-normal), and trans-urethral resection of the prostate (TURP-normal), 
contained 34 PCa tumors. In group II, 16 PCa tumors clustered together with samples derived 
from patients with advanced prostate cancer (LN-PCa and TURP-PCa). Differences between both 
PCa groups reflected distinct prognostic characteristics, as group II PCa tumors were strongly 
associated with significantly increased rate of metastases occurrence after radical prostatectomy 
(P<0.0001), cancer-related death (P=0.0007), ETV1 alterations (P=0.0396), and Gleason score 
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higher than 6 (P=0.0272) (Figure 2b). Poor outcome of group II PCa tumors was independent of 
the TMPRSS:ERG fusion status, the clinical stage of the tumor, or PSA progression. The average 
percentage cancer and percentage epithelium in tissue between both groups were significantly 
different (P=0.0010, and P=0.0261, respectively) however, no significant correlation was found 
between these two parameters (Table S5). 
Within the dataset of 80 miRNAs, 22 were identified to significantly contribute to the separation 
of group I and II PCa tumors (Figure 2c). Subsequent clustering based on the transcriptional 
profiles of these 22 miRNAs accurately separated all PCa tumors from group II in one of the 
branches of the hierarchical tree, while 31 of the 34 (91%) PCa group I tumors fell within the 
other branch suggesting that miRNAs can be used to group tumors per outcome, thus have 
predictive power. As group II PCa tumors were associated with clinical progression and 
development of metastases after radical prostatectomy, we also performed a supervised analysis 
for miRNAs differentially expressed between organ confined PCa tumors that did form 
metastases and those that did not. Supervised clustering based on metastatic status was in an 
overall good agreement with the results obtained from unsupervised analyses. 14 miRNAs were 
found to be common in both analyses (Supplementary Figure S3). Thus, we were able to identify 
distinct sets of miRNAs which could distinguish normal from malignant samples and could be 
associated with disease relapse after radical prostatectomy.  
MiRNAs involved in prostate cancer progression 
To also examine if further alterations of miRNA expression occur during disease progression, we 
tested miRNAs for differential expression between PCa and LN-PCa samples, and compared the 
expression levels of the identified miRNAs with data obtained from primary prostate stroma cells 
(PrSC) and primary prostate epithelial cells PrEC cells. 70 miRNAs were found significantly 
differentially expressed between PCa and LN-PCa (Supplementary Figure S4). From them, 51 
were down regulated in LN-PCa while 19 were up regulated. Comparison of the expression of 
these 70 miRNAs in stroma vs. epithelium primary cells demonstrated that the majority of 
miRNAs with abolished expression in metastatic lymph node were as expected from stromal 
origin. Nevertheless, several miRNAs with decreased expression in group II PCa tumors were 
further down regulated in malignant lymph node, namely miR-1, -133a, -133b, -143, -143*, -145, 
-145*, -204, -221, and  -222. Importantly, the same set of miRNAs was identified as strongly 
down regulated in LN-PCa also in our deep sequencing libraries (Figure 1b). MiR-145 and miR-
222 were also found to be significantly down regulated in malignant compared to normal lymph 
node (Supplementary Table S4). 
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Construction and performance of miRNA derived diagnostic classifier 
We further evaluated the predictive power of miRNA expression profiles by training a Bayesian 
Covariate Compound Predictor Algorithm (Radmacher et al., 2002). To avoid possible over-
fitting, we estimated the prediction error using Leave-One-Out Cross-Validation (LOOCV) 
(Simon et al., 2003). We designed a diagnostic miR-Classifier that can distinguish NAP from 
PCa samples. As an input, we used all 513 significantly expressed miRNAs in the entire 
microarray set. The best statistically significant miR-Classifier (P=0.0130, 1000 random 
permutations) consisted of 54 miRNAs significantly different between the classes (P =0.0005, 
random variance t-test) (Table S6). At a posterior probability threshold of 0.7, the diagnostic 
miR-Classifier correctly classified 54 out of 61 samples (89%). ROC curve analysis resulted in an 
AUC of 0.949, with class sensitivity of 0.636 and class specificity of 0.94 for group NAP. The 
positive and negative predictive values for the same group are 0.7 and 0.922, respectively.  
We further validated the miR-Classifier on an independent data set recently reported by Schaefer 
and colleagues (Schaefer et al., 2010). All 24 paired NAP and PCa samples from that study were 
categorized based on the expression profiles of 43 out of the 54 miRNAs included in our miR-
Classifier. The remaining 11 miRNAs were not included in the miRNA microarray platform used 
by the authors.  Using that external dataset and the same testing parameters as described above, 
our miR-Classifier performed equally well in correctly predicting the class of the samples, 
achieving class sensitivity of 1 and class specificity of 0.667 for group NAP. The positive and 
negative predictive values for the same group are 0.75 and 1, respectively.  ROC analysis 
revealed that MiR-Classifier performed equally well on both datasets with no significant 
difference (P=0.2534) between the derived AUCs (Figure 3). 
Construction and performance of miRNA derived prognostic predictor 
Similarly to the construction of the miR-Classifier we designed a diagnostic miR-Predictor that 
could distinguish group I (good prognosis) from group II (poor prognosis) PCa samples. 
The best statistically significant predictor (P=0.0410, 1000 random permutations) with the lowest 
cross-validation mis-classification rate consisted of 25 miRNAs (Figure 4a) significantly 
different between group I and group II tumors (P =0.0005, random variance t-test). 15 of these 
miRNAs are also included in miR-Classifier and importantly, follow the same direction of 
expression change (Supplementary Figure S5). At a posterior probability threshold of 0.7, miR-
Predictor correctly classified 40 out of 50 samples (11 to group II and 29 to group I). 10 samples 
were not assigned to either of both groups (Figure 4a and 4c). MiR-Predictor reached an AUC of 
0.991 (Figure 4b) and had class sensitivity and class specificity of 0.912 and 0.750, respectively 
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for group I PCa tumors with positive predictive value of 0.886 and negative predictive value of 
0.800 for the same group.  
To assess miR-Predictor as a prognostic factor, we compared its performance to that of other 
clinical parameters (Fig 5). For the described here data set, at an end point of 12 years the 
prognostic signature of miR-Predictor performed better than the other tested clinical parameters 
with lower survival probability for patients assigned to the poor outcome group (0.3463, 
SE=0.1600) compared to Gleason score (0.4375, SE=0.1879), preoperative PSA (0.429, 
SE=0.1574) or pathological stage (0.7272, SE=0.1767). 
Comparison of Solexa deep sequencing and Agilent microarray platforms and Q-RT-PCR 
validation 
To cross validate the results obtained from both platforms, we compared the miRNA expression 
data obtained from Illumina/Solexa deep sequencing and Agilent miRNA microarrays.  We 
identified 725 miRNA sequences in both sequencing reactions. Agilent microarrays used in this 
study contain probes for 723 miRNAs. In all, 483 (67%) miRNAs were represented by both 
platforms (Figure 6a).  
The Agilent microarrays contain probes for 240 miRNAs that were not detected by deep 
sequencing. The hybridization signal of a substantial number of these probes (approximately 
53%) was below the recognized threshold levels in all 102 samples, consequently these miRNAs 
were assigned absent call by the Agilent Feature Extraction Software. The majority of miRNAs 
detected by Solexa but not by microarrays were sequences for which no probes or probes for their 
opposite strands have been included on the miRNA microarrays. 
Comparison of log2 transformed data demonstrated that, despite the much broader dynamic range 
of deep sequencing reactions, the raw signals obtained from sequencing and microarrays are in 
good agreement since, as many as 51% of the miRNAs detected in PCa and 40 % of the miRNAs 
detected in LN-PCa, had comparable expression levels (Figure 6b). After normalization to the 
mean, more than 99% of the miRNAs had a comparable scaled signal within 4 fold difference 
between both platforms (Figure 6c).  
The good agreement between Illumina/Solexa deep sequencing and Agilent microarrays was 
further supported by TaqMan Q-RT-PCR assays performed on a selected set of 12 miRNAs 
which included ten differentially expressed miRNAs between PCa (group I and II) and LN-PCa 
as identified by microarrays and/or Solexa deep sequencing (miR-1, -143, -145, -205, -210, -222, 
-301b, -425-5p, and -451). A negative control miRNA (miR-558), which was not detected in 
either of both deep sequencing libraries and was assigned an absent call in more than 50% of the 
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microarrays derived from PCa and LN-PCa, and a non-changing control miRNA (miR-25) that 
was stably expressed and detected in the Solexa libraries and in all PCa and LN-PCa samples, 
were also included. The overall expression ratios as determined by TaqMan Q-RT-PCR assays 
strongly correlated with the findings from microarrays and deep sequencing (Figure 6d) since not 
only the direction of change (up- or down regulation), but also the relative log2 ratios of 
individual differentially expressed miRNAs were well comparable.  
 
35 
 
DISCUSSION 
At present, consistent data regarding alterations in the expression of miRNA in prostate cancer 
are still limited (reviewed by (Coppola et al., 2010)) and studies addressing the genome-wide 
expression profiling of other small ncRNA in this malignancy are lacking.  
Here we utilized Solexa Illumina Deep Sequencing to examine the entire spectrum of small 
ncRNA in prostate cancer specimens, and further screened for changes in the expression of 723 
miRNAs by microarray-profiling of 102 histologically confirmed malignant and non-malignant 
samples from prostatectomy, lymph node, and TURP origin. 
Comparison of miRNA expression profiling results obtained by deep sequencing and microarray 
analyses demonstrated a high concordance in measuring miRNA expression levels between both 
platforms used for this study and identified similar sets of differentially expressed miRNAs.  
Previously, it has been reported that absolute microarray expression measures correlate better 
than deep-sequencing data with RNA sample-content when synthetic samples mimicking the 
human miRNA pool are used (Willenbrock et al., 2009). However, the correlation between 
absolute miRNA expression values determined by microarrays and by next-generation 
sequencing may differ strongly depending on the platform used for microarray profiling (Git et 
al., 2010), or on the algorithm used for processing of sequencing data. Therefore, to further 
confirm the validity of results obtained in our microarray and deep sequencing data sets we also 
verified the expression of a set of 12 differentially expressed miRNAs by Q-PCR. 
Our deep sequencing experiments revealed that overall, many miRNAs have decreased 
expression in metastatic lymph node PCa compared to organ confined disease. These changes in 
expression were further confirmed by both microarray analysis and by Q-PCR on selected 
miRNAs. It has been suggested that alterations in the expression levels of Dicer may explain 
global changes of miRNA expression in prostate adenocarcinoma (Chiosea et al., 2006; Ambs et 
al., 2008). However, in this study we did not observe significant differences in the expression 
levels of Dicer or Drosha between the studied patient groups (Supplementary Figure S2). 
Alternatively, the decreased levels of many miRNAs observed here may be partially explained by 
their stromal origin and the loss of the stromal compartment in advanced and metastatic prostate 
cancer. 
The independence of prior knowledge (i.e. no required probe design, which would only cover 
known genes) together with the very broad dynamic range of deep sequencing (over 5 orders of 
magnitude) allowed us to detect several novel miRNA with low expression levels in our deep 
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sequencing libraries. Additionally, we also identified many sequence fragments derived from 
tRNA and snoRNA transcripts.  
We further noticed a pronounced increase of tRNA fragments in the metastatic sample pool that 
can be interpreted as a direct evidence of elevated RNA-polymerase III output, which in turn is a 
feature of transformed and cancerous cells (Marshall and White, 2008). The same was observed 
for several snoRNAs, providing further support for high metabolic activity and elevated protein-
synthesis rate, necessary for the fast growth of tumor cells in progressing cancer.  
Interestingly, in addition to their function in ribosomal maturation, snoRNA species or their 
derivates have been implicated in processes associated with carcinogenesis, e.g. alternative 
splicing events (Kishore and Stamm, 2006) and genomic imprinting (Royo et al., 2006). In 
prostate cancer, snoRNA U50 has been reported to be a candidate tumor-suppressor gene and a 
mutation in its sequence has been associated with clinically significant disease (Dong et al., 
2008). Recent findings have demonstrated that discrete in size snoRNA fragments are produced 
from a vast majority of snoRNA loci (Taft et al., 2009) and that they can also function as 
miRNAs (Ender et al., 2008; Brameier et al., 2011). Additional research is needed to investigate 
whether this unconventional function of snoRNAs is a wide spread mechanism of gene regulation 
and whether this holds true for snoRNAs identified in this study.  
 
By performing microarray analysis we were able to identify a miRNA signature that not only 
distinguished normal from malignant specimens, but also identified two subclasses within the 
group of patients with organ confined disease at the time of surgery.  Comparison of this miRNA 
signature to known clinicopathologic parameters associated the separation of both subclasses 
with postoperative occurrence of clinical metastases and poor disease outcome.  To evaluate 
whether the observed associations have a potential clinical diagnostic or prognostic value; we 
trained a diagnostic miR-Classifier and a prognostic miR-Predictor using the Bayesian compound 
covariate method followed by LOOCV analysis. 
The miR-Classifier consists of a set of 54 miRNAs that clearly discriminated normal adjacent 
from prostate cancer specimens. This miR-Classifier performed equally well on the independent 
microarray dataset used for validation (Schaefer et al., 2010) despite the differences in 
microarray platform, experimental design, and sample size, providing evidence that the included 
miRNAs may have a potential value as diagnostic markers for prostate cancer.  
Among the miRNAs included in the miR-Classifier, miR-205 is of particular interest. This 
miRNA was the most strongly down regulated miRNA in PCa compared to NAP and its 
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expression is completely abolished in metastatic lymph node and malignant TURP samples. It 
has been suggested that the tumor suppressive function of miR-205 that takes place through 
counteracting epithelial-to-mesenchymal transition and reducing cell migration and invasion in 
the human prostate (Gandellini et al., 2009; Majid et al., 2010). K27me3 modifications of the 
miR-205 locus was reported to occur in the prostate cancer cell line PC3 (Ke et al., 2009) and in 
muscle invasive bladder tumors and undifferentiated bladder cell lines (Wiklund et al., 2010). 
These findings, together with the early loss of miR-205 during prostate cancer progression 
observed by us and others (Ambs et al., 2008; Porkka et al., 2007; Schaefer et al., 2010) present 
miR-205 as an attractive diagnostic marker for prostate cancer disease.  
The miR-Predictor consists of 25 miRNAs, from which 13 are down regulated and 12 are up-
regulated in prostate cancers with poor outcome. The combined expression profiles of these 
prognostic miRNAs are very specific for patients at high risk of clinical relapse and their 
combined predictive accuracy was higher compared to other clinical variables available for the 
patients included in the study cohort.  Unfortunately, because of the limited number of radical 
prostatectomy samples with a clinical follow-up that includes clinical metastasis occurrence and 
prostate cancer-related death, and the low quantities of available material, it is difficult to obtain 
an independent validation set for miR-Predictor. To our knowledge, there are no publically 
available data sets on genome-wide miRNA expression profiling in prostate cancer that comprise 
samples with sufficiently long follow-up needed for independent testing of MiR-Predictor. To 
partially overcome this drawback, we implied the LOOCV method to reduce over-fitting of our 
diagnostic and predictive models within our patient cohort. LOOCV is a validation method that 
iteratively chooses one sample from a given dataset to be the validation sample and uses the 
remaining samples to build a training set. For each round of iteration, the entire model 
construction is repeated starting with the selection of significant miRNAs. The predictive power 
of each of the miRNAs included in the final model is represented as the percentage of the 
iteration steps in which that miRNA has been identified as predictive.  In our MiR-Predictor we 
included only miRNAs that had 100 % cross-validation support and therefore were predictive for 
any of the tested combinations. We also controlled the misclassification error rate by calculating 
a label-permutation p-value that indicates the chance of obtaining the same or lower 
misclassification for two groups of samples when their sample labels are randomly assigned as 
compared to the real class labels. However, considering the small sample size of our patient 
cohort it should be noted that it is not an equivalent to a validation on an independent dataset. 
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Nevertheless, the robustness of the method was demonstrated by  the validation of the identically 
constructed MiR-Classifier on the external dataset published by Schaefer and colleagues.   
Several miRNAs included in MiR-Predictor have been recently reported to be deregulated in 
clinical prostate cancer samples. Down regulation of let-7b, miR-1, miR-133a, miR-143, miR-
145, miR-221, and miR-222 and up-regulation of miR-25, miR-93, mir-96, miR-183, miR-182 or 
miR-301b has been reported in prostate cancer when compared to BPH or normal prostate tissue 
by at least one research group (Ozen et al., 2008; Porkka et al., 2007; Schaefer et al., 2010; 
Spahn et al., 2010; Szczyrba et al., 2010; Tong et al., 2009; Volinia et al., 2006). In addition, 
over-expression of miR-96 and reduced expression of miR-221 have been associated with 
increased risk of biochemical recurrence and aggressive prostate cancer (Schaefer et al., 2010; 
Spahn et al., 2010). 
The concordant expression of these miRNAs could be in part explained by their genomic 
organization as mir-1/133, mir-143/145, mir-221/222, and mir-96/182/183 are encoded in 
genomic clusters and most likely their expression levels are regulated by identical regulatory 
events. A recent analysis of the methylation signature in prostate cancer cell lines demonstrated 
that indeed histone methylation leads to the silencing of the entire mir-22l/222 cluster (Ke et al., 
2009). Deregulation of several of the down-regulated miRNAs identified in our prognostic profile 
has been demonstrated also in other human malignancies or diseases such as breast, (Wang et al., 
2009) and colorectal cancer (Michael et al., 2003) for the mir-143/145 cluster; breast cancer 
(Zhao et al., 2008), and glioblastoma (Gillies and Lorimer, 2007) for the mir-221/222 cluster; and 
liver cancer (Datta et al., 2008) or cardiac hypertrophy
 
(Care et al., 2007) for the mir-1/133 
cluster.  
MiRNAs function in carcinogenesis and cancer progression by modulating the expression levels 
of, among others, tumor-suppressor genes and oncogenes. To examine the functional relevance of 
miRNAs identified in this study, we performed target-gene network search for the miRNAs 
included in MiR-Classifier and MiR-Predictor by Ingenuity Pathways Analysis (Ingenuity® 
Systems) (Supplementary Data File 1). MiRNA target-genes were significantly enriched in gene 
networks associated with cancer and reproductive system disease affecting cellular development, 
cellular growth and proliferation, cell-to-cell signaling, cell morphology, and cell cycle 
(Supplementary Figures S6 and S7). Several up-regulated miRNAs identified in this study, e.g. 
miR-19a, miR130a, and the mir-20a/106/93 family, target key cancer genes involved in prostate 
cancer signaling. Deregulation of these miRNAs may cause defects in cell cycle checkpoint 
control and further promote cell cycle progression by decreasing the expression levels of tumor 
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suppressors PTEN, p21, and Rb1, which are commonly inactivated in prostate cancer (reviewed 
by Lee et al., 2008). In addition, decreased expression of miR-27, miR-143 and miR-221/222 
may promote increased expression of Notch1, MAPK kinases, and c-KIT, which have been 
associated with epithelial-mesenchymal transition, angiogenesis and metastasis in prostate cancer 
(Bin Hafeez et al., 2009; Paronetto et al., 2004; Mukherjee et al., 2011).    
Deregulation of miRNAs in response to altered androgen signaling in PCa has been studied 
previously (reviewed by Catto et al., 2011). However, based on cell line and xenograft studies, 
only few miRNAs have been suggested to be androgen regulated.  Within the miRNAs included 
in MiR-Classifier and miR-Predictor, only miR-21, miR-32, miR-141, miR-221, and miR-375, 
demonstrate changes of expression concordant with previously published data.  For example, it 
has been shown that elevated expression of miR-21 can enhance PCa tumor growth in vivo and, is 
sufficient for androgen-dependent tumors to overcome castration-mediated growth arrest. (Ribas 
et al., 2009). We recently identified miR-21 together with miR-32, miR-141, miR-221, and miR-
375 as differentially expressed during DHT stimulation of different PCa cell lines or 13 intact-
castrated pairs of PCa-xenografts (Waltering et al., 2011). It has been reported that the mir-
221/222 cluster is up-regulated in matched androgen-dependent and androgen-independent PCa 
cell lines (Sun et al., 2009). In the patient cohort presented in this study, the expression of the 
diagnostic and prognostic miR-221/222 is strongly down-regulated during disease progression. 
Similar down-regulation was observed for PCa cell lines (Waltering et al., 2011). In the latest 
study, only four miRNAs showed similar regulation in both, cell lines and xenograft-pairs, and 
only miR-141 demonstrated concordant expression in castration resistant PCa clinical specimens 
when compared to PCa. The dissimilarity between the response of different miRNAs to androgen 
stimulation in cell lines and xenograft models and when compared to expression in clinical 
samples, may be explained by the direct response to androgens in in vitro studies compared to the 
long term  effects of androgen deprivation in vivo (Waltering et al., 2011). In addition, the 
diagnostic and prognostic profiles obtained in this study are based on clinical samples derived 
early, from patients with organ confined disease, years prior clinical relapse and androgen 
deprivation therapy.  
Taken together, our findings support the role of miRNAs, and implicate snoRNAs in prostate 
oncogenesis. The discovery of a subset of miRNAs, which is associated with the aggressiveness 
of the tumors, suggests that this regulatory system is, at least, partly responsible for the 
progression of the disease. Our miRNA predictor forecasts PCa recurrence after radical 
prostatectomy in the early organ confined stage prior clinical progression. Compared to other 
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prognostic models currently applied in clinical practice, miR-Predictor demonstrates enhanced 
accuracy and suggests novel directions into prognostic prediction of prostate cancer. It is now 
warranted to evaluate whether this panel of miRNA could be clinically useful in optimizing the 
treatment strategies for the prostate cancer patients. 
MATERIALS AND METHODS 
Patient samples, clinical database and cell lines  
For microarray analysis 102 freshly frozen clinical samples were obtained from the tissue bank of 
the Erasmus University Medical Center. Clinical parameters of the patient cohort are listed in 
Table 1. Collection of patient samples has been performed according to national legislation 
concerning ethical requirements. Use of these samples has been approved by the Erasmus MC 
Medical Ethics Committee according to the Medical Research Involving Human Subjects Act 
(MEC-2004-261). 
Two sample pools each comprised of four individual patient samples were used for 
Solexa/Illumina deep sequencing (Table S7).  
Primary PCa and normal prostate samples were obtained by radical prostatectomy. Samples were 
snap frozen and stored in liquid nitrogen. Histological evaluation and Gleason grading were 
performed independently by two pathologists on hematoxylin/eosin-stained frozen sections for all 
analyzed material. Tumor samples in which at least 60% of the cells were cancerous and 
containing at least 60% ducts were selected for analysis. The non-tumor samples contained 0% 
tumor cells and at least 60% ducts. The latter samples were considered “normal” for this study, 
although they were derived from prostates that contained adjacent tumor epithelium.  
Primary human prostate stromal cells (PrSC) and primary human prostate epithelial cells (PrEC) 
were purchased and cultured according to manufacturer’s guidelines (Clonetics Human and 
Animal Cell Systems, Cambrex Bio Science Walkerville Inc., USA). 
RNA isolation 
Total RNA was isolated from frozen tissue samples using RNABee reagent (Campro Scientific, 
GmbH) according to the manufacturer’s protocol. 
Illumina/Solexa small RNA library preparation, genome mapping and annotation 
Total RNA sample pools for small RNA library preparation and sequencing on the Illumina 1G 
Genome Analyzer was outsourced to ServiceXS, Leiden, The Netherlands. RNA library 
preparations were performed according to the “Small RNA Sample Prep v1.5.0 (Prerelease 
protocol, Rev-D)”, (Illumina Inc.,www.illumina.com). Shortly, total RNA pools were size 
fractionated on 15% TBE urea PAGE gel, and the small ncRNA fraction in the size range of 18 to 
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30 nt was extracted and purified. After 5’ and 3’ adapter ligation, cDNA library ready for 
sequencing was constructed by reverse transcription with SuperScript II Reverse Transcriptase 
(Invitrogen) followed by 15 cycles of PCR by Phusion DNA Polymerase (Finnzymes Oy) as 
previously described (Morin et al., 2008).  
Raw reads obtained after sequencing were processed using the mir-Intess™ pipeline by  InteRNA 
Genomics BV, the Netherlands(http://www.internagenomics.com),  which provided annotation of 
miRNA reads according to Homo sapience genome (NCBI build 36) as well as identification of 
novel miRNA candidate genes (Berezikov E et al. 2006; Wit, et al. 2009). Mapping and 
annotation of aligned non-miRNA reads with a minimum sequence length of 18nt (Suplementary 
Figure S1) which contained at least 3 recognizable nucleotides from the 3’ adapter sequence was 
performed by MEGABLAST, according to genomic loci annotations retrieved from the UCSC 
database: hg18 (http://genome.ucsc.edu/) trak tables for sno/miRNA, tRNA, and non-coding 
RNA genes, and MiRBase version: 12.0 (http://www.mirbase.org/) as previously described 
(Morin et al., 2008).  
MiRNA microarrays and analysis 
Microarray analysis of miRNA expression was performed using Human miRNA V2 microarrays 
(Agilent) that contain probe sets for 723 human microRNAs from the Sanger MiRBase, v.10.1. 
Microarray processing and analysis are described in Supplementary data file 1. The array data 
were submitted using Tab2MAGE to the ArrayExpress database 
(http://www.ebi.ac.uk/microarray-as/ae/) with accession number E-TABM-794. 
TaqMan Q-PCR 
Quantitative real-time
 
RT-PCR analysis was done with an ABI Prism 7700 Sequence Detection
 
System using TaqMan® MicroRNA Reverse transcription kit and TaqMan® Universal PCR 
Master Mix, No AmpErase® UNG according to the manufacturer's specifications
 
(Applied 
Biosystems, Foster City, CA). Mature miRNA expression in the same total RNA pools as used 
for deep sequencing was assessed using specific TaqMan® MicroRNA Assays (Applied 
Biosystems). The amount of target gene expressed was
 
normalized to U6 and Z30 endogenous 
controls by the delta Ct method.  
Statistical analysis of clinical data 
The significance of contingency for categorical clinical data was examined by Fisher’s exact test 
(alpha level 0.05). Continuous variables between different groups were compared using two 
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tailed nested t-test (alpha level 0.05). Pearson correlation coefficient was used to evaluate 
possible correlation between clinical parameters.  
Kaplan Meier survival curves and log-rank tests were used to assess the predictive values of 
different prognostic approaches.  
MiR-Classifier and MiR-Predictor construction and evaluation 
MiR-Classifier and MiR-Predictor were constructed using identical algorithm. Models for 
utilizing gene expression for class prediction of future samples were developed using the 
Compound Covariate predictor implemented in the software package “BRB array tools” 
developed by Dr. Richard Simon and BRB-ArrayTools Development Team (Wright and Simon, 
2003). The models incorporated genes that were differentially expressed at the 0.001 significance 
level as assessed by the random variance t-test. We estimated the prediction error of each model 
using leave-one-out cross-validation (LOOCV) (Simon R, et al. 2003). For each LOOCV training 
set, the entire model building process was repeated, including the gene selection process. We also 
evaluated whether the cross-validated error rate estimate for a model was significantly less than 
one would expect from random prediction. The class labels were randomly permuted and the 
entire LOOCV process was repeated. The significance level was defined as the proportion of the 
random permutations that gave a cross-validated error rate no greater than the cross-validated 
error rate obtained with the real data. 1000 random permutations were used.  
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FIGURE LEGENDS 
 
Figure 1. Deep sequencing analysis of differentially expressed small non-coding RNAs in organ 
confined and metastatic prostate cancer. a) Number of ncRNA species per sample pool. b) 
Differentially expressed small RNAs between Organ-confined prostate tumours (PCa) and 
metastatic lymph node (LN-PCa) libraries. We compared the fold change difference in the count 
number of sequences mapped to the same mature snRNA in PCa and LN-PCa libraries. 
Sequences were considered differentially expressed when the fold change in sequence counts 
between the tested conditions was more than four. Plotted are the log2 transformed count 
frequencies of each individual ncRNA in the LN-PCa library (log2 LN-PCa) and the PCa library 
(log2 PCa). Coloured are small RNAs with a fold change bigger than four. In red – miRNA; blue 
– snoRNA; green – t RNA; gray – ncRNAs with a fold change less than 4. Only names of 
miRNA tested by TaqMan Q-RT-PCR are indicated.  
 
Figure 2. Class discovery of miRNAs associated with prostate cancer outcome. A) Hierarchical 
clustering of 80 miRNAs differentially expressed between normal (NAP, LNnorm, and 
TURPnorm) and cancer (PCa, LN-PCa, and TURP-PCa) samples. Organ confined prostate 
cancers (PCa) cluster in two major groups designated group I (green text) and group II (red text). 
Red color, up-regulation; Blue color, down regulation; Yellow color, no change. B) Clinical data 
is presented as a heat map: (1). Gleason score - yellow 6, orange 7, light red 8, red 9 or 10; (2) 
clinical stage – yellow T1, orange T2, light red T3, red T4; (3) hormone refractory tumor; (4) 
PCa-related death; (5) presence of metastases; (6) PSA level progression; (9) ETV1 alteration; 
(10) TMPRSS2:ERG fusion –yellow  no, red yes;  (7) % epithelium in tissue; and (8) % cancer in 
tissue are presented in a color range from 60% to 100%, where darker color indicates higher 
percentage. Grey indicates no data.  C) Unsupervised hierarchical clustering of PCa tumors based 
on the transcriptional profiles of miRNAs differentially expressed between group I and group II 
PCa tumors.  
 
Figure 3. Comparison of the performance of miR-classifier between this study (solid line) and the 
independent validation data-set validation (Schaefer et al., 2010) (dashed line). AUC curves do 
not differ significantly (P value= 0.2534). Sensitivity, specificity, positive, and negative predicted 
values for the validation dataset are given in parentheses.  
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Figure 4. Construction and performance of miR-Predictor. A) Predictions made for the 50 organ 
confined PCa samples in the data set. Samples are ordered by their posterior probability of 
membership in either of each class. The upper panel represents a heat map of the relative median 
centered fold change in log space for each miRNA included in miR-Predictor. Red color, up-
regulation; Blue color, down regulation; Yellow color, no change. Genes are arranged by 
hierarchical clustering. The lower panel represents the clinical data for the corresponding 
samples. Green color indicates good outcome, belongs to group I. Red color indicated poor 
outcome, belongs to group II. Blue color indicates that miR-Predictor could not assign the sample 
to either of both groups based on their posterior probability when a probability cut-off of 0.7 was 
applied. Gray color indicates no available data. B) ROC curve for miR-Predictor applied to organ 
confined PCa samples. When sample‘s posterior probability was greater than the cut-off of 0·7 
sample was considered group I, otherwise it was considered group II. C) Kaplan-Meier curves for 
the three tumor groups identified by miR-Predictor. 
 
Figure 5. Kaplan-Meier survival curves for PCa-related death based on a) MiR-Predictor, b) 
pathological grade (Gleason score), c) pathological stage (PT) and preoperative PSA. 
 
Figure 6. Comparison of miRNAs detected by Solexa Deep Sequencing and/or Agilent miRNA 
microarrays. A) MiRNA detection between both platforms, B) Comparison of the obtained 
expression data between Solexa deep sequencing and Agilent microarrays. The raw log2 
transformed signals of 483 miRNAs are plotted. C) Comparison of the obtained expression data 
between Solexa deep sequencing and Agilent microarrays. The mean scaled log2 transformed 
signals of 483 miRNAs are plotted. Yellow indicates fold change les or equal to 2, red indicates 
fold change between 2 and 4, blue indicates fold change between 4 and 8, green indicates fold 
change higher than 8. D). Q-RT-PCR expression analysis of selected miRNAs in comparison 
with microarray and deep sequencing. Data is represented in normalized log2 ratio of expression. 
MiR-558 was used as a negative control, which was not detected in deep sequencing libraries and 
was assigned an absent call in more than 50% of the microarrays derived from PCa and LN-PCa. 
MiR-25 was used as a non-changing control that was stably expressed and detected in both 
Solexa libraries as well as in all PCa and LN-PCa samples. 
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Table 1 Clinical parameters of patient cohort for microarray analysis 
 
NAP 
(n=11)  
PCa 
(n=50) 
LN-
normal 
(n=3) 
LN-PCa 
(n=12) 
TURP-
normal 
(n=4) 
TURP-
PCa 
(n=22) 
Age at treatment   
average (min-max) 
62 
(54-72) 
62 
(49-73) 
66 
(58-69) 
65 
(39-72) 
75·5 
(71-78) 
73·5 
(49-90) 
Follow-up  (years) 
average (min-max) 
11.0 
(2.8-16) 
11.3 
(1-20.1) 
12.2 
(4.2-16.6) 
10.1 
(2.3-24.6) 
14,6 
(12.1-16.3) 
10.3 
(0.8-16.6) 
Gleason score 
      6 
 
32 (64%) 
 
0 (0%) 
 
3 (14%) 
7 
 
10 (20%) 
 
2 (17%) 
 
5 (23%) 
8 
 
7 (14%) 
 
8 (67%) 
 
13 (59%) 
9 
 
1 (2%) 
 
2 (17%) 
 
1 (4·5%) 
Clinical stage 
      T1 
 
3 (6%) 
 
0 (0%) 
 
0 (0%) 
T2 
 
12 (24%) 
 
2 (17%) 
 
2 (9%) 
T3 
 
16 (32%) 
 
1 (8%) 
 
2 (9%) 
T4 
 
3 (6%) 
 
1 (8%) 
 
0 (9%) 
Pathological stage  
 
 
    
T2 16 (332%) 
T3 22 (44%) 
T4 12 (34%) 
Preoperative PSA 
(n=48)  
average (min-max) 
 
16.8 
(0·3-
181·4) 
    PSA progression 
 
27 (54%) 
 
6 (50%) 
 
7 (32%) 
Hormone 
refractory status  
     hormone refractory 
     
7 (32%) 
non hormone 
refractory 
     
4 (18%) 
unknown 
     
11 (50%) 
PCa-related death 1 8 (16%) 1 (33%) 6 (50%) 0 7 (32%) 
Occurrence of 
metastases 1 10 (20%) 2 (66%) 6 (50%) 0 8 (36%) 
ETV1 alterations 0 3 (6%) 0 (0%) 1 (8%) 0 3 (14%) 
TMPRSS-ERG 
fusion 0 29 (58%) 2 (66%) 9 (75%) 2 11 (50%) 
% epithelium in 
tissue  
average (min-max) 
68 
(60-80) 
77 
(60-100) 
100 
 
90 
(60-100) 
73 
(60-80) 
89 
(70-100) 
% cancer in tissue         
average (min-max) 
 
84 
(60-100) 
 
100 
 
 
98 
(90-100) 
50 
 
Data are n (%) unless stated otherwise. Abbreviations: NAP, normal adjacent prostate; PCa, organ confined 
prostate cancer; LN-normal, normal lymph node; LN-PCa, metastatic lymph node; TURP-normal, non-
malignant trans-urethral resection of the prostate; TURP-PCa, malignant trans-urethral resection of the 
prostate; n, number of patients in each group or category; min, minimum value; max, maximum value.    
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